0001493152-22-025666.txt : 20220913 0001493152-22-025666.hdr.sgml : 20220913 20220912182516 ACCESSION NUMBER: 0001493152-22-025666 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20220731 FILED AS OF DATE: 20220913 DATE AS OF CHANGE: 20220912 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Advaxis, Inc. CENTRAL INDEX KEY: 0001100397 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841521955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36138 FILM NUMBER: 221239461 BUSINESS ADDRESS: STREET 1: 9 DEER PARK DRIVE STREET 2: SUITE K-1 CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 BUSINESS PHONE: 732 545 1590 MAIL ADDRESS: STREET 1: 9 DEER PARK DRIVE STREET 2: SUITE K-1 CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 FORMER COMPANY: FORMER CONFORMED NAME: GREAT EXPECTATIONS & ASSOCIATES INC DATE OF NAME CHANGE: 19991203 10-Q 1 form10-q.htm
0001100397 false --10-31 Q3 0001100397 2021-11-01 2022-07-31 0001100397 2022-09-09 0001100397 2022-07-31 0001100397 2021-10-31 0001100397 ADXS:SeriesDConvertibleRedeemablePreferredStockMember 2022-07-31 0001100397 ADXS:SeriesDConvertibleRedeemablePreferredStockMember 2021-10-31 0001100397 2022-05-01 2022-07-31 0001100397 2021-05-01 2021-07-31 0001100397 2020-11-01 2021-07-31 0001100397 2020-10-31 0001100397 2021-07-31 0001100397 ADXS:SeriesDPreferredStockRedemptionMember 2022-01-31 0001100397 us-gaap:WarrantMember 2021-11-01 2022-07-31 0001100397 us-gaap:WarrantMember 2020-11-01 2021-07-31 0001100397 us-gaap:EmployeeStockOptionMember 2021-11-01 2022-07-31 0001100397 us-gaap:EmployeeStockOptionMember 2020-11-01 2021-07-31 0001100397 ADXS:ResearchAndDevelopmentMember 2020-11-01 2021-07-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2020-11-01 2021-07-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2022-05-01 2022-07-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2021-05-01 2021-07-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2021-11-01 2022-07-31 0001100397 2021-03-01 2021-03-26 0001100397 2021-03-26 0001100397 2021-03-25 0001100397 2021-03-01 2021-03-25 0001100397 us-gaap:WarrantMember 2022-07-31 0001100397 us-gaap:WarrantMember 2021-10-31 0001100397 us-gaap:WarrantMember srt:MinimumMember 2022-07-31 0001100397 us-gaap:WarrantMember srt:MinimumMember 2021-10-31 0001100397 us-gaap:WarrantMember srt:MaximumMember 2022-07-31 0001100397 us-gaap:WarrantMember srt:MaximumMember 2021-10-31 0001100397 ADXS:EquityWarrantsMember 2022-07-31 0001100397 ADXS:EquityWarrantsMember 2021-10-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-07-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 2021-04-30 0001100397 2021-05-01 0001100397 srt:MinimumMember 2021-06-03 0001100397 srt:MaximumMember 2021-06-03 0001100397 ADXS:WarrantLiabilityMember srt:MaximumMember 2022-07-31 0001100397 ADXS:WarrantLiabilityMember srt:MinimumMember 2022-07-31 0001100397 us-gaap:PrivatePlacementMember 2021-11-01 2022-07-31 0001100397 ADXS:ExercisePriceRangeOneMember 2022-07-31 0001100397 ADXS:ExercisePriceRangeOneMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeOneMember 2021-11-01 2022-07-31 0001100397 ADXS:ExercisePriceRangeOneMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2022-07-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2021-11-01 2022-07-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2022-07-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2021-11-01 2022-07-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeFourMember 2022-07-31 0001100397 ADXS:ExercisePriceRangeFourMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeFourMember 2021-11-01 2022-07-31 0001100397 ADXS:ExercisePriceRangeFourMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2022-07-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2021-11-01 2022-07-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2020-11-01 2021-10-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 ADXS:WarrantLiabilityMember 2022-07-31 0001100397 ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember 2022-07-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember 2022-07-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember 2022-07-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:PrivatePlacementMember ADXS:InstitutionalInvestorsMember us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-01-31 0001100397 us-gaap:PrivatePlacementMember ADXS:InstitutionalInvestorsMember us-gaap:SeriesDPreferredStockMember 2021-11-01 2022-07-31 0001100397 us-gaap:SeriesDPreferredStockMember us-gaap:PrivatePlacementMember ADXS:InstitutionalInvestorsMember 2022-07-31 0001100397 us-gaap:SeriesDPreferredStockMember 2022-07-31 0001100397 2022-01-31 0001100397 2022-01-01 2022-01-31 0001100397 us-gaap:SeriesDPreferredStockMember 2022-04-06 0001100397 us-gaap:SeriesDPreferredStockMember 2022-04-04 2022-04-06 0001100397 ADXS:SeriesDConvertiblePreferredStockMember 2022-04-04 2022-04-06 0001100397 2022-04-06 0001100397 ADXS:SeriesDConvertiblePreferredStockMember 2022-04-06 0001100397 us-gaap:MeasurementInputExercisePriceMember 2022-04-06 0001100397 us-gaap:MeasurementInputExercisePriceMember 2022-01-31 0001100397 us-gaap:MeasurementInputSharePriceMember 2022-04-06 0001100397 us-gaap:MeasurementInputSharePriceMember 2022-01-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember 2022-04-06 0001100397 us-gaap:MeasurementInputPriceVolatilityMember 2022-01-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-04-06 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-01-31 0001100397 us-gaap:PreferredStockMember 2020-10-31 0001100397 us-gaap:CommonStockMember 2020-10-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0001100397 us-gaap:RetainedEarningsMember 2020-10-31 0001100397 us-gaap:PreferredStockMember 2020-11-01 2021-01-31 0001100397 us-gaap:CommonStockMember 2020-11-01 2021-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-11-01 2021-01-31 0001100397 us-gaap:RetainedEarningsMember 2020-11-01 2021-01-31 0001100397 2020-11-01 2021-01-31 0001100397 us-gaap:PreferredStockMember 2021-01-31 0001100397 us-gaap:CommonStockMember 2021-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001100397 us-gaap:RetainedEarningsMember 2021-01-31 0001100397 2021-01-31 0001100397 us-gaap:PreferredStockMember 2021-02-01 2021-04-30 0001100397 us-gaap:CommonStockMember 2021-02-01 2021-04-30 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-02-01 2021-04-30 0001100397 us-gaap:RetainedEarningsMember 2021-02-01 2021-04-30 0001100397 2021-02-01 2021-04-30 0001100397 us-gaap:PreferredStockMember 2021-04-30 0001100397 us-gaap:CommonStockMember 2021-04-30 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-04-30 0001100397 us-gaap:RetainedEarningsMember 2021-04-30 0001100397 us-gaap:PreferredStockMember 2021-05-01 2021-07-31 0001100397 us-gaap:CommonStockMember 2021-05-01 2021-07-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-05-01 2021-07-31 0001100397 us-gaap:RetainedEarningsMember 2021-05-01 2021-07-31 0001100397 us-gaap:PreferredStockMember 2021-07-31 0001100397 us-gaap:CommonStockMember 2021-07-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-07-31 0001100397 us-gaap:RetainedEarningsMember 2021-07-31 0001100397 us-gaap:PreferredStockMember 2021-10-31 0001100397 us-gaap:CommonStockMember 2021-10-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-10-31 0001100397 us-gaap:RetainedEarningsMember 2021-10-31 0001100397 us-gaap:PreferredStockMember 2021-11-01 2022-01-31 0001100397 us-gaap:CommonStockMember 2021-11-01 2022-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-11-01 2022-01-31 0001100397 us-gaap:RetainedEarningsMember 2021-11-01 2022-01-31 0001100397 2021-11-01 2022-01-31 0001100397 us-gaap:PreferredStockMember 2022-01-31 0001100397 us-gaap:CommonStockMember 2022-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001100397 us-gaap:RetainedEarningsMember 2022-01-31 0001100397 us-gaap:PreferredStockMember 2022-02-01 2022-04-30 0001100397 us-gaap:CommonStockMember 2022-02-01 2022-04-30 0001100397 us-gaap:AdditionalPaidInCapitalMember 2022-02-01 2022-04-30 0001100397 us-gaap:RetainedEarningsMember 2022-02-01 2022-04-30 0001100397 2022-02-01 2022-04-30 0001100397 us-gaap:PreferredStockMember 2022-04-30 0001100397 us-gaap:CommonStockMember 2022-04-30 0001100397 us-gaap:AdditionalPaidInCapitalMember 2022-04-30 0001100397 us-gaap:RetainedEarningsMember 2022-04-30 0001100397 2022-04-30 0001100397 us-gaap:PreferredStockMember 2022-05-01 2022-07-31 0001100397 us-gaap:CommonStockMember 2022-05-01 2022-07-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2022-05-01 2022-07-31 0001100397 us-gaap:RetainedEarningsMember 2022-05-01 2022-07-31 0001100397 us-gaap:PreferredStockMember 2022-07-31 0001100397 us-gaap:CommonStockMember 2022-07-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2022-07-31 0001100397 us-gaap:RetainedEarningsMember 2022-07-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2022-05-01 2022-07-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2021-05-01 2021-07-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2021-11-01 2022-07-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2020-11-01 2021-07-31 0001100397 srt:ChiefExecutiveOfficerMember 2022-07-31 0001100397 ADXS:DevelopmentLicenseAndSupplyAgreementMember ADXS:OSTherapiesMember 2020-04-29 2020-04-30 0001100397 ADXS:DevelopmentLicenseAndSupplyAgreementMember ADXS:OSTherapiesMember 2018-09-03 2018-09-04 0001100397 ADXS:DevelopmentLicenseAndSupplyAgreementMember ADXS:OSTherapiesMember 2021-04-25 2021-04-30 0001100397 ADXS:DevelopmentLicenseAndSupplyAgreementMember ADXS:OSTherapiesMember 2021-05-01 2021-05-31 0001100397 ADXS:GlobalBioPharmaIncMember us-gaap:LicenseAndServiceMember 2021-11-01 2022-07-31 0001100397 ADXS:GlobalBioPharmaIncMember us-gaap:LicenseAndServiceMember 2020-11-01 2021-07-31 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2022-07-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2022-07-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2022-07-31 0001100397 us-gaap:MoneyMarketFundsMember 2022-07-31 0001100397 us-gaap:FairValueInputsLevel1Member 2022-07-31 0001100397 us-gaap:FairValueInputsLevel2Member 2022-07-31 0001100397 us-gaap:FairValueInputsLevel3Member 2022-07-31 0001100397 us-gaap:FairValueInputsLevel1Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2022-07-31 0001100397 us-gaap:FairValueInputsLevel2Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2022-07-31 0001100397 us-gaap:FairValueInputsLevel3Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2022-07-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2022-07-31 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2021-10-31 0001100397 us-gaap:MoneyMarketFundsMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel1Member 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member 2021-10-31 0001100397 us-gaap:FairValueInputsLevel1Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-10-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:PrivatePlacementMember 2021-10-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2021-10-31 0001100397 ADXS:WarrantLiabilityMember 2021-10-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2021-11-01 2022-07-31 0001100397 ADXS:WarrantLiabilityMember 2021-11-01 2022-07-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2022-07-31 0001100397 ADXS:WarrantLiabilityMember 2022-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ADXS:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended July 31, 2022

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ________ to ________

 

Commission file number 001-36138

 

ADVAXIS, INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware   02-0563870
(State or other jurisdiction   (IRS Employer
of incorporation or organization)   Identification No.)
     
9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ   08852
(Address of principal executive offices)   (Zip Code)

 

(609) 452-9813
(Registrant’s telephone number)

 

Securities registered pursuant to Section 12(b) of the Act:

 

None.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such fling requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer   Accelerated Filer  
Non-accelerated Filer   Smaller Reporting Company  
Emerging growth company        

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

The number of shares of the registrant’s Common Stock, $0.001 par value, outstanding as of September 9, 2022 was 1,815,951.

 

 

 

 

 

 

TABLE OF CONTENTS

 

    Page No.
     
PART I FINANCIAL INFORMATION 5
     
Item 1. Financial Statements (unaudited) 5
     
  Condensed Consolidated Balance Sheets 5
     
  Condensed Consolidated Statements of Operations 6
     
  Condensed Consolidated Statements of Cash Flows 7
     
  Notes to the Condensed Consolidated Financial Statements 8
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 21
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 28
     
Item 4. Controls and Procedures 28
     
PART II OTHER INFORMATION 29
     
Item 1. Legal Proceedings 29
     
Item 1A. Risk Factors 29
     
Item 5. Other Information 29
     
Item 6. Exhibits 29
     
SIGNATURES 30

 

 2 
 

 

CAUTIONARY NOTE REGARDING FORWARD LOOKING-STATEMENTS

 

This quarterly report on Form 10-Q (“Form 10-Q”) of Advaxis, Inc. (the “Company”) includes statements that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, these forward-looking statements can be identified by the use of such terms as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or the negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Form 10-Q and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned discovery and development of drug candidates, the strength and breadth of our intellectual property, our ongoing and planned preclinical studies and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the degree of clinical utility of our product candidates, particularly in specific patient populations, expectations regarding clinical trial data, our results of operations, financial condition, our available cash, liquidity, prospects, growth and strategies, impacts of the ongoing coronavirus (“COVID-19”) pandemic, the ongoing conflict in the Ukraine, inflation and the Federal Reserve’s responses thereto, including increasing interest rates, the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect our industry or us.

 

By their nature, forward-looking statements involve risks and uncertainties because they relate to the occurrence and timing of events or circumstances, many of which are beyond the control of the Company. As a result of these, we cannot assure you that the forward-looking statements in this Form 10-Q will prove to be accurate. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Form 10-Q, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate, are consistent with the forward-looking statements contained in this Form 10-Q, they may not be predictive of results or developments in future periods.

 

Some of the material factors that we believe could cause actual results to differ from those anticipated or predicted include:

 

  the success and timing of our clinical trials, including patient accrual;
     
  our ability to obtain and maintain regulatory approval or reimbursement of our product candidates for marketing;
     
  our ability to obtain the appropriate labeling of our products under any regulatory approval;
     
  our ability to develop and commercialize our products;
     
  the successful development and implementation of our sales and marketing campaigns;
     
  the change of key scientific or management personnel;
     
  the size and growth of the potential markets for our product candidates and our ability to serve those markets;
     
  our ability to successfully compete in the potential markets for our product candidates, if commercialized;
     
  regulatory developments in the United States and foreign countries;

 

 3 
 

 

  new products, product candidates or new uses for existing products or technologies introduced or announced by our competitors and the timing of these introductions or announcements;
     
  market conditions in the pharmaceutical and biotechnology sectors;
     
  our available cash;
     
  the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;
     
  our ability to obtain additional funding;
     
  any outcomes from our review of strategic transactions and options to maximize stockholder value;
     
  the ability of our product candidates to successfully perform in clinical trials and to resolve any clinical holds that may occur;
     
  our ability to obtain and maintain approval of our product candidates for trial initiation;
     
  the performance of third-party manufacturers;
     
  our ability to identify license and collaboration partners and to maintain existing relationships;
     
  the performance of our clinical research organizations, clinical trial sponsors, clinical trial investigators and collaboration partners for any clinical trials we conduct;
     
  our ability to successfully implement our strategy;
     
  our ability to maintain the listing of our common stock on the OTCQX® Best Market (“OTCQX”); and
     
  the factors described in the “Risk Factors” section of the Company’s annual report on Form 10-K for the fiscal year ended October 31, 2021 (the “2021 Annual Report on Form 10-K”), as updated and amended in other filings by the Company with the Securities and Exchange Commission (the “SEC”).

 

You should also read carefully the factors described in the “Risk Factors” section of the 2021 Annual Report on Form 10-K. Any forward-looking statements that we make in this Form 10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Form 10-Q except as required by the federal securities laws.

 

This Form 10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data.

 

 4 
 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

ADVAXIS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

 

   July 31, 2022   October 31, 2021 
   (Unaudited)     
ASSETS          
Current assets:          
Cash and cash equivalents  $28,150   $41,614 
Prepaid expenses and other current assets   1,667    1,643 
Total current assets   29,817    43,257 
           
Property and equipment (net of accumulated depreciation)   73    118 
Intangible assets (net of accumulated amortization)   181    3,354 
Operating right-of-use asset (net of accumulated amortization)   19    40 
Other assets   11    11 
Total assets  $30,101   $46,780 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $90   $87 
Accrued expenses   1,510    2,836 
Current portion of operating lease liability   19    28 
Common stock warrant liability   287    4,929 
Total current liabilities   1,906    7,880 
           
Operating lease liability, net of current portion   -    12 
Total liabilities   1,906    7,892 
           
Contingencies – Note 8   -     -  
           
Series D convertible preferred stock- $0.001 par value; 0 shares authorized, 0 shares issued and outstanding at July 31, 2022 and October 31, 2021.   -    - 
           
Stockholders’ equity:          
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 0 shares issued and outstanding at July 31, 2022 and October 31, 2021.   -    - 
Common stock - $0.001 par value; 170,000,000 shares authorized, 1,815,951 and 1,820,452 shares issued and outstanding at July 31, 2022 and October 31, 2021.   2    2 
Additional paid-in capital   466,561    467,486 
Accumulated deficit   (438,368)   (428,600)
Total stockholders’ equity   28,195    38,888 
Total liabilities and stockholders’ equity  $30,101   $46,780 

 

The accompanying notes should be read in conjunction with the financial statements.

 

 5 
 

 

ADVAXIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(In thousands, except share and per share data)

 

   2022   2021   2022   2021 
   Three Months Ended
July 31,
   Nine Months Ended
July 31,
 
   2022   2021   2022   2021 
                 
Revenue  $-   $250   $250   $3,240 
                     
Operating expenses:                    
Research and development expenses   2,233    1,703    5,371    8,616 
General and administrative expenses   2,053    2,678    6,331    9,038 
Intangible asset impairment   3,005    -    3,005    - 
Total operating expenses   7,291    4,381    14,707    17,654 
                     
Loss from operations   (7,291)   (4,131)   (14,457)   (14,414)
                     
Other income (expense):                    
Interest income, net   50    1    57    3 
Net changes in fair value of derivative liabilities   276    846    4,685    1,814 
Other income (expense)   2    -    (3)   229 
Net loss before income taxes   (6,963)   (3,284)   (9,718)   (12,368)
                     
Income tax expense   -    50    50    50 
                     
Net loss  $(6,963)  $(3,334)  $(9,768)  $(12,418)
Accretion of discount and redemption feature of convertible preferred stock   -    -    (1,025)   - 
Income available to common stockholders   (6,963)   (3,334)   (10,793)   (12,418)
                     
Net loss per common share, basic and diluted  $(3.83)  $(1.83)  $(5.93)  $(8.04)
                     
Weighted average number of common shares outstanding   1,817,761    1,820,452    1,819,545    1,543,927 

 

The accompanying notes should be read in conjunction with the financial statements.

 

 6 
 

 

ADVAXIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

(In thousands)

 

   2022   2021 
   Nine Months Ended
July 31,
 
   2022   2021 
         
OPERATING ACTIVITIES          
Net loss  $(9,768)  $(12,418)
Adjustments to reconcile net loss to net cash used in operating activities:          
Share based compensation   74    511 
Gain on change in value of warrants   (4,642)   (1,814)
Gain on change in value of preferred stock redemption liability   (43)   - 
Loss on disposal of property and equipment   -    1,530 
Abandonment of intangible assets   159    90 
Impairment charges on intangible assets   3,005    - 
Depreciation expense   45    366 
Amortization expense of intangible assets   210    203 
Amortization of right-of-use asset   21    327 
Net gain on write-off of right-of-use asset and lease liability   -    (116)
Change in operating assets and liabilities:          
Prepaid expenses, other current assets and deferred expenses   (24)   488 
Other assets   -    171 
Accounts payable and accrued expenses   (1,323)   513 
Deferred revenue   -    (165)
Operating lease liabilities   (21)   (1,389)
Net cash used in operating activities   (12,307)   (11,703)
           
INVESTING ACTIVITIES          
Proceeds from disposal of property and equipment   -    219 
Cost of intangible assets   (201)   (323)
Net cash used in investing activities   (201)   (104)
           
FINANCING ACTIVITIES          
Net proceeds of issuance of Series D preferred stock   4,312    - 
Net proceeds of issuance of common stock and warrants   -    28,115 
Fractional shares cashed out   (18)   - 
Redemption of Series D preferred stock   (5,250)   - 
Warrant exercises   -    3,771 
Net cash (used in) provided by financing activities   (956)   31,886 
           
Net (decrease) increase in cash and cash equivalents   (13,464)   20,079 
Cash and cash equivalents at beginning of period   41,614    25,178 
Cash and cash equivalents at end of period  $28,150   $45,257 
           
SUPPLEMENTAL CASH FLOW INFORMATION          
Cash paid for taxes  $50   $50 
           
SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES          
Reclassification of preferred stock redemption liability into equity upon redemption of preferred stock   44    - 
Accretion of discount and redemption feature of convertible preferred stock   1,025    - 

 

The accompanying notes should be read in conjunction with the financial statements.

 

 7 
 

 

ADVAXIS, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

1. NATURE OF OPERATIONS

 

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (“Lm”)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm TechnologyTM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:

 

  Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;
     
  Attacking the tumor by generating a strong, cancer-specific T cell response; and
     
  Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

 

Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.

 

COVID-19

 

On March 11, 2020, the World Health Organization characterized the outbreak of the novel coronavirus (“COVID-19”) as a global pandemic and recommended containment and mitigation measures. Since then, extraordinary actions have been taken by international, federal, state, and local public health and governmental authorities to contain and combat the outbreak and spread of COVID-19 in regions throughout the world. The continued impact of the COVID-19 pandemic cannot be predicted at this time.

 

Liquidity and Capital Resources

 

Liquidity and Management’s Plans

 

Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future.

 

As of July 31, 2022, the Company had approximately $28.2 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least one year from the issuance of these consolidated financial statements, the actual amount of cash that it will need to operate is subject to many factors.

 

The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

 

 8 
 

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

 

Basis of Presentation/Estimates

 

The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed consolidated balance sheet as of July 31, 2022 has been derived from the Company’s October 31, 2021 audited financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.

 

Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.

 

These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2021 and notes thereto contained in the Company’s 2021 Annual Report on Form 10-K, as filed with the SEC on February 14, 2022.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

 

Restricted Cash

 

On January 31, 2022, the Company transferred $5,250,000 into an escrow fund to fund a potential Series D preferred stock redemption. On April 6, 2022, the Series D convertible preferred stock was redeemed utilizing the entire amount held in the escrow fund.

 

Convertible Preferred Stock

 

Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (“mezzanine”) until such time as the conditions are removed or lapse.

 

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For share-based derivative financial instruments, the Company used the Monte Carlo simulation model, the Black Scholes model and a binomial model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months after the balance sheet date.

 

 9 
 

 

Net Income (Loss) per Share

 

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:

 

   2022   2021 
   As of July 31, 
   2022   2021 
Warrants   377,818    377,818 
Stock options   11,118    12,892 
Total   388,936    390,710 

 

Reverse Stock Split

 

On March 31, 2022, the Company’s stockholders voted to approve an amendment to allow the Company to execute a reverse stock split of common stock within a range of 1 for 20 to 1 for 80, without reducing the authorized number of shares of the common stock, at the discretion of the Board of Directors. On June 3, 2022, the Board of Directors approved a 1 for 80 reverse stock split, which became effective on June 6, 2022. All references in this Report to number of shares, price per share and weighted average number of shares of common stock outstanding prior to this reverse stock split have been adjusted to reflect the reverse stock split on a retroactive basis, unless otherwise noted.

 

Recent Accounting Standards

 

In December 2019, the FASB issued ASU 2019-12, Simplification of Income Taxes (Topic 740) Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

 

In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share (“EPS”) calculations as a result of these changes. The standard will be effective for the Company for fiscal years beginning after December 15, 2023 and can be applied on either a fully retrospective or modified retrospective basis. Early adoption is permitted for fiscal years beginning after December 15, 2020. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

 

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.

 

3. PROPERTY AND EQUIPMENT

 

Property and equipment, net consisted of the following (in thousands):

 

   July 31, 2022   October 31, 2021 
Laboratory equipment  $179   $179 
Computer equipment   241    241 
Total property and equipment   420    420 
Accumulated depreciation   (347)   (302)
Net property and equipment  $73   $118 

 

Depreciation expense for the three months ended July 31, 2022 and 2021 was approximately $13,000 and $50,000, respectively. Depreciation expense for the nine months ended July 31, 2022 and 2021 was approximately $45,000 and $366,000, respectively. During the nine months ended July 31, 2021, the Company incurred a loss on disposal of equipment of approximately $1,530,000, $968,000 of which is reflected in the research and development expenses and $562,000 of which is reflected in the general and administrative expenses in the condensed consolidated statement of operations.

 

 10 
 

 

4. INTANGIBLE ASSETS

 

Intangible assets, net consisted of the following (in thousands):

 

   July 31, 2022   October 31, 2021 
         
Patents  $275   $4,836 
License   44    777 
Software   98    98 
Total intangibles   417    5,711 
Accumulated amortization   (236)   (2,357)
Intangible assets  $181   $3,354 

 

The expiration dates of the existing patents range from 2022 to 2039 but the expiration dates can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to further pursue the application. Patent applications having a net book value of approximately $29,000 and $21,000 were abandoned and were charged to general and administrative expenses in the condensed consolidated statement of operations for the three months ended July 31, 2022 and 2021, respectively. Patent applications having a net book value of approximately $159,000 and $90,000 were abandoned and were charged to general and administrative expenses in the condensed consolidated statement of operations for the nine months ended July 31, 2022 and 2021, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the condensed consolidated statement of operations aggregated approximately $70,000 and $68,000 for the three months ended July 31, 2022 and 2021, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the condensed consolidated statement of operations aggregated approximately $210,000 and $203,000 for the nine months ended July 31, 2022 and 2021, respectively.

 

Management reviews its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents related to ADXS-HPV (AXAL), ADXS-HOT, ADXS-PSA, ADXS-HER2 and other products that are in development, and the Lm technology licensed from the University of Pennsylvania. There are various scenarios under which an impairment charge may be recorded, which include if a competitor were to gain FDA approval for a similar treatment before the Company, if future clinical trials fail to meet the targeted endpoints, or if a drug application is rejected or fails to be issued. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets.

 

During the three months ended July 31, 2022, the Company identified the following indicators of impairment under ASC 360 indicating that the patents and license carrying amounts might not be recoverable:

 

  Adverse changes in the business climate for biotechnology companies, particularly raising capital; and
  A significant reduction in the Company’s market capitalization during the nine months ended July 31, 2022.

 

The Company performed an impairment test under ASC 350 on its patents owned and in-licensed intellectual property. Under this test a fair value of the relevant asset is compared with the carrying amount of such asset. Fair value is calculated using a discounted cash flow analysis. Cash flows are discounted using a weighted average cost of capital derived from comparable companies, which reflects the costs of borrowing as well as the associated risk. The results of the impairment test indicated that the carrying value of the patents owned and in-licensed intellectual property exceeded the fair value. During the three months ended July 31, 2022, the Company recorded an impairment charge for patents owned and in-licensed intellectual property of approximately $3,005,000 in its condensed consolidated statement of operations.

 

 11 
 

 

As of July 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

 

    Fiscal year ending October 31, 
      
2022 (Remaining)   $24 
2023    94 
2024    63 
Total   $181 

 

5. ACCRUED EXPENSES:

 

The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):

  

   July 31, 2022   October 31, 2021 
         
Salaries and other compensation  $116   $55 
Vendors   851    1,968 
Professional fees   343    613 
Other   200    200 
Total accrued expenses  $1,510   $2,836 

 

6. LEASES

 

Operating Leases

 

The Company previously leased a corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that was set to expire in November 2025. On March 26, 2021, the Company entered into a Lease Termination and Surrender Agreement with respect to this lease agreement. The Lease Termination and Surrender Agreement provides for the early termination of the lease, which became effective on March 31, 2021. In connection with the early termination of the lease, the Company was required to pay a $1,000,000 termination payment. The unapplied security deposit totaling approximately $182,000 was credited against the termination fee for a net payment of approximately $818,000. The Company wrote off of the remaining right-of-use asset of approximately $4,512,000 and lease liability of approximately $5,628,000. After consideration of the termination payment and write off of the remaining right-of-use asset and lease liability, the Company recorded a net gain of approximately $116,000.

 

On March 25, 2021, the Company entered into a new one-year lease agreement for its corporate office/lab with base rent of approximately $29,000 per year, plus other expenses. This lease was accounted for as a short-term lease at inception, and the Company elected not to recognize a right-of-use asset and lease liability. In September 2021, the Company exercised its option to renew the lease, extending the lease term until March 25, 2023. Since the renewed lease term exceeded one-year, the lease no longer qualified for the short-term lease exception, resulting in the recognition of a right-of-use asset and operating lease liability of approximately $43,000.

 

Supplemental balance sheet information related to leases was as follows (in thousands):

  

   July 31, 2022   October 31, 2021 
Operating leases:           
Operating lease right-of-use assets  $19   $40 
           
Operating lease liability  $19   $28 
Operating lease liability, net of current portion   -    12 
Total operating lease liabilities  $19   $40 

 

 12 
 

 

Supplemental lease expense related to leases was as follows (in thousands):

  

Lease Cost (in thousands)  Statements of Operations Classification 

For the Three

Months Ended

July 31, 2022

  

For the Nine

Months Ended

July 31, 2022

 
Operating lease cost  General and administrative  $7   $22 
Variable lease cost  General and administrative   17    36 
Total lease expense     $24   $58 

 

Lease Cost (in thousands)  Statements of Operations Classification 

For the Three

Months Ended

July 31, 2021

  

For the nine

Months Ended

July 31, 2021

 
Operating lease cost  General and administrative  $-   $1,301 
Short-term lease cost  General and administrative   12    16 
Variable lease cost  General and administrative   4    165 
Total lease expense     $16   $1,482 

 

Other information related to leases where the Company is the lessee is as follows:

 

   July 31, 2022   October 31, 2021 
Weighted-average remaining lease term  0.7 years   1.4 years 
Weighted-average discount rate   3.79%   3.79%

 

Supplemental cash flow information related to operating leases was as follows:

 

  

For the Nine

Months Ended

July 31, 2022

  

For the Nine

Months Ended

July 31, 2021

 
Cash paid for operating lease liabilities  $22   $1,363 

 

Future minimum lease payments under non-cancellable leases as of July 31, 2022 were as follows:

 

      
Fiscal Year ending October 31,    
2022 (Remaining)  $7 
2023   13 
Total minimum lease payments   20 
Less: Imputed interest   1 
Total  $19 

 

 13 
 

 

7. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

 

Warrants

 

As of July 31, 2022 and October 31, 2021, there were outstanding and exercisable warrants to purchase 377,818 shares of our common stock with exercise prices ranging from $20.00 to $224.00 per share. Information on the outstanding warrants is as follows:

 

Exercise Price  

Number of

Shares

Underlying

Warrants

   Expiration Date  Type of Financing
$20.00    879   September 2024  September 2018 Public Offering
$224.00    4,092   July 2024  July 2019 Public Offering
$28.00    57,230   November 2025  November 2020 Public Offering
$56.00    140,552   April 2026  April 2021 Registered Direct Offering (Accompanying Warrants)
$56.00    175,065   5 years after the date such warrants become exercisable, if ever  April 2021 Private Placement (Private Placement Warrants)
 Grand Total    377,818       

 

As of July 31, 2022 and October 31, 2021, the Company had 201,874 of its total 377,818 outstanding warrants classified as equity (equity warrants).

 

Warrant Liability

 

As of July 31, 2022 and October 31, 2021, the Company had 175,944 of its total 377,818 outstanding warrants from an April 2021 private offering of common stock and warrants (the “April 2021 Private Placement”) and a September 2018 public offering of common stock and warrants (the “September 2018 Public Offering”) classified as liabilities (liability warrants).

 

The warrants issued in the April 2021 Private Placement will become exercisable only on such day, if ever, that is 14 days after the Company files an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares. These warrants expire five years after the date they become exercisable. As of July 31, 2022, the Company did not have sufficient authorized common stock to allow for the issuance of common stock underlying these warrants. The Company did not receive stockholder authorization to increase the authorized shares from 170,000,000 to 300,000,000 shares at the stockholder’s meeting commenced on June 3, 2021. The Company was subsequently required to file a proxy to seek an increase in the number of authorized shares and did not file such a proxy but rather elected to seek a reverse stock split to, among other things, increase the shares available. Accordingly, based on certain indemnification provisions of the securities purchase agreement, the Company concluded that liability classification is warranted. The Company utilized the Black Scholes model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

 

In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at July 31, 2022 and October 31, 2021, the Company used the following inputs in its Black Scholes model:

  

   July 31, 2022   October 31, 2021 
Exercise Price  $56.00   $56.00 
Stock Price  $3.73   $38.80 
Expected Term   5.00 years    5.00 years 
Volatility %   112%   106%
Risk Free Rate   2.70%   1.18%

 

The September 2018 Public Offering warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of July 31, 2022, the down round feature was triggered four times and the exercise price of the warrants were reduced from $1,800.00 to $20.00. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

 

 14 
 

 

In measuring the warrant liability for the September 2018 Public Offering warrants at July 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:

 

   July 31, 2022   October 31, 2021 
Exercise Price  $20.00   $24.00 
Stock Price  $3.73   $38.80 
Expected Term   2.12 years    2.87 years 
Volatility %   104%   123%
Risk Free Rate   2.89%   0.77%

 

At July 31, 2022 and October 31, 2021, the fair value of the warrant liability was approximately $287,000 and $4,929,000, respectively. For the three months ended July 31, 2022 and 2021, the Company reported income of approximately $276,000 and $846,000, respectively, due to changes in the fair value of the warrant liability. For the nine months ended July 31, 2022 and 2021, the Company reported income of approximately $4,642,000 and $1,814,000, respectively, due to changes in the fair value of the warrant liability.

 

8. COMMITMENTS AND CONTINGENCIES

 

Atachbarian

 

On November 15, 2021, a purported stockholder of the Company commenced an action against the Company and certain of its directors in the U.S. District Court for the District of New Jersey, entitled Atachbarian v. Advaxis, Inc., et al., No. 3:21-cv-20006. The plaintiff alleges that the defendants breached their fiduciary duties and violated Section 14(a) and Rule 20(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder by allegedly failing to disclose certain matters in its Registration Statement on Form S-4 (Commission File No. 333-259065 (the “Registration Statement”) filed in connection with a proposed merger with Biosight Ltd. (the “Previously Proposed Merger”). On December 15, 2021, pursuant to an understanding reached with the plaintiff, the Company made certain other additional disclosures that mooted the demands asserted in the complaint. On December 17, 2021, the plaintiff filed a notice of voluntary dismissal with prejudice. On February 7, 2022, the Company and the plaintiff reached a settlement agreement, which is recorded in general and administrative expenses in the condensed consolidated statement of operations.

 

Purported Stockholder Claims Related to Biosight Transaction

 

Between September 16, 2021, and November 4, 2021, the Company received demand letters on behalf of six purported stockholders of the Company, alleging that the Company failed to disclose certain matters in the Registration Statement, and demanding that the Company disclose such information in a supplemental disclosure filed with the SEC. On October 14, 2021, the Company filed an amendment to the Registration Statement and on November 8, 2021, the Company made certain other additional disclosures that mooted the demands asserted in the above-referenced letters. The six plaintiffs have made settlement demands. On May 20, 2022, the Company and one of the plaintiffs have reached a settlement agreement, which is recorded in general and administrative expenses in the condensed consolidated statement of operations. The Company believes it has adequately accrued for settlements with the other five shareholders, which is recorded in accrued expenses in the condensed consolidated balance sheet.

 

In addition, the Company received certain additional demands from stockholders asserting that the proxy materials filed by the Company in connection with the Previously Proposed Merger contained alleged material misstatements and/or omissions. Certain stockholders also demanded books and records of the Company pursuant to Delaware law. In response to these demands, the Company agreed to make, and did make, certain supplemental disclosures to the proxy materials. The stockholders have made settlement demands. On July 18, 2022, the Company and the plaintiffs reached settlement agreements, which is recorded in general and administrative expenses in the condensed consolidated statement of operations.

 

 15 
 

 

Purported Stockholder Claims Related to Series D Convertible Preferred Stock Offering

 

On February 17, 2022, the Company received a letter on behalf of purported stockholders of the Company, demanding certain books and records pursuant to Delaware law regarding the proposed issuance of super voting preferred stock. The Company agreed to provide certain books and records to the stockholders and agreed to make, and did make, a supplemental disclosure to the proxy materials. The stockholders have made settlement demands. On July 18, 2022, the Company and the plaintiffs reached settlement agreements, which is recorded in general and administrative expenses in the condensed consolidated statement of operations.

 

9. TEMPORARY EQUITY

 

Series D Convertible Preferred Stock Offering

 

On January 31, 2022, the Company consummated an offering with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock (the “Series D Preferred Stock”). The shares, which have since been redeemed in accordance with their terms as described below, and are thus no longer outstanding as of July 31, 2022, had an aggregate stated value of $5,000,000. Each share of the Series D preferred stock had a purchase price of $4.75, representing an original issue discount of 5% of the stated value. The shares of Series D Preferred Stock were convertible into shares of the Company’s common stock, upon the occurrence of certain events, at a conversion price of $20.00 per share. The conversion, at the option of the stockholder, could occur at any time following the receipt of the stockholders’ approval for a reverse stock split. The Company was permitted to compel conversion of the Series D Preferred Stock after the fulfillment of certain conditions and subject to certain limitations. The Series D Preferred Stock also had a liquidation preference over the shares of common stock, and could be redeemed by the investors, in accordance with certain terms, for a redemption price equal to 105% of the stated value, or in certain circumstances, 110% of the stated value. Total net proceeds from the offering, after deducting the financial advisor’s fees and other estimated offering expenses, were approximately $4.3 million.

 

Since the Series D preferred stock had a redemption feature at the option of the holder, it was classified as temporary equity. At the January 31, 2022 issuance date, the Series D preferred stock was recorded on the balance sheet at approximately $4,225,000, which is the $4,312,000 net proceeds less the $87,000 value of the bifurcated preferred stock redemption liability (see below).

 

On April 6, 2022, the holders of all 1,000,000 outstanding shares of the Series D Preferred Stock exercised their right to cause the Company to redeem all of such shares at a price per share equal to 105% of the stated value per share of $5.00, and such shares were redeemed accordingly. The $1,025,000 accretion of the Series D convertible preferred stock to its redemption value was recorded as a reduction in additional paid-in capital (see Note 10).

 

Preferred Stock Redemption Liability

 

The Company evaluated the preferred stock redemption feature under ASC 815. Since the preferred stock redemption feature is not considered to be clearly and closely related to the preferred stock host and the redemption feature meets the four characteristics of a derivative under ASC 815, the preferred stock redemption feature is required to be bifurcated from the preferred stock host and valued as a liability. The Company utilized a binomial model to calculate the fair value of the preferred stock redemption feature at issuance.

 

In measuring the preferred stock redemption liability at April 6, 2021 (redemption date) and January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:

 

   April 6, 2022   January 31, 2022 
Exercise Price  $20.00   $20.00 
Stock Price  $9.04   $10.88 
Volatility %   96%   105%
Risk Free Rate   1.25%   1.00%

 

At April 6, 2022 and January 31, 2022, the fair value of the preferred stock redemption liability was approximately $44,000 and $87,000, respectively. On April 6, 2022, the Series D convertible preferred stock was redeemed, and the $44,000 preferred stock redemption liability was reclassified into other paid-in capital (see Note 10). For the three months and nine months ended July 31, 2022, the Company reported income of approximately $0 and $44,000, respectively, due to a change in the fair value of the preferred stock redemption liability.

 

 16 
 

 

10. STOCKHOLDERS’ EQUITY

 

A summary of the changes in stockholders’ equity for the nine months ended July 31, 2022 and 2021 is presented below (in thousands, except share data):

   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
   Preferred Stock   Common Stock   Additional Paid-In   Accumulated   Total  Shareholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at November 1, 2020   -   $-    975,897   $2   $440,916   $(410,738)  $30,180 
Stock-based compensation         -           -    -           -    236    -    236 
Advaxis public offerings, net of offering costs   -    -    383,333    -    8,550    -    8,550 
Warrant exercises   -    -    92,375    -    2,586    -    2,586 
Net loss   -    -    -    -    -    (3,977)   (3,977)
Balance at January 31, 2021   -   $-    1,451,605   $2   $452,288   $(414,715)  $37,575 
Stock-based compensation   -    -    69    -    215    -    215 
Stock option exercises   -    -    4    -    -    -    - 
Advaxis public offerings, net of offering costs   -    -    230,794    -    13,683    -    13,683 
Warrant exercises   -    -    137,968    -    1,185    -    1,185 
Issuance of shares to employees under ESPP Plan   -    -    12    -    -    -    - 
Net loss   -    -    -    -    -    (5,107)   (5,107)
Balance at April 30, 2021   -   $-    1,820,452   $2   $467,371   $(419,822)  $47,551 
Stock-based compensation   -    -    -    -    60    -    60 
Net loss   -    -    -    -    -    (3,334)   (3,334)
Balance at July 31, 2021   -   $-    1,820,452   $2   $467,431   $(423,156)  $44,277 

 

   Preferred Stock   Common Stock   Additional Paid-In   Accumulated   Total  Shareholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at November 1, 2021   -   $-    1,820,452   $2   $467,486   $(428,600)  $38,888 
Stock-based compensation          -           -    -             -    26    -    26 
Net loss   -    -    -    -    -    (365)   (365)
Balance at January 31, 2022   -   $-    1,820,452   $2   $467,512   $(428,965)  $38,549 
Stock-based compensation   -    -    -    -    23    -    23 
Accretion of discount and redemption feature of convertible preferred stock   -    -    -    -    (1,025)   -    (1,025)
Convertible preferred stock redemption   -    -    -    -    44    -    44 
Net loss   -    -    -    -    -    (2,440)   (2,440)
Balance at April 30, 2022   -   $-    1,820,452   $2   $466,554   $(431,405)  $35,151 
Stock-based compensation   -    -    -    -    25    -    25 
Fractional shares cashed out   -    -    (4,501)   -    (18)   -    (18)
Net loss   -    -    -    -    -    (6,963)   (6,963)
Balance at July 31, 2022   -    -    1,815,951    2    466,561    (438,368)   28,195 

 

 17 
 

 

11. SHARE BASED COMPENSATION

 

The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):

   2022   2021   2022   2021 
  

Three Months Ended

July 31,

  

Nine Months Ended

July 31,

 
   2022   2021   2022   2021 
Research and development  $12   $29   $36   $142 
General and administrative   13    31    38    369 
Total  $25   $60   $74   $511 

 

Stock Options

 

A summary of changes in the stock option plan for the nine months ended July 31, 2022 is as follows:

 

   Shares  

Weighted Average Exercise

Price

   Weighted Average Remaining Contractual Life In Years   Aggregate Intrinsic Value (in thousands) 
Outstanding as of October 31, 2021   11,192   $1,550.26    7.80   $34 
Cancelled or expired   (74)   22,200.00           
Outstanding as of July 31, 2022   11,118   $1,412.82    7.06   $       - 
Vested and exercisable at July 31, 2022   7,490   $2,077.20    6.64   $- 

 

The following table summarizes information about the outstanding and exercisable options at July 31, 2022:

  

Options Outstanding  Options Exercisable 
       Weighted   Weighted       Weighted   Weighted 
       Average   Average       Average   Average 
Exercise  Number   Remaining   Exercise   Number   Remaining   Exercise 
Price Range  Outstanding   Contractual   Price   Exercisable   Contractual   Price 
$ 24.00-$50.00   4,241    7.86   $32.53    1,964    7.69   $30.40 
$ 50.01-$100.00   4,174    7.74   $53.33    2,824    7.73   $53.58 
$ 100.01-20,664.00   2,703    4.75   $5,677.84    2,703    4.75   $5,677.84 

 

As of July 31, 2022, there was approximately $77,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 0.94 years.

 

Potential Acceleration of Stock Options

 

In the event of a merger transaction, similar to the Previously Proposed Merger Agreement, all of the Chief Executive Officer’s 624 unvested stock options as of July 31, 2022, pursuant to his employment agreement, would accelerate.

 

 18 
 

 

12. LICENSING AGREEMENTS

 

OS Therapies LLC

 

On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieved its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis initiated the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.

 

In December 2020 and January 2021, the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement and recorded $1,615,000 in revenue. The Company therefore transferred, and OST took full ownership of, the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development.

 

In April 2021, the Company achieved the second milestone set forth in the license agreement for evaluation in the treatment of osteosarcoma in humans and recorded $1,375,000 in revenue. The Company received the amount due from OS Therapies of $1,375,000 in May 2021.

 

Global BioPharma Inc.

 

On December 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of axalimogene filolisbac with Global BioPharma, Inc. (“GBP”), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC). During each of the nine months ended July 31, 2022 and 2021, the Company recorded $250,000 in revenue for the annual license fee renewal. Since Advaxis has no significant obligation to perform after the license transfer and has provided GBP with the right to use its intellectual property, performance is satisfied when the license renews.

 

13. FAIR VALUE

 

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

 

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

 

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

 

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

 

 19 
 

 

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of July 31, 2022 and October 31, 2021 (in thousands):

   Level 1   Level 2   Level 3   Total 
Fair Value Measured at July 31, 2022
   Level 1   Level 2   Level 3   Total 
Financial assets at fair value:                    
Cash equivalents (money market funds)  $17,183   $-   $-   $17,183 
Total Financial Assets at Fair Value  $17,183   $-   $-   $17,183 
                     
Financial liabilities at fair value:                    
Common stock warrant liability, warrants exercisable at $20.00 through September 2024  $-   $            -   $2   $2 
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)   -    -    285    285 
Total financial liabilities at fair value  $-   $-   $287   $287 

 

   Level 1   Level 2   Level 3   Total 
Fair Value Measured at October 31, 2021
   Level 1   Level 2   Level 3   Total 
Financial assets at fair value:                    
Cash equivalents (money market funds)  $17,153   $-   $-   $17,153 
Total Financial Assets at Fair Value  $17,153   $-   $-   $17,153 
                     
Financial liabilities at fair value:                    
Common stock warrant liability, warrants exercisable at $24.00 through September 2024  $-   $          -   $27   $27 
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)   -    -    4,902    4,902 
Total financial liabilities at fair value  $-   $-   $4,929   $4,929 

 

The following table presents changes in Level 3 liabilities measured at fair value (in thousands) for the nine months ended July 31, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.

 

             
  

Preferred

Stock

Redemption

Liability

  

Warrant

Liabilities

   Total 
Fair value at October 31, 2021  $-   $4,929   $4,929 
Additions   87    -    87 
Change in fair value   (43)   (4,642)   (4,685)
Redemption   (44)   -    (44)
Fair value at July 31, 2022  $-   $287   $287 

 

 

 20 
 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis contains forward-looking statements about our plans and expectations of what may happen in the future. Forward-looking statements are based on a number of assumptions and estimates that are inherently subject to significant risks and uncertainties, and our results could differ materially from the results indicated by our forward-looking statements as a result of many known or unknown factors, including, but not limited to, those factors discussed in Part I Item 1A. “Risk Factors” in our 2021 Annual Report on Form 10-K, below in Part II Item 1A. “Risk Factors” of this Form 10-Q and in the “Cautionary Note Regarding Forward-Looking Statements” set forth at the beginning of this report.

 

You should read the following discussion and analysis in conjunction with the unaudited financial statements, and the related footnotes thereto, appearing elsewhere in this Form 10-Q, and in conjunction with management’s discussion and analysis and the audited financial statements included in our Annual Report on Form 10-K. In addition, we intend to use our media and investor relations website (www.advaxis.com/investor-relations), SEC filings, press releases, public conference calls and webcasts to communicate with the public about Advaxis, its services and other issues.

 

Overview

 

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm Technology antigen delivery products based on a platform technology that utilizes live attenuated Listeria monocytogenes, or Lm, bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy by accessing and directing antigen presenting cells to stimulate anti-tumor T cell immunity, stimulate and activate the innate immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the Tumor Microenvironment, or TME, to enable the T cells to attack tumor cells.

 

The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, our product candidates (i.e., ADXS-PSA, ADXS-503 and ADXS-504) have the potential to optimize, enhance checkpoint performance of other oncology treatments, while having a generally well-tolerated safety profile.

 

Advaxis is currently winding down or has wound down clinical studies of Lm Technology immunotherapies in three program areas:

 

  Human Papilloma Virus (“HPV”)-associated cancers
  Personalized neoantigen-directed therapies
  Human epidermal growth factor receptor-2 (HER-2) associated cancers

 

All these clinical program areas are anchored in the Company’s Lm TechnologyTM, a unique platform designed for its ability to safely and effectively target various cancers in multiple ways. While we are currently winding down clinical studies of Lm Technology immunotherapies in these three program areas, our license agreements continue with OS Therapies, LLC for ADXS-HER2 and with Global BioPharma, or GBP, for the exclusive license for the development and commercialization of ADXS-HPV, or AXAL, in Asia, Africa, and the former USSR territory, exclusive of India and certain other countries.

 

Recent Developments

 

COVID-19 Impact

 

In response to the ongoing novel coronavirus (“COVID-19”) pandemic, the Company implemented remote working and thus far, has not experienced a significant disruption or delay in its operations as it relates to the clinical development or drug production of our drug candidates by third parties. We continue to monitor the COVID-19 pandemic and take steps intended to mitigate the potential risks to our workforce and our operations. The COVID-19 pandemic has, and may continue to, directly or indirectly affect the pace of enrollment in our clinical trials as patients may avoid or may not be able to travel to healthcare facilities and physicians’ offices unless due to a health emergency and clinical trial staff can no longer get to the clinic. Nonetheless, thus far, the COVID-19 pandemic has not had a significant impact on our business or results of operations. However, we remain in contact with the clinical sites in our study and are in discussion with additional sites to combat any potential impact in enrollment. We are unable to determine or predict the extent, duration or scope of the overall impact of the COVID-19 pandemic on our business, operations, financial condition or liquidity.

 

 21 
 

 

Results of Operations for the Three Months Ended July 31, 2022 and 2021

 

Revenue

 

Revenue was $0 for the three months ended July 31, 2022 compared to $250,000 for the three months ended July 31, 2021. In the prior period, we received the annual licensing fee from GBP.

 

Research and Development Expenses

 

We invest in research and development to advance our Lm technology through our pre-clinical and clinical development programs. Research and development expenses for the three months ended July 31, 2022 and July 31, 2021 were categorized as follows (in thousands):

 

  

Three Months Ended

July 31,

  

Increase

(Decrease)

 
   2022   2021   $   % 
                 
Hotspot/Off-the-Shelf therapies  $1,271   $546   $725    133%
Prostate cancer   32    113    (81)   (72)%
HPV-associated cancers   247    420    (173)   (41)%
Personalized neoantigen-directed therapies   -    7    (7)   (100)%
Other expenses   683    617    66    11%
Total research & development expense  $2,233   $1,703   $530    31%
                     
Stock-based compensation expense included in research and development expense  $12   $29   $(17)   (59)%

 

Hotspot/Off-the-Shelf Therapies (ADXS-HOT)

 

Research and development costs associated with our hotspot mutation-based therapy for the three months ended July 31, 2022 increased approximately 133% to $1,271,000 compared to the same period in 2021. The increase is attributable to patient recruitment costs and manufacturing costs pertaining to the ADXS-503 study incurred in the current period.

 

Prostate Cancer (ADXS-PSA)

 

Research and development costs associated with our prostate cancer therapy for the three months ended July 31, 2022 decreased 72% to $32,000 compared to the same period in 2021. The study has been completed and we do not anticipate that we will continue to incur significant costs associated with the wind down of the study.

 

HPV-Associated Cancers (AXAL)

 

The majority of the HPV-associated research and development costs include clinical trial and other related costs associated with our AXAL programs in cervical and head and neck cancers. HPV-associated costs for the three months ended July 31, 2022 decreased approximately $173,000, or 41%, compared to the same period in 2021. The decrease is attributable to wind down costs associated with the closure of our Phase 3 AIM2CERV study in high-risk locally advanced cervical cancer. We do not anticipate that we will continue to incur significant costs associated with the wind down of our Phase 3 AIM2CERV study.

 

 22 
 

 

Personalized Neoantigen-Directed Therapies (ADXS-NEO)

 

Research and development costs associated with personalized neoantigen-directed therapies for the three months ended July 31, 2022 decreased approximately $7,000 compared to the same period in 2021. The study has been completed and we do not anticipate that we will continue to incur significant costs associated with the wind down of the study.

 

Other Expenses

 

Other expenses include salary and benefit costs, stock-based compensation expense, professional fees, laboratory costs and other internal and external costs associated with our research & development activities. Other expenses for the three months ended July 31, 2022 increased approximately $66,000, or 11%, compared to the same period in 2021. The increase was not significant.

 

General and Administrative Expenses

 

General and administrative expenses primarily include salary and benefit costs and stock-based compensation expense for employees included in our finance, legal and administrative organizations, outside legal and professional services, and facilities costs. General and administrative expenses for the three months ended July 31, 2022 and July 31, 2021 were as follows (in thousands):

 

  

Three Months Ended

July 31,

  

Increase

(Decrease)

 
   2022   2021   $   % 
                 
General and administrative expense  $2,053   $2,678   $(625)   (23)%
                     
Stock-based compensation expense included in general and administrative expense  $13   $31   $(18)   (58)%

 

General and administrative expenses for the three months ended July 31, 2022 decreased approximately $625,000, or 23%, compared to the same period in 2021. This decrease primarily relates to (1) legal and consulting fees related to the Previously Proposed Merger in the prior period and (2) the annual meeting proxy solicitation fees in the prior period. Those decreases were partially offset by an increase in amounts paid in settlement of shareholder demand letters in the current period.

 

Intangible Asset Impairment

 

During the three months ended July 31, 2022, the Company recorded an impairment charge under ASC 350 for its patents owned and in-licensed intellectual property of approximately $3,005,000.

 

Changes in Fair Values

 

For the three months ended July 31, 2022, we recorded non-cash income from changes in the fair value of derivative liabilities of approximately $276,000. The decrease in the derivative liabilities is attributable to a decrease in our share price from $6.56 at April 30, 2022 to $3.73 at July 31, 2022.

 

For the three months ended July 31, 2021, we recorded non-cash income from changes in the fair value of the warrant liability of approximately $0.8 million. The decrease in the fair value of liability warrants resulted from resulted from a decrease in our share price from $0.49 at April 30, 2021 to $0.41 at July 31, 2021.

 

 23 
 

 

Results of Operations for the Nine Months Ended July 31, 2022 and 2021

 

Revenue

 

Revenue was $250,000 for the nine months ended July 31, 2022 compared to $3,240,000 for the nine months ended July 31, 2021. In the prior period, we recognized royalty payments from OST.

 

Research and Development Expenses

 

We invest in research and development to advance our Lm technology through our pre-clinical and clinical development programs. Research and development expenses for the nine months ended July 31, 2022 and July 31, 2021 were categorized as follows (in thousands):

 

  

Nine Months Ended

July 31,

  

Increase

(Decrease)

 
   2022   2021   $   % 
                 
Hotspot/Off-the-Shelf therapies  $3,076   $2,531   $545    22%
Prostate cancer   85    207    (122)   (59)%
HPV-associated cancers   332    1,865    (1,533)   (82)%
Personalized neoantigen-directed therapies   8    400    (392)   (98)%
Other expenses   1,870    3,613    (1,743)   (48)%
Total research & development expense  $5,371   $8,616   $(3,245)   (38)%
                     
Stock-based compensation expense included in research and development expense  $36   $142   $(106)   (75)%

 

Hotspot/Off-the-Shelf Therapies (ADXS-HOT)

 

Research and development costs associated with our hotspot mutation-based therapy for the nine months ended July 31, 2022 increased approximately 22% to $3,076,000 compared to the same period in 2021. The increase is attributable to patient recruitment costs and manufacturing costs pertaining to the HOT-503 study incurred in the current period.

 

Prostate Cancer (ADXS-PSA)

 

Research and development costs associated with our prostate cancer therapy for the nine months ended July 31, 2022 decreased approximately $122,000, or 59%, compared to the same period in 2021. The study has been completed and we do not anticipate that we will continue to incur significant costs associated with the wind down of the study.

 

HPV-Associated Cancers (AXAL)

 

The majority of the HPV-associated research and development costs include clinical trial and other related costs associated with our AXAL programs in cervical and head and neck cancers. HPV-associated costs for the nine months ended July 31, 2022 decreased approximately $1,533,000, or 82%, compared to the same period in 2021. The decrease is attributable to wind down costs associated with the closure of our Phase 3 AIM2CERV study in high-risk locally advanced cervical cancer. We do not anticipate that we will continue to incur significant costs associated with the wind down of our Phase 3 AIM2CERV study.

 

Personalized Neoantigen-Directed Therapies (ADXS-NEO)

 

Research and development costs associated with personalized neoantigen-directed therapies for the nine months ended July 31, 2022 decreased approximately $392,000, or 98%, compared to the same period in 2021. The study has been completed and we do not anticipate that we will continue to incur significant costs associated with the wind down of the study.

 

 24 
 

 

Other Expenses

 

Other expenses include salary and benefit costs, stock-based compensation expense, professional fees, laboratory costs and other internal and external costs associated with our research & development activities. Other expenses for the nine months ended July 31, 2022 decreased approximately $1,743,000, or 48%, compared to the same period in 2021. The decrease is attributable to (1) prior period losses on disposal of property and equipment in connection with the termination of our office lease at our former location, (2) decrease in personnel costs due to decreases in headcount, stock compensation and bonus accruals, and (3) decrease in depreciation expense.

 

General and Administrative Expenses

 

General and administrative expenses primarily include salary and benefit costs and stock-based compensation expense for employees included in our finance, legal and administrative organizations, outside legal and professional services, and facilities costs. General and administrative expenses for the nine months ended July 31, 2022 and July 31, 2021 were as follows (in thousands):

 

   Nine Months Ended
July 31,
   Increase
(Decrease)
 
   2022   2021   $   % 
                 
General and administrative expense  $6,331   $9,038   $(2,707)   (30)%
                     
Stock-based compensation expense included in general and administrative expense  $38   $369   $(331)   (90)%

 

General and administrative expenses for the nine months ended July 31, 2022 decreased approximately $2,707,000, or 30%, compared to the same period in 2021. This decrease primarily relates to (1) legal and consulting fees related to the Previously Proposed Merger in the prior period, (2) prior period losses on disposal of property and equipment in connection with the termination of our office lease at our former location, (3) prior period sublicense fees paid to the University of Pennsylvania for the OST milestones reached, (4) decrease in personnel costs due to decreases in stock compensation and bonus accruals, and (5) decreases in rent, utilities and depreciation due to the termination of our office lease at our former location. These decreases were partially offset by (1) an increase in proxy solicitation fees related to the Previously Proposed Merger and the reverse stock split and (2) an increase in amounts paid in settlement of shareholder demand letters in the current period.

 

Intangible Asset Impairment

 

During the nine months ended July 31, 2022, the Company recorded an impairment charge under ASC 350 for its patents owned and in-licensed intellectual property of approximately $3,005,000.

 

Changes in Fair Values

 

For the nine months ended July 31, 2022, we recorded non-cash income from changes in the fair value of derivative liabilities of approximately $4,685,000. The decrease in the derivative liabilities was attributable to a decrease in our share price from $38.80 at October 31, 2021 to $3.73 at July 31, 2022.

 

For the nine months ended July 31, 2021, we recorded non-cash income from changes in the fair value of the warrant liability of approximately $1,814,000. The decrease in the fair value of liability warrants resulted primarily from the issuance of warrants in the April 2021 Private Placement. The warrants issued in the April 2021 Private Placement had a decrease in fair value of approximately $1,821,000 from date of issuance to July 31, 2021, which resulted from a decrease in our share price from $45.60 at April 14, 2021 to $32.80 at July 31, 2021.

 

Liquidity and Capital Resources

 

Management’s Plans

 

Similar to other development stage biotechnology companies, our products that are being developed have not generated significant revenue. As a result, we have historically suffered recurring losses and we have required significant cash resources to execute our business plans. These losses are expected to continue for the foreseeable future.

 

 25 
 

 

Historically, the Company’s major sources of cash have comprised proceeds from various public and private offerings of its securities (including common stock), debt financings, clinical collaborations, option and warrant exercises, income earned on investments and grants, and interest income. From October 2013 through July 31, 2022, the Company raised approximately $339.4 million in gross proceeds from various public and private offerings of our common stock. The Company has sustained losses from operations in each fiscal year since our inception, and we expect losses to continue for the indefinite future. As of July 31, 2022 and October 31, 2021, the Company had an accumulated deficit of approximately $438.4 million and $428.6 million, respectively, and stockholders’ equity of approximately $28.2 million and $38.9 million, respectively.

 

The COVID-19 pandemic has created significant volatility and disruption of financial markets. An extended period of economic disruption could negatively affect the Company’s business, financial condition, and access to sources of liquidity. As of July 31, 2022, the Company had approximately $28.2 million in cash and cash equivalents. The actual amount of cash that the Company will need to continue operating is subject to many factors.

 

The Company recognizes that it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that the Company will be able to obtain financing on terms acceptable to it or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations. The Company believes it has sufficient capital to fund its obligations, as they become due, in the ordinary course of business into the third fiscal quarter of 2024. The Company based this estimate on assumptions that may prove to be incorrect, and we could use available capital resources sooner than currently expected.

 

Cash Flows

 

Operating Activities

 

Net cash used in operating activities includes spending associated with our clinical trial programs and general and administrative activities. Net cash used in operating activities was approximately $12,307,000 for the nine months ended July 31, 2022 compared to $11,703,000 for the nine months ended July 31, 2021. The variance is due to fluctuations in cash collected from revenue generated, as well as timing of disbursements relating to accounts payable and accrued expenses.

 

Investing Activities

 

Net cash used in investing activities was approximately $201,000 for nine months ended July 31, 2022 compared to $104,000 for the nine months ended July 31, 2021. The decrease is the result of proceeds on a prior period disposal of property and equipment partially offset by reductions in purchases for intangible assets.

 

Financing Activities

 

Net cash used in financing activities was approximately $956,000 for the nine months ended July 31, 2022 compared to net cash provided by financing activities of $31,886,000 for the nine months ended July 31, 2021. On January 31, 2022, the Company closed on an offering with certain institutional investors for the private placement of 1,000,000 shares of Series D Preferred Stock. The shares sold had an aggregate stated value of $5,000,000. Each share of the Series D Preferred Stock was sold for a purchase price of $4.75, representing an original issue discount of 5% of the stated value. Total net proceeds from the offering, after deducting the financial advisor’s fees and other estimated offering expenses, were approximately $4.3 million. The Series D preferred stock also had a liquidation preference over the shares of common stock, and could be redeemed by the investors, in accordance with certain terms, for a redemption price equal to 105% of the stated value, or in certain circumstances, 110% of the stated value. On April 6, 2022, the holders of all 1,000,000 outstanding shares of the Series D Preferred Stock exercised their right to cause the Company to redeem all of such shares at a price per share equal to 105% of the stated value per share of $5.00, and such shares were redeemed accordingly.

 

 26 
 

 

In November 2020, the Company closed on a public offering of 383,333 shares of its common stock at a public offering price of $24.00 per share. After deducting the underwriting discounts and commissions and other offering expenses, the net proceeds from the offering were approximately $8.5 million. In addition, the Company also undertook a concurrent private placement of warrants to purchase up to 191,667 shares of common stock. The warrants have an exercise price per share of $28.00, are exercisable immediately and will expire five years from the date of issuance.

 

On April 12, 2021, the Company completed an offering of (i) 219,718 shares of common stock, (ii) 95,899 pre-funded warrants to purchase 95,899 shares of common stock and (iii) registered common share purchase warrants to purchase 140,552 shares of common stock with two healthcare focused, institutional investors. The Company also issued to the investors, in a concurrent private placement, unregistered common share purchase warrants to purchase 175,065 shares of the Company’s common stock. We received gross proceeds of approximately $20 million, before deducting the fees and expenses payable by us in connection with the offering.

 

During the nine months ended July 31, 2021, warrant holders from the Company’s November 2020 and April 2021 offerings exercised 230,343 warrants in exchange for 230,343 shares of the Company’s common stock. Pursuant to these warrant exercises, the Company received aggregate proceeds of approximately $3.8 million.

 

Off-Balance Sheet Arrangements

 

As of July 31, 2022, we had no off-balance sheet arrangements.

 

Critical Accounting Estimates

 

The preparation of condensed financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting estimates:

 

Warrant Liabilities

 

We account for our warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for liability classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

 

Some of our warrants meet the criteria as liability classified derivative instruments and are recorded at fair value on the grant date and re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Warrant liabilities are classified on the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. Volatility in our common stock may result in significant changes in the value of the warrant liabilities and resulting gains and losses on our condensed consolidated statement of operations.

 

Intangible Assets

 

Intangible assets primarily consist of legal and filing costs associated with obtaining patents and licenses and are amortized on a straight-line basis over their remaining useful lives which are estimated to be twenty years from the effective dates of the University of Pennsylvania (Penn) License Agreements, beginning in July 1, 2002. These legal and filing costs are invoiced to the Company through Penn and its patent attorneys.

 

 27 
 

 

Management reviews its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents related to ADXS-HPV (AXAL), ADXS-HOT, ADXS-PSA, ADXS-HER2 and other products that are in development, and the Lm technology licensed from the University of Pennsylvania. There are various scenarios under which an impairment charge may be recorded, which include if a competitor were to gain FDA approval for a similar treatment before the Company, if future clinical trials fail to meet the targeted endpoints, or if a drug application is rejected or fails to be issued. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets.

Recently Issued Accounting Standards Not Yet Effective or Adopted

 

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

At July 31, 2022, we had approximately $28.2 million in cash and cash equivalents, which consisted primarily of bank deposits and money market funds. Our investment policy and strategy are focused on preservation of capital and supporting our liquidity requirements. We use a combination of internal and external management to execute our investment strategy and achieve our investment objectives. We typically invest in highly-rated securities (such as money market funds), and our investment policy generally limits the amount of credit exposure to any one issuer. The policy requires investments generally to be investment grade, with the primary objective of minimizing the potential risk of principal loss. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations of interest income have not been significant.

 

We have not been exposed nor do we anticipate being exposed to material risks due to changes in interest rates. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our financial statements.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our chief executive officer and interim principal financial officer of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (“the Exchange Act”). Based upon this evaluation, our chief executive officer and principal financial officer concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (1) accumulated and communicated to our management, including our chief executive officer, as appropriate to allow timely decisions regarding required disclosure; and (2) recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

 

Changes in Internal Control over Financial Reporting

 

During the quarter ended July 31, 2022, there were no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

 

Limitations on Effectiveness of Controls

 

Our management, including our Principal Executive, Financial and Accounting Officers, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected.

 

 28 
 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

The Company is from time to time involved in legal proceedings in the ordinary course of our business. The Company does not believe that any of these claims or proceedings against us is likely to have, individually or in the aggregate, a material adverse effect on the financial condition or results of operations. For more information regarding legal proceedings involving the Company, please see Note 8 – Commitments and Contingencies to our condensed consolidated financial statements.

 

Item 1A. Risk Factors

 

We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, an ongoing military conflict between Russia and Ukraine, and record inflation. Our business, financial condition and results of operations could be materially adversely affected by any negative impact on the global economy and capital markets resulting from the conflict in Ukraine, geopolitical tensions, or record inflation.

 

U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. On February 24, 2022, a full-scale military invasion of Ukraine by Russian troops was reported. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine has led to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions, which has caused record inflation globally. We are continuing to monitor the situation in Ukraine and globally and assessing its potential impact on our business.

 

Although, to date, our business has not been materially impacted by the ongoing military conflict between Russian and Ukraine, geopolitical tensions, or record inflation, it is impossible to predict the extent to which our operations will be impacted in the short and long term, or the ways in which the conflict in Ukraine, geopolitical tensions, or record inflation may impact our business. The extent and duration of the conflict in Ukraine, geopolitical tensions, record inflation and resulting market disruptions are impossible to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks described in our 2021 Annual Report.

 

For additional risk factors, please see our 2021 Annual Report.

 

Item 5. Other Information

 

All terms not defined herein shall have the meanings ascribed in Mr. Berlins Employment Agreement, dated as of April 10, 2018 (the “Employment Agreement”).

 

On September 12, 2022, the Company and Mr. Berlin entered into Amendment No. 1 to his Employment Agreement. Under the terms of Amendment No. 1, the multiplier applicable to his annual Base Salary and target Bonus Percentage that Mr. Berlin would receive if his employment were terminated without Just Cause, or he terminated his employment for Good Reason during the period three months prior and 18 months following a Change of Control (such period, the “CIC Protection Period”), is being increased from 1.75 to 2, with such amount to be payable in a single lump sum within sixty (60) days of the termination. In addition, the number of months for which he would receive continued health and welfare benefits is increased from 21 months to 24 months. Amendment No. 1 further provides, that in the event Mr. Berlin’s employment were terminated without Just Cause, or he terminated his employment for Good Reason, other than during the CIC Protection Period, he would receive equal monthly installments of 1.25 times his applicable Base Salary (increased from 1.0 times), and that he would receive this amount for 15 months rather than 12. In addition, the number of months for which he would receive continued health and welfare benefits in this circumstance is increased from 12 months to 15 months.

 

A copy of Amendment No. 1 is filed herewith as Exhibit 10.1 and the foregoing description of the Amendment No. is qualified in its entirety by reference thereto and the Employment Agreement filed as Exhibit 10.1 on to the Form 8-K filed on April 23, 2018.

 

Item 6. Exhibits

 

Exhibit No.   Description
     
10.1*   Amendment No. 1 to the employment agreement between Advaxis, Inc. and Kenneth A. Berlin, dated September 12, 2022.
     
31.1*   Certification of Principal Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
     
31.2*   Certification of Principal Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002
     
32.1*   Certification of Principal Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002
     
32.2*   Certification of Principal Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS   Inline XBRL INSTANCE DOCUMENT
     
101.SCH   Inline XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
     
101.CAL   Inline XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
     
101.DEF   Inline XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
     
101.LAB   Inline XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
     
101.PRE   Inline XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

 

 29 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereto duly authorized.

 

September 12, 2022

 

  ADVAXIS, INC.
     
  By: /s/ Igor Gitelman
  Name: Igor Gitelman
  Title: Interim Chief Financial Officer and VP of Finance

 

  By: /s/ Kenneth Berlin
  Name: Kenneth Berlin
  Title: President and Chief Executive Officer

 

 30 

 

EX-10.1 2 ex10-1.htm

 

Exhibit 10.1

 

ADVAXIS, Inc.

 

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT

 

This Amendment No. 1, dated as of September 12, 2022 (this “Amendment”), is made to the Employment Agreement, dated as of April 10, 2018 (the “Agreement”), by and between Advaxis, Inc., a Delaware corporation (the “Company”), and Kenneth A. Berlin (“Executive”). Each capitalized term used but not otherwise defined herein shall have the meaning ascribed to such term in the Agreement.

 

WHEREAS, the Company and Executive desire to amend the Agreement as set forth herein effective as of the date hereof for the purpose of changing the terms of the Agreement as set forth herein and reaffirming the other terms and provisions of the Agreement.

 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

 

AMENDMENT PROVISIONS

 

1. The Agreement is hereby amended as of the date hereof as set forth below:

 

  (a) The first sentence of Section 4(b)(1)(i) of the Agreement shall be amended to read as follows (with deleted text shown as stricken and new text shown as double underscored):
     
    equal monthly installments at 1.25 times the applicable Base Salary rate then in effect, as determined on the first day of the calendar month immediately preceding the day of termination, to be paid beginning on the first day of the month following such Termination Date and continuing for fifteen (15) twelve (12) months following the Termination Date (the “Non-CIC Severance Period”).
     
  (b) Section 4(b)(1)(ii) of the Agreement shall be amended so that the reference in the second sentence to “twelve (12) months” shall be replaced by “fifteen (15) months.”
     
  (c) Section 4(b)(2)(i) of the Agreement shall be amended so that the reference to “1.75 times” shall be replaced by “2.0 times.”
     
  (d) Section 4(b)(2)(ii) of the Agreement shall be amended so that both references to “twenty-one (21) months” shall be replaced by “twenty-four (24) months.”

 

GENERAL PROVISIONS

 

2. Except to the extent of the changes described in Section 1 above, the Agreement shall remain in full force and effect and any dispute under this Amendment shall be resolved in accordance with the terms of the Agreement.

 

3. This Amendment shall in all respects be interpreted, enforced, and governed by and continued and enforced in accordance with the internal substantive laws (and not the laws of choice of laws) of the State of New Jersey applicable to contracts entered into and to be performed in New Jersey.

 

4. This Amendment, to the extent signed and delivered by means of a photographic, photostatic, facsimile, portable document format (.pdf), or similar reproduction of such signed writing using a facsimile machine or electronic mail shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party hereto or to any such agreement or instrument, each other party hereto or thereto shall re-execute the original form thereof and deliver it to all other parties. No party hereto shall raise the use of a facsimile machine or electronic mail to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of a facsimile machine or electronic mail as a defense to the formation or enforceability of a contract and each such party forever waives any such defense.

 

5. Unless the context otherwise requires, any other document or agreement that refers to the Agreement shall be deemed to refer to the Agreement, giving effect to this Amendment (and any other amendments to the Agreement made from time to time pursuant to its terms).

 

2

 

 

IN WITNESS WHEREOF, each of the undersigned ratifies and approves this Amendment No. 1 to the Employment Agreement by and between Advaxis, Inc., a Delaware corporation (the “Company”), and Kenneth A. Berlin (“Executive”).

 

  advaxis, Inc.
     
  By: /s/ Igor Gitelman
  Name: Igor Gitelman
  Title: Interim CFO
     
  EXECUTIVE
   
  /s/ Kenneth A. Berlin
  Kenneth A. Berlin

 

3

EX-31.1 3 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18.U.S.C. 7350

(SECTION 302 OF THE SARBANES OXLEY ACT OF 2002)

 

I, Kenneth Berlin, certify that:

 

1. I have reviewed this annual report on Form 10-Q for the quarter ended July 31, 2022 of Advaxis, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

September 12, 2022  
     
By: /s/ Kenneth Berlin  
Name:  Kenneth Berlin  
Title: President and Chief Executive Officer  

 

 

 

EX-31.2 4 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18. U.S.C. 7350

(SECTION 302 OF THE SARBANES OXLEY ACT OF 2002)

 

I, Igor Gitelman, certify that:

 

1. I have reviewed this annual report on Form 10-Q for the quarter ended July 31, 2022 of Advaxis, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

September 12, 2022  
     
By: /s/ Igor Gitelman  
Name:  Igor Gitelman  
Title: Interim Chief Financial Officer and VP of Finance  

 

 

 

EX-32.1 5 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Advaxis, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended July 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, the Chief Executive Officer, hereby certifies pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 that, to the undersigned’s knowledge:

 

(1) the Report of the Company filed today fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

September 12, 2022 By: /s/ Kenneth Berlin
  Name:  Kenneth Berlin
  Title: President and Chief Executive Officer

 

 

 

EX-32.2 6 ex32-2.htm

 

EXHIBIT 32.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Advaxis, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended July 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, the Chief Financial Officer, hereby certifies pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 that, to the undersigned’s knowledge:

 

(1) the Report of the Company filed today fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

September 12, 2022 By: /s/ Igor Gitelman
  Name:  Igor Gitelman
  Title: Interim Chief Financial Officer and VP of Finance

 

 

 

EX-101.SCH 7 adxs-20220731.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - TEMPORARY EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SHARE BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - LICENSING AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - TEMPORARY EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - STOCKHOLDERS’ EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SHARE BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - NATURE OF OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SUMMARY OF INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - SCHEDULE OF LEASE EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - SCHEDULE OF COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - TEMPORARY EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - SUMMARY OF STOCKHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - SHARE BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - LICENSING AGREEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 adxs-20220731_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 adxs-20220731_def.xml XBRL DEFINITION FILE EX-101.LAB 10 adxs-20220731_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series D Convertible Redeemable Preferred Stock [Member] Series D Preferred Stock Redemption [Member] Antidilutive Securities [Axis] Warrant [Member] Share-Based Payment Arrangement, Option [Member] Income Statement Location [Axis] Research And Development [Member] General and Administrative Expense [Member] Equity Components [Axis] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Equity Warrants [Member] Warrant Liability [Member] Sale of Stock [Axis] Private Placement [Member] Derivative Instrument [Axis] Exercise Price Range One [Member] Exercise Price Range Two [Member] Exercise Price Range Three [Member] Exercise Price Range Four [Member] Exercise Price Range Five [Member] Measurement Input Type [Axis] Measurement Input, Expected Term [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Related Party [Axis] Institutional Investors [Member] Series D Preferred Stock [Member] Series D convertible preferred stock [Member] Measurement Input, Exercise Price [Member] Measurement Input, Share Price [Member] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Research and Development Expense [Member] Title of Individual [Axis] Chief Executive Officer [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Development, License and Supply Agreement [Member] Scenario [Axis] OS Therapies [Member] Global BioPharma, Inc [Member] Product and Service [Axis] License and Service [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Cash and Cash Equivalents [Axis] Money Market Funds [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Award Type [Axis] Through September 2024 [Member] Liability Class [Axis] Preferred stock redemption liability [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Prepaid expenses and other current assets Total current assets Property and equipment (net of accumulated depreciation) Intangible assets (net of accumulated amortization) Operating right-of-use asset (net of accumulated amortization) Other assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable Accrued expenses Current portion of operating lease liability Common stock warrant liability Total current liabilities Operating lease liability, net of current portion Total liabilities Contingencies – Note 8 Series D convertible preferred stock- $0.001 par value; 0 shares authorized, 0 shares issued and outstanding at July 31, 2022 and October 31, 2021. Stockholders’ equity: Preferred stock, $0.001 par value; 5,000,000 shares authorized, 0 shares issued and outstanding at July 31, 2022 and October 31, 2021. Common stock - $0.001 par value; 170,000,000 shares authorized, 1,815,951 and 1,820,452 shares issued and outstanding at July 31, 2022 and October 31, 2021. Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Statement [Table] Statement [Line Items] Temporary equity, par value Temporary equity, shares authorized Temporary equity, shares issued Temporary equity, shares outstanding Preferred stock, par value Preferred Stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Operating expenses: Research and development expenses General and administrative expenses Intangible asset impairment Total operating expenses Loss from operations Other income (expense): Interest income, net Net changes in fair value of derivative liabilities Other income (expense) Net loss before income taxes Income tax expense Net loss Accretion of discount and redemption feature of convertible preferred stock Income available to common stockholders Net loss per common share, basic and diluted Weighted average number of common shares outstanding Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Share based compensation Gain on change in value of warrants Gain on change in value of preferred stock redemption liability Loss on disposal of property and equipment Abandonment of intangible assets Impairment charges on intangible assets Depreciation expense Amortization expense of intangible assets Amortization of right-of-use asset Net gain on write-off of right-of-use asset and lease liability Change in operating assets and liabilities: Prepaid expenses, other current assets and deferred expenses Other assets Accounts payable and accrued expenses Deferred revenue Operating lease liabilities Net cash used in operating activities INVESTING ACTIVITIES Proceeds from disposal of property and equipment Cost of intangible assets Net cash used in investing activities FINANCING ACTIVITIES Net proceeds of issuance of Series D preferred stock Net proceeds of issuance of common stock and warrants Fractional shares cashed out Redemption of Series D preferred stock Warrant exercises Net cash (used in) provided by financing activities Net (decrease) increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period SUPPLEMENTAL CASH FLOW INFORMATION Cash paid for taxes SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES Reclassification of preferred stock redemption liability into equity upon redemption of preferred stock Accretion of discount and redemption feature of convertible preferred stock Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS Payables and Accruals [Abstract] ACCRUED EXPENSES Leases LEASES Common Stock Purchase Warrants And Warrant Liability COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Temporary Equity TEMPORARY EQUITY Equity [Abstract] STOCKHOLDERS’ EQUITY Share-Based Payment Arrangement [Abstract] SHARE BASED COMPENSATION Licensing Agreements LICENSING AGREEMENTS Fair Value Disclosures [Abstract] FAIR VALUE Basis of Presentation/Estimates Principles of Consolidation Restricted Cash Convertible Preferred Stock Derivative Financial Instruments Net Income (Loss) per Share Reverse Stock Split Recent Accounting Standards SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE SCHEDULE OF PROPERTY AND EQUIPMENT SUMMARY OF INTANGIBLE ASSETS SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS SUMMARY OF ACCRUED EXPENSES SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES SCHEDULE OF LEASE EXPENSES SCHEDULE OF OTHER INFORMATION RELATED TO LEASES SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] SCHEDULE OF COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY SUMMARY OF STOCKHOLDERS EQUITY SUMMARY OF SHARE BASED COMPENSATION EXPENSE SUMMARY OF CHANGES IN STOCK OPTION PLAN SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS Cash and cash equivalents, at carrying value Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Restricted cash Laboratory equipment Computer equipment Total property and equipment Accumulated depreciation Net property and equipment Impaired Assets to be Disposed of by Method Other than Sale [Table] Impaired Assets to be Disposed of by Method Other than Sale [Line Items] Gain loss on sale of property plant equipment Patents License Software Total intangibles Accumulated amortization Intangible assets 2022 (Remaining) 2023 2024 Schedule of Goodwill [Table] Goodwill [Line Items] Book value patent applications, net Intangible asset amortization expense Asset impairment charges Salaries and other compensation Vendors Professional fees Other Total accrued expenses Schedule Of Supplemental Balance Sheet Related To Leases Operating lease right-of-use assets Operating lease liability Total operating lease liabilities Operating lease cost Variable lease cost Total lease expense Short-term lease cost Schedule Of Other Information Related To Leases Weighted-average remaining lease term Weighted-average discount rate Cash paid for operating lease liabilities 2022 (Remaining) 2023 Total minimum lease payments Less: Imputed interest Total Lease expiration date Lease termination Security deposit Net payment for termination fee Operating lease, right of use asset Operating lease liability Net gain on leases Payment of rent Lessee finance lease renewal term date Offsetting Assets [Table] Offsetting Assets [Line Items] Exercise Price Grand Total Number of Shares Underlying Warrants Expiration Date Type of financing Stock Price Expected Term Measurement input percentage Warrants outstanding Number of warrants to purchase common stock Warrant exercise price per share Common stock shares authorized Fair value of the warrant liability Income on fair value of warrants Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Measurement input percentage Shares issued Stock issued during period value new issues Share purchase price Issue discount Preferred stock conversion price Temporary equity stock stated value accumulated dividends Temporary equity stock stated value accumulated dividends on extension Proceeds from issuance or estimated offering Temporary equity, carrying amount, attributable to parent Preferred stock, redemption amount Temporary equity shares outstanding Temporary equity par value Change in preferred stock, redemption liability amount Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Beginning balance Beginning balance, shares Stock-based compensation Stock-based compensation, shares Advaxis public offerings, net of offering costs Advaxis public offerings, net of offering costs, shares Warrant exercises Warrant exercises, shares Stock option exercises Stock option exercises, shares Issuance of shares to employees under ESPP Plan Issuance of shares to employees under ESPP Plan, shares Ending balance Ending balance, shares Accretion of discount and redemption feature of convertible preferred stock Convertible preferred stock redemption Fractional shares cashed out Fractional shares cashed out, shares Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total Shares Outstanding, Beginning Balance Weighted Average Exercise Price, Outstanding, Beginning Weighted Average Remaining Contractual Life In Years, Beginning Aggregate Intrinsic Value, Beginning Shares, Cancelled or Expired Weighted Average Exercise Price, Cancelled or Expired Shares, Outstanding, Ending Balance Weighted Average Exercise Price, Outstanding, Ending Weighted Average Remaining Contractual Life In Years, Ending Balance Aggregate Intrinsic Value, Ending Shares, Vested and Exercisable Weighted Average Exercise Price, Vested and Exercisable Weighted Average Remaining Contractual Life In Years, Vested and Exercisable Aggregate Intrinsic Value, Vested and Exercisable Exercise Price Range, lower limit Exercise Price Range, upper limit Number Outstanding, Options Outstanding Weighted Average Remaining Contractual, Options Outstanding Weighted Average Exercise Price, Options Outstanding Number Exercisable, Options Exercisable Weighted Average Remaining Contractual Term Exercisable, Options Exercisable Weighted Average Exercise Price, Options Exercisable Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Unrecognized compensation cost Unrecognized weighted average vesting period Unvested stock options Revenue Funding milestone payment Milestone achievement, description Funding for milestone payment Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents (money market funds) Total Financial Assets at Fair Value Common stock warrant liability, warrants exercisable Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants) Total financial liabilities at fair value Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair value at October 31, 2021 Additions Change in fair value Redemption Fair value at July 31, 2022 Finite-lived software, gross. Common stock warrant liability. Series D Preferred Stock Redemption [Member] Convertable Preferred Stock [Policy Text Block] Gain on change in value of warrants. Gain on change in value of preferred stock redemption liability. Loss on sale of property plant equipment. Net gain on write off of right-of-use asset and lease liability. Increase decrease in operating lease liabilities. Redemption of series D preferredStock. Accretion of discount and redemption feature of convertible preferred stock. Series D Convertible Redeemable Preferred Stock [Member] Research And Development [Member] Payments for rent. Lessee finance lease renewal term. Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block] Schedule Of Other Information [TableTextBlock] Fractional shares cashed out. Lease expiration date description Common Stock Purchase Warrants And Warrant Liability [Text Block] Schedule Of Outstanding Warrants [Table Text Block] Exercise Price Range One [Member] Exercise Price Range Two [Member] Exercise Price Range Three [Member] Exercise Price Range Four [Member] Exercise Price Range Five [Member]. Warrants expiration description. Type of Financing. Equity Warrants [Member] Warrant Liability [Member] Fair value of the warrant liability. Temporary Equity Disclosure [Text Block] Institutional Investors [Member] Preferred stock discount rate percentage Temporary equity stock stated value accumulated dividends. Temporary equity stock stated value accumulated dividends on extension. Proceeds from issuance or estimated offering Series D convertible preferred stock [Member] Preferred Stock Redemption Liability [Table Text Block] Value of stock issued as a result of the exercise of warrants. Stock issued during period value employees under ESPP plan. Stock issued during period value accretion of discount and redemption feature of convertible preferred stock. Stock issued during period value convertible preferred stock redemption. Stock issued during period shares warrants exercised. Stock issued during period shares employees under ESPP plan. Fractional shares cashed out shares. Sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term ending. Licensing Agreements Disclosures [Text Block] Development, License and Supply Agreement [Member] OS Therapies [Member] Funding milestone payment. Milestone achievement description Funding for second milestone payment. Global BioPharma, Inc [Member] Common stock warrant liability. Preferred stock redemption liability [Member] Fair value measurement with unobservable inputs reconciliation recurring basis liability period redemption. Impairment charges in intangible assets. Through September 2024 [Member] Reverse Stock Split [Policy Text Block] Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Preferred Stock Dividends and Other Adjustments Net Income (Loss) Available to Common Stockholders, Basic GainOnChangeInValueOfWarrants GainOnChangeInValueOfPreferredStockRedemptionLiability NetGainOnWriteOffOfRightofuseAssetAndLeaseLiability Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Other Operating Assets Net Cash Provided by (Used in) Operating Activities Payments to Acquire Intangible Assets Net Cash Provided by (Used in) Investing Activities RedemptionOfSeriesDPreferredStock Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Net Lease, Cost Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid Equity Securities, FV-NI, Measurement Input Shares, Outstanding StockIssuedDuringPeriodValueWarrantsExercised StockIssuedDuringPeriodValueAccretionOfDiscountAndRedemptionFeatureOfConvertiblePreferredStock Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Revenues Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value EX-101.PRE 11 adxs-20220731_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - shares
9 Months Ended
Jul. 31, 2022
Sep. 09, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jul. 31, 2022  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --10-31  
Entity File Number 001-36138  
Entity Registrant Name ADVAXIS, INC.  
Entity Central Index Key 0001100397  
Entity Tax Identification Number 02-0563870  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 9 Deer Park Drive  
Entity Address, Address Line Two Suite K-1  
Entity Address, City or Town Monmouth Junction  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 08852  
City Area Code (609)  
Local Phone Number 452-9813  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   1,815,951
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
Jul. 31, 2022
Oct. 31, 2021
Current assets:    
Cash and cash equivalents $ 28,150,000 $ 41,614,000
Prepaid expenses and other current assets 1,667,000 1,643,000
Total current assets 29,817,000 43,257,000
Property and equipment (net of accumulated depreciation) 73,000 118,000
Intangible assets (net of accumulated amortization) 181,000 3,354,000
Operating right-of-use asset (net of accumulated amortization) 19,000 40,000
Other assets 11,000 11,000
Total assets 30,101,000 46,780,000
Current liabilities:    
Accounts payable 90,000 87,000
Accrued expenses 1,510,000 2,836,000
Current portion of operating lease liability 19,000 28,000
Common stock warrant liability 287,000 4,929,000
Total current liabilities 1,906,000 7,880,000
Operating lease liability, net of current portion 12,000
Total liabilities 1,906,000 7,892,000
Contingencies – Note 8
Series D convertible preferred stock- $0.001 par value; 0 shares authorized, 0 shares issued and outstanding at July 31, 2022 and October 31, 2021.
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 0 shares issued and outstanding at July 31, 2022 and October 31, 2021.
Common stock - $0.001 par value; 170,000,000 shares authorized, 1,815,951 and 1,820,452 shares issued and outstanding at July 31, 2022 and October 31, 2021. 2,000 2,000
Additional paid-in capital 466,561,000 467,486,000
Accumulated deficit (438,368,000) (428,600,000)
Total stockholders’ equity 28,195,000 38,888,000
Total liabilities and stockholders’ equity $ 30,101,000 $ 46,780,000
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jul. 31, 2022
Oct. 31, 2021
Preferred stock, par value $ 0.001 $ 0.001
Preferred Stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 170,000,000 170,000,000
Common stock, shares issued 1,815,951 1,820,452
Common stock, shares outstanding 1,815,951 1,820,452
Series D Convertible Redeemable Preferred Stock [Member]    
Temporary equity, par value $ 0.001 $ 0.001
Temporary equity, shares authorized 0 0
Temporary equity, shares issued 0 0
Temporary equity, shares outstanding 0 0
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Jul. 31, 2022
Jul. 31, 2021
Income Statement [Abstract]        
Revenue $ 250,000 $ 250,000 $ 3,240,000
Operating expenses:        
Research and development expenses 2,233,000 1,703,000 5,371,000 8,616,000
General and administrative expenses 2,053,000 2,678,000 6,331,000 9,038,000
Intangible asset impairment 3,005,000 3,005,000
Total operating expenses 7,291,000 4,381,000 14,707,000 17,654,000
Loss from operations (7,291,000) (4,131,000) (14,457,000) (14,414,000)
Other income (expense):        
Interest income, net 50,000 1,000 57,000 3,000
Net changes in fair value of derivative liabilities 276,000 846,000 4,685,000 1,814,000
Other income (expense) 2,000 (3,000) 229,000
Net loss before income taxes (6,963,000) (3,284,000) (9,718,000) (12,368,000)
Income tax expense 50,000 50,000 50,000
Net loss (6,963,000) (3,334,000) (9,768,000) (12,418,000)
Accretion of discount and redemption feature of convertible preferred stock (1,025,000)
Income available to common stockholders $ (6,963,000) $ (3,334,000) $ (10,793,000) $ (12,418,000)
Net loss per common share, basic and diluted $ (3.83) $ (1.83) $ (5.93) $ (8.04)
Weighted average number of common shares outstanding 1,817,761 1,820,452 1,819,545 1,543,927
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Jul. 31, 2022
Jul. 31, 2021
OPERATING ACTIVITIES    
Net loss $ (9,768,000) $ (12,418,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share based compensation 74,000 511,000
Gain on change in value of warrants (4,642,000) (1,814,000)
Gain on change in value of preferred stock redemption liability (43,000)
Loss on disposal of property and equipment 1,530,000
Abandonment of intangible assets 159,000 90,000
Impairment charges on intangible assets 3,005,000
Depreciation expense 45,000 366,000
Amortization expense of intangible assets 210,000 203,000
Amortization of right-of-use asset 21,000 327,000
Net gain on write-off of right-of-use asset and lease liability (116,000)
Change in operating assets and liabilities:    
Prepaid expenses, other current assets and deferred expenses (24,000) 488,000
Other assets 171,000
Accounts payable and accrued expenses (1,323,000) 513,000
Deferred revenue (165,000)
Operating lease liabilities (21,000) (1,389,000)
Net cash used in operating activities (12,307,000) (11,703,000)
INVESTING ACTIVITIES    
Proceeds from disposal of property and equipment 219,000
Cost of intangible assets (201,000) (323,000)
Net cash used in investing activities (201,000) (104,000)
FINANCING ACTIVITIES    
Net proceeds of issuance of Series D preferred stock 4,312,000
Net proceeds of issuance of common stock and warrants 28,115,000
Fractional shares cashed out (18,000)
Redemption of Series D preferred stock (5,250,000)
Warrant exercises 3,771,000
Net cash (used in) provided by financing activities (956,000) 31,886,000
Net (decrease) increase in cash and cash equivalents (13,464,000) 20,079,000
Cash and cash equivalents at beginning of period 41,614,000 25,178,000
Cash and cash equivalents at end of period 28,150,000 45,257,000
SUPPLEMENTAL CASH FLOW INFORMATION    
Cash paid for taxes 50,000 50,000
SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES    
Reclassification of preferred stock redemption liability into equity upon redemption of preferred stock 44,000
Accretion of discount and redemption feature of convertible preferred stock $ 1,025,000
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
NATURE OF OPERATIONS
9 Months Ended
Jul. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS

1. NATURE OF OPERATIONS

 

Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (“Lm”)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated Lm called Lm TechnologyTM. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:

 

  Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;
     
  Attacking the tumor by generating a strong, cancer-specific T cell response; and
     
  Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.

 

Advaxis’ proprietary Lm platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that Lm Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.

 

COVID-19

 

On March 11, 2020, the World Health Organization characterized the outbreak of the novel coronavirus (“COVID-19”) as a global pandemic and recommended containment and mitigation measures. Since then, extraordinary actions have been taken by international, federal, state, and local public health and governmental authorities to contain and combat the outbreak and spread of COVID-19 in regions throughout the world. The continued impact of the COVID-19 pandemic cannot be predicted at this time.

 

Liquidity and Capital Resources

 

Liquidity and Management’s Plans

 

Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future.

 

As of July 31, 2022, the Company had approximately $28.2 million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least one year from the issuance of these consolidated financial statements, the actual amount of cash that it will need to operate is subject to many factors.

 

The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.

 

 

XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION
9 Months Ended
Jul. 31, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

 

Basis of Presentation/Estimates

 

The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed consolidated balance sheet as of July 31, 2022 has been derived from the Company’s October 31, 2021 audited financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.

 

Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.

 

These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2021 and notes thereto contained in the Company’s 2021 Annual Report on Form 10-K, as filed with the SEC on February 14, 2022.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

 

Restricted Cash

 

On January 31, 2022, the Company transferred $5,250,000 into an escrow fund to fund a potential Series D preferred stock redemption. On April 6, 2022, the Series D convertible preferred stock was redeemed utilizing the entire amount held in the escrow fund.

 

Convertible Preferred Stock

 

Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (“mezzanine”) until such time as the conditions are removed or lapse.

 

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For share-based derivative financial instruments, the Company used the Monte Carlo simulation model, the Black Scholes model and a binomial model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months after the balance sheet date.

 

 

Net Income (Loss) per Share

 

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:

 

   2022   2021 
   As of July 31, 
   2022   2021 
Warrants   377,818    377,818 
Stock options   11,118    12,892 
Total   388,936    390,710 

 

Reverse Stock Split

 

On March 31, 2022, the Company’s stockholders voted to approve an amendment to allow the Company to execute a reverse stock split of common stock within a range of 1 for 20 to 1 for 80, without reducing the authorized number of shares of the common stock, at the discretion of the Board of Directors. On June 3, 2022, the Board of Directors approved a 1 for 80 reverse stock split, which became effective on June 6, 2022. All references in this Report to number of shares, price per share and weighted average number of shares of common stock outstanding prior to this reverse stock split have been adjusted to reflect the reverse stock split on a retroactive basis, unless otherwise noted.

 

Recent Accounting Standards

 

In December 2019, the FASB issued ASU 2019-12, Simplification of Income Taxes (Topic 740) Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

 

In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share (“EPS”) calculations as a result of these changes. The standard will be effective for the Company for fiscal years beginning after December 15, 2023 and can be applied on either a fully retrospective or modified retrospective basis. Early adoption is permitted for fiscal years beginning after December 15, 2020. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

 

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.

 

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT
9 Months Ended
Jul. 31, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

3. PROPERTY AND EQUIPMENT

 

Property and equipment, net consisted of the following (in thousands):

 

   July 31, 2022   October 31, 2021 
Laboratory equipment  $179   $179 
Computer equipment   241    241 
Total property and equipment   420    420 
Accumulated depreciation   (347)   (302)
Net property and equipment  $73   $118 

 

Depreciation expense for the three months ended July 31, 2022 and 2021 was approximately $13,000 and $50,000, respectively. Depreciation expense for the nine months ended July 31, 2022 and 2021 was approximately $45,000 and $366,000, respectively. During the nine months ended July 31, 2021, the Company incurred a loss on disposal of equipment of approximately $1,530,000, $968,000 of which is reflected in the research and development expenses and $562,000 of which is reflected in the general and administrative expenses in the condensed consolidated statement of operations.

 

 

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
INTANGIBLE ASSETS
9 Months Ended
Jul. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS

4. INTANGIBLE ASSETS

 

Intangible assets, net consisted of the following (in thousands):

 

   July 31, 2022   October 31, 2021 
         
Patents  $275   $4,836 
License   44    777 
Software   98    98 
Total intangibles   417    5,711 
Accumulated amortization   (236)   (2,357)
Intangible assets  $181   $3,354 

 

The expiration dates of the existing patents range from 2022 to 2039 but the expiration dates can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to further pursue the application. Patent applications having a net book value of approximately $29,000 and $21,000 were abandoned and were charged to general and administrative expenses in the condensed consolidated statement of operations for the three months ended July 31, 2022 and 2021, respectively. Patent applications having a net book value of approximately $159,000 and $90,000 were abandoned and were charged to general and administrative expenses in the condensed consolidated statement of operations for the nine months ended July 31, 2022 and 2021, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the condensed consolidated statement of operations aggregated approximately $70,000 and $68,000 for the three months ended July 31, 2022 and 2021, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the condensed consolidated statement of operations aggregated approximately $210,000 and $203,000 for the nine months ended July 31, 2022 and 2021, respectively.

 

Management reviews its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents related to ADXS-HPV (AXAL), ADXS-HOT, ADXS-PSA, ADXS-HER2 and other products that are in development, and the Lm technology licensed from the University of Pennsylvania. There are various scenarios under which an impairment charge may be recorded, which include if a competitor were to gain FDA approval for a similar treatment before the Company, if future clinical trials fail to meet the targeted endpoints, or if a drug application is rejected or fails to be issued. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets.

 

During the three months ended July 31, 2022, the Company identified the following indicators of impairment under ASC 360 indicating that the patents and license carrying amounts might not be recoverable:

 

  Adverse changes in the business climate for biotechnology companies, particularly raising capital; and
  A significant reduction in the Company’s market capitalization during the nine months ended July 31, 2022.

 

The Company performed an impairment test under ASC 350 on its patents owned and in-licensed intellectual property. Under this test a fair value of the relevant asset is compared with the carrying amount of such asset. Fair value is calculated using a discounted cash flow analysis. Cash flows are discounted using a weighted average cost of capital derived from comparable companies, which reflects the costs of borrowing as well as the associated risk. The results of the impairment test indicated that the carrying value of the patents owned and in-licensed intellectual property exceeded the fair value. During the three months ended July 31, 2022, the Company recorded an impairment charge for patents owned and in-licensed intellectual property of approximately $3,005,000 in its condensed consolidated statement of operations.

 

 

As of July 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

 

    Fiscal year ending October 31, 
      
2022 (Remaining)   $24 
2023    94 
2024    63 
Total   $181 

 

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
ACCRUED EXPENSES
9 Months Ended
Jul. 31, 2022
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

5. ACCRUED EXPENSES:

 

The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):

  

   July 31, 2022   October 31, 2021 
         
Salaries and other compensation  $116   $55 
Vendors   851    1,968 
Professional fees   343    613 
Other   200    200 
Total accrued expenses  $1,510   $2,836 

 

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
LEASES
9 Months Ended
Jul. 31, 2022
Leases  
LEASES

6. LEASES

 

Operating Leases

 

The Company previously leased a corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that was set to expire in November 2025. On March 26, 2021, the Company entered into a Lease Termination and Surrender Agreement with respect to this lease agreement. The Lease Termination and Surrender Agreement provides for the early termination of the lease, which became effective on March 31, 2021. In connection with the early termination of the lease, the Company was required to pay a $1,000,000 termination payment. The unapplied security deposit totaling approximately $182,000 was credited against the termination fee for a net payment of approximately $818,000. The Company wrote off of the remaining right-of-use asset of approximately $4,512,000 and lease liability of approximately $5,628,000. After consideration of the termination payment and write off of the remaining right-of-use asset and lease liability, the Company recorded a net gain of approximately $116,000.

 

On March 25, 2021, the Company entered into a new one-year lease agreement for its corporate office/lab with base rent of approximately $29,000 per year, plus other expenses. This lease was accounted for as a short-term lease at inception, and the Company elected not to recognize a right-of-use asset and lease liability. In September 2021, the Company exercised its option to renew the lease, extending the lease term until March 25, 2023. Since the renewed lease term exceeded one-year, the lease no longer qualified for the short-term lease exception, resulting in the recognition of a right-of-use asset and operating lease liability of approximately $43,000.

 

Supplemental balance sheet information related to leases was as follows (in thousands):

  

   July 31, 2022   October 31, 2021 
Operating leases:           
Operating lease right-of-use assets  $19   $40 
           
Operating lease liability  $19   $28 
Operating lease liability, net of current portion   -    12 
Total operating lease liabilities  $19   $40 

 

 

Supplemental lease expense related to leases was as follows (in thousands):

  

Lease Cost (in thousands)  Statements of Operations Classification 

For the Three

Months Ended

July 31, 2022

  

For the Nine

Months Ended

July 31, 2022

 
Operating lease cost  General and administrative  $7   $22 
Variable lease cost  General and administrative   17    36 
Total lease expense     $24   $58 

 

Lease Cost (in thousands)  Statements of Operations Classification 

For the Three

Months Ended

July 31, 2021

  

For the nine

Months Ended

July 31, 2021

 
Operating lease cost  General and administrative  $-   $1,301 
Short-term lease cost  General and administrative   12    16 
Variable lease cost  General and administrative   4    165 
Total lease expense     $16   $1,482 

 

Other information related to leases where the Company is the lessee is as follows:

 

   July 31, 2022   October 31, 2021 
Weighted-average remaining lease term  0.7 years   1.4 years 
Weighted-average discount rate   3.79%   3.79%

 

Supplemental cash flow information related to operating leases was as follows:

 

  

For the Nine

Months Ended

July 31, 2022

  

For the Nine

Months Ended

July 31, 2021

 
Cash paid for operating lease liabilities  $22   $1,363 

 

Future minimum lease payments under non-cancellable leases as of July 31, 2022 were as follows:

 

      
Fiscal Year ending October 31,    
2022 (Remaining)  $7 
2023   13 
Total minimum lease payments   20 
Less: Imputed interest   1 
Total  $19 

 

 

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY
9 Months Ended
Jul. 31, 2022
Common Stock Purchase Warrants And Warrant Liability  
COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

7. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

 

Warrants

 

As of July 31, 2022 and October 31, 2021, there were outstanding and exercisable warrants to purchase 377,818 shares of our common stock with exercise prices ranging from $20.00 to $224.00 per share. Information on the outstanding warrants is as follows:

 

Exercise Price  

Number of

Shares

Underlying

Warrants

   Expiration Date  Type of Financing
$20.00    879   September 2024  September 2018 Public Offering
$224.00    4,092   July 2024  July 2019 Public Offering
$28.00    57,230   November 2025  November 2020 Public Offering
$56.00    140,552   April 2026  April 2021 Registered Direct Offering (Accompanying Warrants)
$56.00    175,065   5 years after the date such warrants become exercisable, if ever  April 2021 Private Placement (Private Placement Warrants)
 Grand Total    377,818       

 

As of July 31, 2022 and October 31, 2021, the Company had 201,874 of its total 377,818 outstanding warrants classified as equity (equity warrants).

 

Warrant Liability

 

As of July 31, 2022 and October 31, 2021, the Company had 175,944 of its total 377,818 outstanding warrants from an April 2021 private offering of common stock and warrants (the “April 2021 Private Placement”) and a September 2018 public offering of common stock and warrants (the “September 2018 Public Offering”) classified as liabilities (liability warrants).

 

The warrants issued in the April 2021 Private Placement will become exercisable only on such day, if ever, that is 14 days after the Company files an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, $0.001 par value per share from 170,000,000 shares to 300,000,000 shares. These warrants expire five years after the date they become exercisable. As of July 31, 2022, the Company did not have sufficient authorized common stock to allow for the issuance of common stock underlying these warrants. The Company did not receive stockholder authorization to increase the authorized shares from 170,000,000 to 300,000,000 shares at the stockholder’s meeting commenced on June 3, 2021. The Company was subsequently required to file a proxy to seek an increase in the number of authorized shares and did not file such a proxy but rather elected to seek a reverse stock split to, among other things, increase the shares available. Accordingly, based on certain indemnification provisions of the securities purchase agreement, the Company concluded that liability classification is warranted. The Company utilized the Black Scholes model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

 

In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at July 31, 2022 and October 31, 2021, the Company used the following inputs in its Black Scholes model:

  

   July 31, 2022   October 31, 2021 
Exercise Price  $56.00   $56.00 
Stock Price  $3.73   $38.80 
Expected Term   5.00 years    5.00 years 
Volatility %   112%   106%
Risk Free Rate   2.70%   1.18%

 

The September 2018 Public Offering warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of July 31, 2022, the down round feature was triggered four times and the exercise price of the warrants were reduced from $1,800.00 to $20.00. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.

 

 

In measuring the warrant liability for the September 2018 Public Offering warrants at July 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:

 

   July 31, 2022   October 31, 2021 
Exercise Price  $20.00   $24.00 
Stock Price  $3.73   $38.80 
Expected Term   2.12 years    2.87 years 
Volatility %   104%   123%
Risk Free Rate   2.89%   0.77%

 

At July 31, 2022 and October 31, 2021, the fair value of the warrant liability was approximately $287,000 and $4,929,000, respectively. For the three months ended July 31, 2022 and 2021, the Company reported income of approximately $276,000 and $846,000, respectively, due to changes in the fair value of the warrant liability. For the nine months ended July 31, 2022 and 2021, the Company reported income of approximately $4,642,000 and $1,814,000, respectively, due to changes in the fair value of the warrant liability.

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES
9 Months Ended
Jul. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

8. COMMITMENTS AND CONTINGENCIES

 

Atachbarian

 

On November 15, 2021, a purported stockholder of the Company commenced an action against the Company and certain of its directors in the U.S. District Court for the District of New Jersey, entitled Atachbarian v. Advaxis, Inc., et al., No. 3:21-cv-20006. The plaintiff alleges that the defendants breached their fiduciary duties and violated Section 14(a) and Rule 20(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder by allegedly failing to disclose certain matters in its Registration Statement on Form S-4 (Commission File No. 333-259065 (the “Registration Statement”) filed in connection with a proposed merger with Biosight Ltd. (the “Previously Proposed Merger”). On December 15, 2021, pursuant to an understanding reached with the plaintiff, the Company made certain other additional disclosures that mooted the demands asserted in the complaint. On December 17, 2021, the plaintiff filed a notice of voluntary dismissal with prejudice. On February 7, 2022, the Company and the plaintiff reached a settlement agreement, which is recorded in general and administrative expenses in the condensed consolidated statement of operations.

 

Purported Stockholder Claims Related to Biosight Transaction

 

Between September 16, 2021, and November 4, 2021, the Company received demand letters on behalf of six purported stockholders of the Company, alleging that the Company failed to disclose certain matters in the Registration Statement, and demanding that the Company disclose such information in a supplemental disclosure filed with the SEC. On October 14, 2021, the Company filed an amendment to the Registration Statement and on November 8, 2021, the Company made certain other additional disclosures that mooted the demands asserted in the above-referenced letters. The six plaintiffs have made settlement demands. On May 20, 2022, the Company and one of the plaintiffs have reached a settlement agreement, which is recorded in general and administrative expenses in the condensed consolidated statement of operations. The Company believes it has adequately accrued for settlements with the other five shareholders, which is recorded in accrued expenses in the condensed consolidated balance sheet.

 

In addition, the Company received certain additional demands from stockholders asserting that the proxy materials filed by the Company in connection with the Previously Proposed Merger contained alleged material misstatements and/or omissions. Certain stockholders also demanded books and records of the Company pursuant to Delaware law. In response to these demands, the Company agreed to make, and did make, certain supplemental disclosures to the proxy materials. The stockholders have made settlement demands. On July 18, 2022, the Company and the plaintiffs reached settlement agreements, which is recorded in general and administrative expenses in the condensed consolidated statement of operations.

 

 

Purported Stockholder Claims Related to Series D Convertible Preferred Stock Offering

 

On February 17, 2022, the Company received a letter on behalf of purported stockholders of the Company, demanding certain books and records pursuant to Delaware law regarding the proposed issuance of super voting preferred stock. The Company agreed to provide certain books and records to the stockholders and agreed to make, and did make, a supplemental disclosure to the proxy materials. The stockholders have made settlement demands. On July 18, 2022, the Company and the plaintiffs reached settlement agreements, which is recorded in general and administrative expenses in the condensed consolidated statement of operations.

 

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
TEMPORARY EQUITY
9 Months Ended
Jul. 31, 2022
Temporary Equity  
TEMPORARY EQUITY

9. TEMPORARY EQUITY

 

Series D Convertible Preferred Stock Offering

 

On January 31, 2022, the Company consummated an offering with certain institutional investors for the private placement of 1,000,000 shares of Series D convertible redeemable preferred stock (the “Series D Preferred Stock”). The shares, which have since been redeemed in accordance with their terms as described below, and are thus no longer outstanding as of July 31, 2022, had an aggregate stated value of $5,000,000. Each share of the Series D preferred stock had a purchase price of $4.75, representing an original issue discount of 5% of the stated value. The shares of Series D Preferred Stock were convertible into shares of the Company’s common stock, upon the occurrence of certain events, at a conversion price of $20.00 per share. The conversion, at the option of the stockholder, could occur at any time following the receipt of the stockholders’ approval for a reverse stock split. The Company was permitted to compel conversion of the Series D Preferred Stock after the fulfillment of certain conditions and subject to certain limitations. The Series D Preferred Stock also had a liquidation preference over the shares of common stock, and could be redeemed by the investors, in accordance with certain terms, for a redemption price equal to 105% of the stated value, or in certain circumstances, 110% of the stated value. Total net proceeds from the offering, after deducting the financial advisor’s fees and other estimated offering expenses, were approximately $4.3 million.

 

Since the Series D preferred stock had a redemption feature at the option of the holder, it was classified as temporary equity. At the January 31, 2022 issuance date, the Series D preferred stock was recorded on the balance sheet at approximately $4,225,000, which is the $4,312,000 net proceeds less the $87,000 value of the bifurcated preferred stock redemption liability (see below).

 

On April 6, 2022, the holders of all 1,000,000 outstanding shares of the Series D Preferred Stock exercised their right to cause the Company to redeem all of such shares at a price per share equal to 105% of the stated value per share of $5.00, and such shares were redeemed accordingly. The $1,025,000 accretion of the Series D convertible preferred stock to its redemption value was recorded as a reduction in additional paid-in capital (see Note 10).

 

Preferred Stock Redemption Liability

 

The Company evaluated the preferred stock redemption feature under ASC 815. Since the preferred stock redemption feature is not considered to be clearly and closely related to the preferred stock host and the redemption feature meets the four characteristics of a derivative under ASC 815, the preferred stock redemption feature is required to be bifurcated from the preferred stock host and valued as a liability. The Company utilized a binomial model to calculate the fair value of the preferred stock redemption feature at issuance.

 

In measuring the preferred stock redemption liability at April 6, 2021 (redemption date) and January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:

 

   April 6, 2022   January 31, 2022 
Exercise Price  $20.00   $20.00 
Stock Price  $9.04   $10.88 
Volatility %   96%   105%
Risk Free Rate   1.25%   1.00%

 

At April 6, 2022 and January 31, 2022, the fair value of the preferred stock redemption liability was approximately $44,000 and $87,000, respectively. On April 6, 2022, the Series D convertible preferred stock was redeemed, and the $44,000 preferred stock redemption liability was reclassified into other paid-in capital (see Note 10). For the three months and nine months ended July 31, 2022, the Company reported income of approximately $0 and $44,000, respectively, due to a change in the fair value of the preferred stock redemption liability.

 

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS’ EQUITY
9 Months Ended
Jul. 31, 2022
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

10. STOCKHOLDERS’ EQUITY

 

A summary of the changes in stockholders’ equity for the nine months ended July 31, 2022 and 2021 is presented below (in thousands, except share data):

   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
   Preferred Stock   Common Stock   Additional Paid-In   Accumulated   Total  Shareholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at November 1, 2020   -   $-    975,897   $2   $440,916   $(410,738)  $30,180 
Stock-based compensation         -           -    -           -    236    -    236 
Advaxis public offerings, net of offering costs   -    -    383,333    -    8,550    -    8,550 
Warrant exercises   -    -    92,375    -    2,586    -    2,586 
Net loss   -    -    -    -    -    (3,977)   (3,977)
Balance at January 31, 2021   -   $-    1,451,605   $2   $452,288   $(414,715)  $37,575 
Stock-based compensation   -    -    69    -    215    -    215 
Stock option exercises   -    -    4    -    -    -    - 
Advaxis public offerings, net of offering costs   -    -    230,794    -    13,683    -    13,683 
Warrant exercises   -    -    137,968    -    1,185    -    1,185 
Issuance of shares to employees under ESPP Plan   -    -    12    -    -    -    - 
Net loss   -    -    -    -    -    (5,107)   (5,107)
Balance at April 30, 2021   -   $-    1,820,452   $2   $467,371   $(419,822)  $47,551 
Stock-based compensation   -    -    -    -    60    -    60 
Net loss   -    -    -    -    -    (3,334)   (3,334)
Balance at July 31, 2021   -   $-    1,820,452   $2   $467,431   $(423,156)  $44,277 

 

   Preferred Stock   Common Stock   Additional Paid-In   Accumulated   Total  Shareholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at November 1, 2021   -   $-    1,820,452   $2   $467,486   $(428,600)  $38,888 
Stock-based compensation          -           -    -             -    26    -    26 
Net loss   -    -    -    -    -    (365)   (365)
Balance at January 31, 2022   -   $-    1,820,452   $2   $467,512   $(428,965)  $38,549 
Stock-based compensation   -    -    -    -    23    -    23 
Accretion of discount and redemption feature of convertible preferred stock   -    -    -    -    (1,025)   -    (1,025)
Convertible preferred stock redemption   -    -    -    -    44    -    44 
Net loss   -    -    -    -    -    (2,440)   (2,440)
Balance at April 30, 2022   -   $-    1,820,452   $2   $466,554   $(431,405)  $35,151 
Stock-based compensation   -    -    -    -    25    -    25 
Fractional shares cashed out   -    -    (4,501)   -    (18)   -    (18)
Net loss   -    -    -    -    -    (6,963)   (6,963)
Balance at July 31, 2022   -    -    1,815,951    2    466,561    (438,368)   28,195 

 

 

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHARE BASED COMPENSATION
9 Months Ended
Jul. 31, 2022
Share-Based Payment Arrangement [Abstract]  
SHARE BASED COMPENSATION

11. SHARE BASED COMPENSATION

 

The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):

   2022   2021   2022   2021 
  

Three Months Ended

July 31,

  

Nine Months Ended

July 31,

 
   2022   2021   2022   2021 
Research and development  $12   $29   $36   $142 
General and administrative   13    31    38    369 
Total  $25   $60   $74   $511 

 

Stock Options

 

A summary of changes in the stock option plan for the nine months ended July 31, 2022 is as follows:

 

   Shares  

Weighted Average Exercise

Price

   Weighted Average Remaining Contractual Life In Years   Aggregate Intrinsic Value (in thousands) 
Outstanding as of October 31, 2021   11,192   $1,550.26    7.80   $34 
Cancelled or expired   (74)   22,200.00           
Outstanding as of July 31, 2022   11,118   $1,412.82    7.06   $       - 
Vested and exercisable at July 31, 2022   7,490   $2,077.20    6.64   $- 

 

The following table summarizes information about the outstanding and exercisable options at July 31, 2022:

  

Options Outstanding  Options Exercisable 
       Weighted   Weighted       Weighted   Weighted 
       Average   Average       Average   Average 
Exercise  Number   Remaining   Exercise   Number   Remaining   Exercise 
Price Range  Outstanding   Contractual   Price   Exercisable   Contractual   Price 
$ 24.00-$50.00   4,241    7.86   $32.53    1,964    7.69   $30.40 
$ 50.01-$100.00   4,174    7.74   $53.33    2,824    7.73   $53.58 
$ 100.01-20,664.00   2,703    4.75   $5,677.84    2,703    4.75   $5,677.84 

 

As of July 31, 2022, there was approximately $77,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of 0.94 years.

 

Potential Acceleration of Stock Options

 

In the event of a merger transaction, similar to the Previously Proposed Merger Agreement, all of the Chief Executive Officer’s 624 unvested stock options as of July 31, 2022, pursuant to his employment agreement, would accelerate.

 

 

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
LICENSING AGREEMENTS
9 Months Ended
Jul. 31, 2022
Licensing Agreements  
LICENSING AGREEMENTS

12. LICENSING AGREEMENTS

 

OS Therapies LLC

 

On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $25,000 per month (“Monthly Payment”) starting on April 30, 2020 until it achieved its funding milestone of $2,337,500. Upon receipt of the first Monthly Payment, Advaxis initiated the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.

 

In December 2020 and January 2021, the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement and recorded $1,615,000 in revenue. The Company therefore transferred, and OST took full ownership of, the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development.

 

In April 2021, the Company achieved the second milestone set forth in the license agreement for evaluation in the treatment of osteosarcoma in humans and recorded $1,375,000 in revenue. The Company received the amount due from OS Therapies of $1,375,000 in May 2021.

 

Global BioPharma Inc.

 

On December 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of axalimogene filolisbac with Global BioPharma, Inc. (“GBP”), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC). During each of the nine months ended July 31, 2022 and 2021, the Company recorded $250,000 in revenue for the annual license fee renewal. Since Advaxis has no significant obligation to perform after the license transfer and has provided GBP with the right to use its intellectual property, performance is satisfied when the license renews.

 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE
9 Months Ended
Jul. 31, 2022
Fair Value Disclosures [Abstract]  
FAIR VALUE

13. FAIR VALUE

 

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

 

● Level 1 — Quoted prices in active markets for identical assets or liabilities.

 

● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

 

● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

 

 

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of July 31, 2022 and October 31, 2021 (in thousands):

   Level 1   Level 2   Level 3   Total 
Fair Value Measured at July 31, 2022
   Level 1   Level 2   Level 3   Total 
Financial assets at fair value:                    
Cash equivalents (money market funds)  $17,183   $-   $-   $17,183 
Total Financial Assets at Fair Value  $17,183   $-   $-   $17,183 
                     
Financial liabilities at fair value:                    
Common stock warrant liability, warrants exercisable at $20.00 through September 2024  $-   $            -   $2   $2 
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)   -    -    285    285 
Total financial liabilities at fair value  $-   $-   $287   $287 

 

   Level 1   Level 2   Level 3   Total 
Fair Value Measured at October 31, 2021
   Level 1   Level 2   Level 3   Total 
Financial assets at fair value:                    
Cash equivalents (money market funds)  $17,153   $-   $-   $17,153 
Total Financial Assets at Fair Value  $17,153   $-   $-   $17,153 
                     
Financial liabilities at fair value:                    
Common stock warrant liability, warrants exercisable at $24.00 through September 2024  $-   $          -   $27   $27 
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)   -    -    4,902    4,902 
Total financial liabilities at fair value  $-   $-   $4,929   $4,929 

 

The following table presents changes in Level 3 liabilities measured at fair value (in thousands) for the nine months ended July 31, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.

 

             
  

Preferred

Stock

Redemption

Liability

  

Warrant

Liabilities

   Total 
Fair value at October 31, 2021  $-   $4,929   $4,929 
Additions   87    -    87 
Change in fair value   (43)   (4,642)   (4,685)
Redemption   (44)   -    (44)
Fair value at July 31, 2022  $-   $287   $287 

 

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies)
9 Months Ended
Jul. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation/Estimates

Basis of Presentation/Estimates

 

The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed consolidated balance sheet as of July 31, 2022 has been derived from the Company’s October 31, 2021 audited financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.

 

Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.

 

These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2021 and notes thereto contained in the Company’s 2021 Annual Report on Form 10-K, as filed with the SEC on February 14, 2022.

 

Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.

 

Restricted Cash

Restricted Cash

 

On January 31, 2022, the Company transferred $5,250,000 into an escrow fund to fund a potential Series D preferred stock redemption. On April 6, 2022, the Series D convertible preferred stock was redeemed utilizing the entire amount held in the escrow fund.

 

Convertible Preferred Stock

Convertible Preferred Stock

 

Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (“mezzanine”) until such time as the conditions are removed or lapse.

 

Derivative Financial Instruments

Derivative Financial Instruments

 

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For share-based derivative financial instruments, the Company used the Monte Carlo simulation model, the Black Scholes model and a binomial model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months after the balance sheet date.

 

 

Net Income (Loss) per Share

Net Income (Loss) per Share

 

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:

 

   2022   2021 
   As of July 31, 
   2022   2021 
Warrants   377,818    377,818 
Stock options   11,118    12,892 
Total   388,936    390,710 

 

Reverse Stock Split

Reverse Stock Split

 

On March 31, 2022, the Company’s stockholders voted to approve an amendment to allow the Company to execute a reverse stock split of common stock within a range of 1 for 20 to 1 for 80, without reducing the authorized number of shares of the common stock, at the discretion of the Board of Directors. On June 3, 2022, the Board of Directors approved a 1 for 80 reverse stock split, which became effective on June 6, 2022. All references in this Report to number of shares, price per share and weighted average number of shares of common stock outstanding prior to this reverse stock split have been adjusted to reflect the reverse stock split on a retroactive basis, unless otherwise noted.

 

Recent Accounting Standards

Recent Accounting Standards

 

In December 2019, the FASB issued ASU 2019-12, Simplification of Income Taxes (Topic 740) Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

 

In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share (“EPS”) calculations as a result of these changes. The standard will be effective for the Company for fiscal years beginning after December 15, 2023 and can be applied on either a fully retrospective or modified retrospective basis. Early adoption is permitted for fiscal years beginning after December 15, 2020. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.

 

Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables)
9 Months Ended
Jul. 31, 2022
Accounting Policies [Abstract]  
SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE

 

   2022   2021 
   As of July 31, 
   2022   2021 
Warrants   377,818    377,818 
Stock options   11,118    12,892 
Total   388,936    390,710 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT (Tables)
9 Months Ended
Jul. 31, 2022
Property, Plant and Equipment [Abstract]  
SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment, net consisted of the following (in thousands):

 

   July 31, 2022   October 31, 2021 
Laboratory equipment  $179   $179 
Computer equipment   241    241 
Total property and equipment   420    420 
Accumulated depreciation   (347)   (302)
Net property and equipment  $73   $118 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
INTANGIBLE ASSETS (Tables)
9 Months Ended
Jul. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
SUMMARY OF INTANGIBLE ASSETS

Intangible assets, net consisted of the following (in thousands):

 

   July 31, 2022   October 31, 2021 
         
Patents  $275   $4,836 
License   44    777 
Software   98    98 
Total intangibles   417    5,711 
Accumulated amortization   (236)   (2,357)
Intangible assets  $181   $3,354 
SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS

As of July 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):

 

    Fiscal year ending October 31, 
      
2022 (Remaining)   $24 
2023    94 
2024    63 
Total   $181 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
ACCRUED EXPENSES (Tables)
9 Months Ended
Jul. 31, 2022
Payables and Accruals [Abstract]  
SUMMARY OF ACCRUED EXPENSES

The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):

  

   July 31, 2022   October 31, 2021 
         
Salaries and other compensation  $116   $55 
Vendors   851    1,968 
Professional fees   343    613 
Other   200    200 
Total accrued expenses  $1,510   $2,836 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
LEASES (Tables)
9 Months Ended
Jul. 31, 2022
Leases  
SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES

Supplemental balance sheet information related to leases was as follows (in thousands):

  

   July 31, 2022   October 31, 2021 
Operating leases:           
Operating lease right-of-use assets  $19   $40 
           
Operating lease liability  $19   $28 
Operating lease liability, net of current portion   -    12 
Total operating lease liabilities  $19   $40 
SCHEDULE OF LEASE EXPENSES

Supplemental lease expense related to leases was as follows (in thousands):

  

Lease Cost (in thousands)  Statements of Operations Classification 

For the Three

Months Ended

July 31, 2022

  

For the Nine

Months Ended

July 31, 2022

 
Operating lease cost  General and administrative  $7   $22 
Variable lease cost  General and administrative   17    36 
Total lease expense     $24   $58 

 

Lease Cost (in thousands)  Statements of Operations Classification 

For the Three

Months Ended

July 31, 2021

  

For the nine

Months Ended

July 31, 2021

 
Operating lease cost  General and administrative  $-   $1,301 
Short-term lease cost  General and administrative   12    16 
Variable lease cost  General and administrative   4    165 
Total lease expense     $16   $1,482 
SCHEDULE OF OTHER INFORMATION RELATED TO LEASES

Other information related to leases where the Company is the lessee is as follows:

 

   July 31, 2022   October 31, 2021 
Weighted-average remaining lease term  0.7 years   1.4 years 
Weighted-average discount rate   3.79%   3.79%
SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES

Supplemental cash flow information related to operating leases was as follows:

 

  

For the Nine

Months Ended

July 31, 2022

  

For the Nine

Months Ended

July 31, 2021

 
Cash paid for operating lease liabilities  $22   $1,363 
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES

Future minimum lease payments under non-cancellable leases as of July 31, 2022 were as follows:

 

      
Fiscal Year ending October 31,    
2022 (Remaining)  $7 
2023   13 
Total minimum lease payments   20 
Less: Imputed interest   1 
Total  $19 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables)
9 Months Ended
Jul. 31, 2022
Subsidiary, Sale of Stock [Line Items]  
SCHEDULE OF COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY

 

Exercise Price  

Number of

Shares

Underlying

Warrants

   Expiration Date  Type of Financing
$20.00    879   September 2024  September 2018 Public Offering
$224.00    4,092   July 2024  July 2019 Public Offering
$28.00    57,230   November 2025  November 2020 Public Offering
$56.00    140,552   April 2026  April 2021 Registered Direct Offering (Accompanying Warrants)
$56.00    175,065   5 years after the date such warrants become exercisable, if ever  April 2021 Private Placement (Private Placement Warrants)
 Grand Total    377,818       
SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY

In measuring the warrant liability for the September 2018 Public Offering warrants at July 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:

 

   July 31, 2022   October 31, 2021 
Exercise Price  $20.00   $24.00 
Stock Price  $3.73   $38.80 
Expected Term   2.12 years    2.87 years 
Volatility %   104%   123%
Risk Free Rate   2.89%   0.77%
Private Placement [Member]  
Subsidiary, Sale of Stock [Line Items]  
SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY

In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at July 31, 2022 and October 31, 2021, the Company used the following inputs in its Black Scholes model:

  

   July 31, 2022   October 31, 2021 
Exercise Price  $56.00   $56.00 
Stock Price  $3.73   $38.80 
Expected Term   5.00 years    5.00 years 
Volatility %   112%   106%
Risk Free Rate   2.70%   1.18%
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
TEMPORARY EQUITY (Tables)
9 Months Ended
Jul. 31, 2022
Temporary Equity  
SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY

In measuring the preferred stock redemption liability at April 6, 2021 (redemption date) and January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:

 

   April 6, 2022   January 31, 2022 
Exercise Price  $20.00   $20.00 
Stock Price  $9.04   $10.88 
Volatility %   96%   105%
Risk Free Rate   1.25%   1.00%
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS’ EQUITY (Tables)
9 Months Ended
Jul. 31, 2022
Equity [Abstract]  
SUMMARY OF STOCKHOLDERS EQUITY

A summary of the changes in stockholders’ equity for the nine months ended July 31, 2022 and 2021 is presented below (in thousands, except share data):

   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
   Preferred Stock   Common Stock   Additional Paid-In   Accumulated   Total  Shareholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at November 1, 2020   -   $-    975,897   $2   $440,916   $(410,738)  $30,180 
Stock-based compensation         -           -    -           -    236    -    236 
Advaxis public offerings, net of offering costs   -    -    383,333    -    8,550    -    8,550 
Warrant exercises   -    -    92,375    -    2,586    -    2,586 
Net loss   -    -    -    -    -    (3,977)   (3,977)
Balance at January 31, 2021   -   $-    1,451,605   $2   $452,288   $(414,715)  $37,575 
Stock-based compensation   -    -    69    -    215    -    215 
Stock option exercises   -    -    4    -    -    -    - 
Advaxis public offerings, net of offering costs   -    -    230,794    -    13,683    -    13,683 
Warrant exercises   -    -    137,968    -    1,185    -    1,185 
Issuance of shares to employees under ESPP Plan   -    -    12    -    -    -    - 
Net loss   -    -    -    -    -    (5,107)   (5,107)
Balance at April 30, 2021   -   $-    1,820,452   $2   $467,371   $(419,822)  $47,551 
Stock-based compensation   -    -    -    -    60    -    60 
Net loss   -    -    -    -    -    (3,334)   (3,334)
Balance at July 31, 2021   -   $-    1,820,452   $2   $467,431   $(423,156)  $44,277 

 

   Preferred Stock   Common Stock   Additional Paid-In   Accumulated   Total  Shareholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at November 1, 2021   -   $-    1,820,452   $2   $467,486   $(428,600)  $38,888 
Stock-based compensation          -           -    -             -    26    -    26 
Net loss   -    -    -    -    -    (365)   (365)
Balance at January 31, 2022   -   $-    1,820,452   $2   $467,512   $(428,965)  $38,549 
Stock-based compensation   -    -    -    -    23    -    23 
Accretion of discount and redemption feature of convertible preferred stock   -    -    -    -    (1,025)   -    (1,025)
Convertible preferred stock redemption   -    -    -    -    44    -    44 
Net loss   -    -    -    -    -    (2,440)   (2,440)
Balance at April 30, 2022   -   $-    1,820,452   $2   $466,554   $(431,405)  $35,151 
Stock-based compensation   -    -    -    -    25    -    25 
Fractional shares cashed out   -    -    (4,501)   -    (18)   -    (18)
Net loss   -    -    -    -    -    (6,963)   (6,963)
Balance at July 31, 2022   -    -    1,815,951    2    466,561    (438,368)   28,195 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHARE BASED COMPENSATION (Tables)
9 Months Ended
Jul. 31, 2022
Share-Based Payment Arrangement [Abstract]  
SUMMARY OF SHARE BASED COMPENSATION EXPENSE

The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):

   2022   2021   2022   2021 
  

Three Months Ended

July 31,

  

Nine Months Ended

July 31,

 
   2022   2021   2022   2021 
Research and development  $12   $29   $36   $142 
General and administrative   13    31    38    369 
Total  $25   $60   $74   $511 
SUMMARY OF CHANGES IN STOCK OPTION PLAN

A summary of changes in the stock option plan for the nine months ended July 31, 2022 is as follows:

 

   Shares  

Weighted Average Exercise

Price

   Weighted Average Remaining Contractual Life In Years   Aggregate Intrinsic Value (in thousands) 
Outstanding as of October 31, 2021   11,192   $1,550.26    7.80   $34 
Cancelled or expired   (74)   22,200.00           
Outstanding as of July 31, 2022   11,118   $1,412.82    7.06   $       - 
Vested and exercisable at July 31, 2022   7,490   $2,077.20    6.64   $- 
SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS

The following table summarizes information about the outstanding and exercisable options at July 31, 2022:

  

Options Outstanding  Options Exercisable 
       Weighted   Weighted       Weighted   Weighted 
       Average   Average       Average   Average 
Exercise  Number   Remaining   Exercise   Number   Remaining   Exercise 
Price Range  Outstanding   Contractual   Price   Exercisable   Contractual   Price 
$ 24.00-$50.00   4,241    7.86   $32.53    1,964    7.69   $30.40 
$ 50.01-$100.00   4,174    7.74   $53.33    2,824    7.73   $53.58 
$ 100.01-20,664.00   2,703    4.75   $5,677.84    2,703    4.75   $5,677.84 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE (Tables)
9 Months Ended
Jul. 31, 2022
Fair Value Disclosures [Abstract]  
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of July 31, 2022 and October 31, 2021 (in thousands):

   Level 1   Level 2   Level 3   Total 
Fair Value Measured at July 31, 2022
   Level 1   Level 2   Level 3   Total 
Financial assets at fair value:                    
Cash equivalents (money market funds)  $17,183   $-   $-   $17,183 
Total Financial Assets at Fair Value  $17,183   $-   $-   $17,183 
                     
Financial liabilities at fair value:                    
Common stock warrant liability, warrants exercisable at $20.00 through September 2024  $-   $            -   $2   $2 
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)   -    -    285    285 
Total financial liabilities at fair value  $-   $-   $287   $287 

 

   Level 1   Level 2   Level 3   Total 
Fair Value Measured at October 31, 2021
   Level 1   Level 2   Level 3   Total 
Financial assets at fair value:                    
Cash equivalents (money market funds)  $17,153   $-   $-   $17,153 
Total Financial Assets at Fair Value  $17,153   $-   $-   $17,153 
                     
Financial liabilities at fair value:                    
Common stock warrant liability, warrants exercisable at $24.00 through September 2024  $-   $          -   $27   $27 
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)   -    -    4,902    4,902 
Total financial liabilities at fair value  $-   $-   $4,929   $4,929 
SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS

The following table presents changes in Level 3 liabilities measured at fair value (in thousands) for the nine months ended July 31, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.

 

             
  

Preferred

Stock

Redemption

Liability

  

Warrant

Liabilities

   Total 
Fair value at October 31, 2021  $-   $4,929   $4,929 
Additions   87    -    87 
Change in fair value   (43)   (4,642)   (4,685)
Redemption   (44)   -    (44)
Fair value at July 31, 2022  $-   $287   $287 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
NATURE OF OPERATIONS (Details Narrative) - USD ($)
$ in Thousands
Jul. 31, 2022
Oct. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Cash and cash equivalents, at carrying value $ 28,150 $ 41,614
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) - shares
9 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 388,936 390,710
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 377,818 377,818
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 11,118 12,892
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative)
Jan. 31, 2022
USD ($)
Series D Preferred Stock Redemption [Member]  
Restricted cash $ 5,250,000
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)
$ in Thousands
Jul. 31, 2022
Oct. 31, 2021
Property, Plant and Equipment [Abstract]    
Laboratory equipment $ 179 $ 179
Computer equipment 241 241
Total property and equipment 420 420
Accumulated depreciation (347) (302)
Net property and equipment $ 73 $ 118
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Jul. 31, 2022
Jul. 31, 2021
Impaired Assets to be Disposed of by Method Other than Sale [Line Items]        
Depreciation expense $ 13,000 $ 50,000 $ 45,000 $ 366,000
Gain loss on sale of property plant equipment       1,530,000
Research And Development [Member]        
Impaired Assets to be Disposed of by Method Other than Sale [Line Items]        
Gain loss on sale of property plant equipment       968,000
General and Administrative Expense [Member]        
Impaired Assets to be Disposed of by Method Other than Sale [Line Items]        
Gain loss on sale of property plant equipment       $ 562,000
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF INTANGIBLE ASSETS (Details) - USD ($)
$ in Thousands
Jul. 31, 2022
Oct. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
Patents $ 275 $ 4,836
License 44 777
Software 98 98
Total intangibles 417 5,711
Accumulated amortization (236) (2,357)
Intangible assets $ 181 $ 3,354
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details) - USD ($)
$ in Thousands
Jul. 31, 2022
Oct. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]    
2022 (Remaining) $ 24  
2023 94  
2024 63  
Intangible assets $ 181 $ 3,354
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
INTANGIBLE ASSETS (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Jul. 31, 2022
Jul. 31, 2021
Goodwill [Line Items]        
Book value patent applications, net     $ 159,000 $ 90,000
Intangible asset amortization expense     210,000 203,000
Asset impairment charges $ 3,005,000 3,005,000
General and Administrative Expense [Member]        
Goodwill [Line Items]        
Book value patent applications, net 29,000 21,000 159,000 90,000
Intangible asset amortization expense $ 70,000 $ 68,000 $ 210,000 $ 203,000
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF ACCRUED EXPENSES (Details) - USD ($)
$ in Thousands
Jul. 31, 2022
Oct. 31, 2021
Payables and Accruals [Abstract]    
Salaries and other compensation $ 116 $ 55
Vendors 851 1,968
Professional fees 343 613
Other 200 200
Total accrued expenses $ 1,510 $ 2,836
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details) - USD ($)
Jul. 31, 2022
Oct. 31, 2021
Mar. 26, 2021
Mar. 25, 2021
Leases        
Operating lease right-of-use assets $ 19,000 $ 40,000 $ 4,512,000 $ 43,000
Operating lease liability 19,000 28,000    
Operating lease liability, net of current portion 12,000    
Total operating lease liabilities $ 19,000 $ 40,000 $ 5,628,000 $ 43,000
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF LEASE EXPENSES (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Jul. 31, 2022
Jul. 31, 2021
Total lease expense $ 24 $ 16 $ 58 $ 1,482
General and Administrative Expense [Member]        
Operating lease cost 7 22 1,301
Variable lease cost $ 17 4 $ 36 165
Short-term lease cost   $ 12   $ 16
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details)
Jul. 31, 2022
Oct. 31, 2021
Leases    
Weighted-average remaining lease term 8 months 12 days 1 year 4 months 24 days
Weighted-average discount rate 3.79% 3.79%
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details) - USD ($)
$ in Thousands
9 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Leases    
Cash paid for operating lease liabilities $ 22 $ 1,363
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details) - USD ($)
Jul. 31, 2022
Oct. 31, 2021
Mar. 26, 2021
Mar. 25, 2021
Leases        
2022 (Remaining) $ 7,000      
2023 13,000      
Total minimum lease payments 20,000      
Less: Imputed interest 1,000      
Total $ 19,000 $ 40,000 $ 5,628,000 $ 43,000
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
LEASES (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended
Mar. 26, 2021
Mar. 25, 2021
Jul. 31, 2022
Oct. 31, 2021
Leases        
Lease expiration date     November 2025  
Lease termination $ 1,000,000      
Security deposit 182,000      
Net payment for termination fee 818,000      
Operating lease, right of use asset 4,512,000 $ 43,000 $ 19,000 $ 40,000
Operating lease liability 5,628,000 43,000 $ 19,000 $ 40,000
Net gain on leases $ 116,000      
Payment of rent   $ 29,000    
Lessee finance lease renewal term date   Mar. 25, 2023    
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details) - $ / shares
9 Months Ended 12 Months Ended
Jul. 31, 2022
Oct. 31, 2021
Offsetting Assets [Line Items]    
Exercise Price $ 20.00 $ 24.00
Grand Total Number of Shares Underlying Warrants 377,818 377,818
Exercise Price Range One [Member]    
Offsetting Assets [Line Items]    
Exercise Price $ 20.00 $ 20.00
Grand Total Number of Shares Underlying Warrants 879 879
Expiration Date September 2024 September 2024
Type of financing September 2018 Public Offering September 2018 Public Offering
Exercise Price Range Two [Member]    
Offsetting Assets [Line Items]    
Exercise Price $ 224.00 $ 224.00
Grand Total Number of Shares Underlying Warrants 4,092 4,092
Expiration Date July 2024 July 2024
Type of financing July 2019 Public Offering July 2019 Public Offering
Exercise Price Range Three [Member]    
Offsetting Assets [Line Items]    
Exercise Price $ 28.00 $ 28.00
Grand Total Number of Shares Underlying Warrants 57,230 57,230
Expiration Date November 2025 November 2025
Type of financing November 2020 Public Offering November 2020 Public Offering
Exercise Price Range Four [Member]    
Offsetting Assets [Line Items]    
Exercise Price $ 56.00 $ 56.00
Grand Total Number of Shares Underlying Warrants 140,552 140,552
Expiration Date April 2026 April 2026
Type of financing April 2021 Registered Direct Offering (Accompanying Warrants) April 2021 Registered Direct Offering (Accompanying Warrants)
Exercise Price Range Five [Member]    
Offsetting Assets [Line Items]    
Exercise Price $ 56.00 $ 56.00
Grand Total Number of Shares Underlying Warrants 175,065 175,065
Expiration Date 5 years after the date such warrants become exercisable, if ever 5 years after the date such warrants become exercisable, if ever
Type of financing April 2021 Private Placement (Private Placement Warrants) April 2021 Private Placement (Private Placement Warrants)
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details)
Jul. 31, 2022
$ / shares
Oct. 31, 2021
$ / shares
Exercise Price $ 20.00 $ 24.00
Private Placement [Member]    
Exercise Price 56.00 56.00
Warrant Liability [Member]    
Exercise Price 20.00 24.00
Stock Price $ 3.73 $ 38.80
Warrant Liability [Member] | Measurement Input, Expected Term [Member]    
Expected Term 2 years 1 month 13 days 2 years 10 months 13 days
Warrant Liability [Member] | Measurement Input, Price Volatility [Member]    
Measurement input percentage 104 123
Warrant Liability [Member] | Measurement Input, Risk Free Interest Rate [Member]    
Measurement input percentage 2.89 0.77
Warrant Liability [Member] | Private Placement [Member]    
Exercise Price $ 56.00 $ 56.00
Stock Price $ 3.73 $ 38.80
Warrant Liability [Member] | Private Placement [Member] | Measurement Input, Expected Term [Member]    
Expected Term 5 years 5 years
Warrant Liability [Member] | Private Placement [Member] | Measurement Input, Price Volatility [Member]    
Measurement input percentage 112 106
Warrant Liability [Member] | Private Placement [Member] | Measurement Input, Risk Free Interest Rate [Member]    
Measurement input percentage 2.70 1.18
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Jul. 31, 2022
Jul. 31, 2021
Oct. 31, 2021
Jun. 03, 2021
May 01, 2021
Apr. 30, 2021
Number of warrants to purchase common stock 377,818   377,818   377,818      
Warrant exercise price per share $ 20.00   $ 20.00   $ 24.00      
Common stock, par value $ 0.001   $ 0.001   $ 0.001     $ 0.001
Common stock shares authorized 170,000,000   170,000,000   170,000,000   300,000,000 170,000,000
Fair value of the warrant liability $ 287,000   $ 287,000   $ 4,929,000      
Income on fair value of warrants $ 276,000 $ 846,000 $ 4,642,000 $ 1,814,000        
Private Placement [Member]                
Warrant exercise price per share $ 56.00   $ 56.00   $ 56.00      
Minimum [Member]                
Common stock shares authorized           170,000,000    
Maximum [Member]                
Common stock shares authorized           300,000,000    
Warrant [Member]                
Warrants outstanding 377,818   377,818   377,818      
Number of warrants to purchase common stock 377,818   377,818   377,818      
Warrant [Member] | Minimum [Member]                
Warrant exercise price per share $ 20.00   $ 20.00   $ 20.00      
Warrant [Member] | Maximum [Member]                
Warrant exercise price per share $ 224.00   $ 224.00   $ 224.00      
Equity Warrants [Member]                
Warrants outstanding 377,818   377,818   377,818      
Number of warrants to purchase common stock 201,874   201,874   201,874      
Warrant Liability [Member]                
Warrant exercise price per share $ 20.00   $ 20.00   $ 24.00      
Warrant Liability [Member] | Private Placement [Member]                
Warrants outstanding 377,818   377,818   377,818      
Number of warrants to purchase common stock 175,944   175,944   175,944      
Warrant exercise price per share $ 56.00   $ 56.00   $ 56.00      
Warrant Liability [Member] | Minimum [Member]                
Warrant exercise price per share 20.00   20.00          
Warrant Liability [Member] | Maximum [Member]                
Warrant exercise price per share $ 1,800.00   $ 1,800.00          
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY (Details)
Apr. 06, 2022
Jan. 31, 2022
Measurement Input, Exercise Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Measurement input percentage 20.00 20.00
Measurement Input, Share Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Measurement input percentage 9.04 10.88
Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Measurement input percentage 96 105
Measurement Input, Risk Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Measurement input percentage 1.25 1.00
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
TEMPORARY EQUITY (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Apr. 06, 2022
Jan. 31, 2022
Jul. 31, 2022
Apr. 30, 2021
Jan. 31, 2021
Jul. 31, 2022
Oct. 31, 2021
Subsidiary, Sale of Stock [Line Items]              
Stock issued during period value new issues       $ 13,683,000 $ 8,550,000    
Issue discount           5.00%  
Temporary equity stock stated value accumulated dividends           105.00%  
Temporary equity stock stated value accumulated dividends on extension           110.00%  
Proceeds from issuance or estimated offering   $ 4,312,000       $ 4,300,000  
Temporary equity, carrying amount, attributable to parent   4,225,000    
Preferred stock, redemption amount $ 44,000 $ 87,000          
Change in preferred stock, redemption liability amount     $ 0     $ 44,000  
Series D Preferred Stock [Member]              
Subsidiary, Sale of Stock [Line Items]              
Preferred stock conversion price     $ 20.00     $ 20.00  
Temporary equity stock stated value accumulated dividends 105.00%            
Temporary equity shares outstanding 1,000,000            
Temporary equity par value $ 5.00            
Series D convertible preferred stock [Member]              
Subsidiary, Sale of Stock [Line Items]              
Stock issued during period value new issues $ 1,025,000            
Preferred stock, redemption amount $ 44,000            
Private Placement [Member] | Institutional Investors [Member] | Series D Preferred Stock [Member]              
Subsidiary, Sale of Stock [Line Items]              
Shares issued   1,000,000          
Stock issued during period value new issues           $ 5,000,000  
Share purchase price     $ 4.75     $ 4.75  
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF STOCKHOLDERS EQUITY (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jul. 31, 2022
Apr. 30, 2022
Jan. 31, 2022
Jul. 31, 2021
Apr. 30, 2021
Jan. 31, 2021
Jul. 31, 2022
Jul. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Beginning balance $ 35,151 $ 38,549 $ 38,888 $ 47,551 $ 37,575 $ 30,180 $ 38,888 $ 30,180
Stock-based compensation 25 23 26 60 215 236    
Advaxis public offerings, net of offering costs         13,683 8,550    
Warrant exercises         1,185 2,586    
Net loss (6,963) (2,440) (365) (3,334) (5,107) (3,977) (9,768) (12,418)
Stock option exercises              
Issuance of shares to employees under ESPP Plan              
Ending balance 28,195 35,151 38,549 44,277 47,551 37,575 28,195 44,277
Accretion of discount and redemption feature of convertible preferred stock   (1,025)            
Convertible preferred stock redemption   44            
Fractional shares cashed out (18)           18
Preferred Stock [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Beginning balance
Beginning balance, shares
Stock-based compensation    
Advaxis public offerings, net of offering costs            
Warrant exercises            
Net loss    
Stock option exercises              
Issuance of shares to employees under ESPP Plan              
Ending balance
Ending balance, shares
Accretion of discount and redemption feature of convertible preferred stock              
Convertible preferred stock redemption              
Fractional shares cashed out              
Common Stock [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Beginning balance $ 2 $ 2 $ 2 $ 2 $ 2 $ 2 $ 2 $ 2
Beginning balance, shares 1,820,452 1,820,452 1,820,452 1,820,452 1,451,605 975,897 1,820,452 975,897
Stock-based compensation    
Stock-based compensation, shares         69    
Advaxis public offerings, net of offering costs            
Advaxis public offerings, net of offering costs, shares         230,794 383,333    
Warrant exercises            
Warrant exercises, shares         137,968 92,375    
Net loss    
Stock option exercises              
Stock option exercises, shares         4      
Issuance of shares to employees under ESPP Plan              
Issuance of shares to employees under ESPP Plan, shares         12      
Ending balance $ 2 $ 2 $ 2 $ 2 $ 2 $ 2 $ 2 $ 2
Ending balance, shares 1,815,951 1,820,452 1,820,452 1,820,452 1,820,452 1,451,605 1,815,951 1,820,452
Accretion of discount and redemption feature of convertible preferred stock              
Convertible preferred stock redemption              
Fractional shares cashed out              
Fractional shares cashed out, shares (4,501)              
Additional Paid-in Capital [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Beginning balance $ 466,554 467,512 $ 467,486 $ 467,371 $ 452,288 $ 440,916 $ 467,486 $ 440,916
Stock-based compensation 25 23 26 60 215 236    
Advaxis public offerings, net of offering costs         13,683 8,550    
Warrant exercises         1,185 2,586    
Net loss    
Stock option exercises              
Issuance of shares to employees under ESPP Plan              
Ending balance 466,561 466,554 467,512 467,431 467,371 452,288 466,561 467,431
Accretion of discount and redemption feature of convertible preferred stock   (1,025)            
Convertible preferred stock redemption   44            
Fractional shares cashed out (18)              
Retained Earnings [Member]                
Accumulated Other Comprehensive Income (Loss) [Line Items]                
Beginning balance (431,405) (428,965) (428,600) (419,822) (414,715) (410,738) (428,600) (410,738)
Stock-based compensation    
Advaxis public offerings, net of offering costs            
Warrant exercises            
Net loss (6,963) (2,440) (365) (3,334) (5,107) (3,977)    
Stock option exercises              
Issuance of shares to employees under ESPP Plan              
Ending balance (438,368) (431,405) $ (428,965) $ (423,156) $ (419,822) $ (414,715) $ (438,368) $ (423,156)
Accretion of discount and redemption feature of convertible preferred stock              
Convertible preferred stock redemption              
Fractional shares cashed out              
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Jul. 31, 2022
Jul. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total $ 25 $ 60 $ 74 $ 511
Research and Development Expense [Member]        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total 12 29 36 142
General and Administrative Expense [Member]        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total $ 13 $ 31 $ 38 $ 369
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details)
$ / shares in Units, $ in Thousands
9 Months Ended
Jul. 31, 2022
USD ($)
$ / shares
shares
Share-Based Payment Arrangement [Abstract]  
Shares Outstanding, Beginning Balance | shares 11,192
Weighted Average Exercise Price, Outstanding, Beginning | $ / shares $ 1,550.26
Weighted Average Remaining Contractual Life In Years, Beginning 7 years 9 months 18 days
Aggregate Intrinsic Value, Beginning | $ $ 34
Shares, Cancelled or Expired | shares (74)
Weighted Average Exercise Price, Cancelled or Expired | $ / shares $ 22,200.00
Shares, Outstanding, Ending Balance | shares 11,118
Weighted Average Exercise Price, Outstanding, Ending | $ / shares $ 1,412.82
Weighted Average Remaining Contractual Life In Years, Ending Balance 7 years 21 days
Aggregate Intrinsic Value, Ending | $
Shares, Vested and Exercisable | shares 7,490
Weighted Average Exercise Price, Vested and Exercisable | $ / shares $ 2,077.20
Weighted Average Remaining Contractual Life In Years, Vested and Exercisable 6 years 7 months 20 days
Aggregate Intrinsic Value, Vested and Exercisable | $
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details)
9 Months Ended
Jul. 31, 2022
$ / shares
shares
Exercise Price Range One [Member]  
Offsetting Assets [Line Items]  
Exercise Price Range, lower limit $ 24.00
Exercise Price Range, upper limit $ 50.00
Number Outstanding, Options Outstanding | shares 4,241
Weighted Average Remaining Contractual, Options Outstanding 7 years 10 months 9 days
Weighted Average Exercise Price, Options Outstanding $ 32.53
Number Exercisable, Options Exercisable | shares 1,964
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable 7 years 8 months 8 days
Weighted Average Exercise Price, Options Exercisable $ 30.40
Exercise Price Range Two [Member]  
Offsetting Assets [Line Items]  
Exercise Price Range, lower limit 50.01
Exercise Price Range, upper limit $ 100.00
Number Outstanding, Options Outstanding | shares 4,174
Weighted Average Remaining Contractual, Options Outstanding 7 years 8 months 26 days
Weighted Average Exercise Price, Options Outstanding $ 53.33
Number Exercisable, Options Exercisable | shares 2,824
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable 7 years 8 months 23 days
Weighted Average Exercise Price, Options Exercisable $ 53.58
Exercise Price Range Three [Member]  
Offsetting Assets [Line Items]  
Exercise Price Range, lower limit 100.01
Exercise Price Range, upper limit $ 20,664.00
Number Outstanding, Options Outstanding | shares 2,703
Weighted Average Remaining Contractual, Options Outstanding 4 years 9 months
Weighted Average Exercise Price, Options Outstanding $ 5,677.84
Number Exercisable, Options Exercisable | shares 2,703
Weighted Average Remaining Contractual Term Exercisable, Options Exercisable 4 years 9 months
Weighted Average Exercise Price, Options Exercisable $ 5,677.84
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHARE BASED COMPENSATION (Details Narrative)
$ in Thousands
9 Months Ended
Jul. 31, 2022
USD ($)
shares
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]  
Unrecognized compensation cost | $ $ 77,000
Unrecognized weighted average vesting period 11 months 8 days
Chief Executive Officer [Member]  
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]  
Unvested stock options | shares 624
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
LICENSING AGREEMENTS (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended
Apr. 30, 2021
Apr. 30, 2020
Sep. 04, 2018
May 31, 2021
Jul. 31, 2022
Jul. 31, 2021
Milestone achievement, description         the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement and recorded $1,615,000 in revenue.  
Global BioPharma, Inc [Member] | License and Service [Member]            
Revenue         $ 250,000 $ 250,000
Development, License and Supply Agreement [Member] | OS Therapies [Member]            
Revenue $ 1,375,000 $ 25,000        
Funding milestone payment     $ 2,337,500      
Funding for milestone payment       $ 1,375,000    
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)
$ in Thousands
Jul. 31, 2022
Oct. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total Financial Assets at Fair Value $ 17,183 $ 17,153
Common stock warrant liability, warrants exercisable 287 4,929
Total financial liabilities at fair value 287 4,929
Private Placement [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants) 285 4,902
Through September 2024 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable 2 27
Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents (money market funds) 17,183 17,153
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total Financial Assets at Fair Value 17,183 17,153
Total financial liabilities at fair value
Fair Value, Inputs, Level 1 [Member] | Private Placement [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)
Fair Value, Inputs, Level 1 [Member] | Through September 2024 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents (money market funds) 17,183 17,153
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total Financial Assets at Fair Value
Total financial liabilities at fair value
Fair Value, Inputs, Level 2 [Member] | Private Placement [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)
Fair Value, Inputs, Level 2 [Member] | Through September 2024 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents (money market funds)
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total Financial Assets at Fair Value
Total financial liabilities at fair value 287 4,929
Fair Value, Inputs, Level 3 [Member] | Private Placement [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants) 285 4,902
Fair Value, Inputs, Level 3 [Member] | Through September 2024 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Common stock warrant liability, warrants exercisable 2 27
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents (money market funds)
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical) - $ / shares
Jul. 31, 2022
Oct. 31, 2021
Subsidiary, Sale of Stock [Line Items]    
Warrant exercise price per share $ 20.00 $ 24.00
Private Placement [Member]    
Subsidiary, Sale of Stock [Line Items]    
Warrant exercise price per share $ 56.00 $ 56.00
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS (Details)
$ in Thousands
9 Months Ended
Jul. 31, 2022
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Fair value at October 31, 2021 $ 4,929
Additions 87
Change in fair value (4,685)
Redemption (44)
Fair value at July 31, 2022 287
Preferred stock redemption liability [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Fair value at October 31, 2021
Additions 87
Change in fair value (43)
Redemption (44)
Fair value at July 31, 2022
Warrant Liability [Member]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]  
Fair value at October 31, 2021 4,929
Additions
Change in fair value (4,642)
Redemption
Fair value at July 31, 2022 $ 287
XML 70 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001100397 2021-11-01 2022-07-31 0001100397 2022-09-09 0001100397 2022-07-31 0001100397 2021-10-31 0001100397 ADXS:SeriesDConvertibleRedeemablePreferredStockMember 2022-07-31 0001100397 ADXS:SeriesDConvertibleRedeemablePreferredStockMember 2021-10-31 0001100397 2022-05-01 2022-07-31 0001100397 2021-05-01 2021-07-31 0001100397 2020-11-01 2021-07-31 0001100397 2020-10-31 0001100397 2021-07-31 0001100397 ADXS:SeriesDPreferredStockRedemptionMember 2022-01-31 0001100397 us-gaap:WarrantMember 2021-11-01 2022-07-31 0001100397 us-gaap:WarrantMember 2020-11-01 2021-07-31 0001100397 us-gaap:EmployeeStockOptionMember 2021-11-01 2022-07-31 0001100397 us-gaap:EmployeeStockOptionMember 2020-11-01 2021-07-31 0001100397 ADXS:ResearchAndDevelopmentMember 2020-11-01 2021-07-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2020-11-01 2021-07-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2022-05-01 2022-07-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2021-05-01 2021-07-31 0001100397 us-gaap:GeneralAndAdministrativeExpenseMember 2021-11-01 2022-07-31 0001100397 2021-03-01 2021-03-26 0001100397 2021-03-26 0001100397 2021-03-25 0001100397 2021-03-01 2021-03-25 0001100397 us-gaap:WarrantMember 2022-07-31 0001100397 us-gaap:WarrantMember 2021-10-31 0001100397 srt:MinimumMember us-gaap:WarrantMember 2022-07-31 0001100397 srt:MinimumMember us-gaap:WarrantMember 2021-10-31 0001100397 srt:MaximumMember us-gaap:WarrantMember 2022-07-31 0001100397 srt:MaximumMember us-gaap:WarrantMember 2021-10-31 0001100397 ADXS:EquityWarrantsMember 2022-07-31 0001100397 ADXS:EquityWarrantsMember 2021-10-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-07-31 0001100397 ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 2021-04-30 0001100397 2021-05-01 0001100397 srt:MinimumMember 2021-06-03 0001100397 srt:MaximumMember 2021-06-03 0001100397 srt:MaximumMember ADXS:WarrantLiabilityMember 2022-07-31 0001100397 srt:MinimumMember ADXS:WarrantLiabilityMember 2022-07-31 0001100397 us-gaap:PrivatePlacementMember 2021-11-01 2022-07-31 0001100397 ADXS:ExercisePriceRangeOneMember 2022-07-31 0001100397 ADXS:ExercisePriceRangeOneMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeOneMember 2021-11-01 2022-07-31 0001100397 ADXS:ExercisePriceRangeOneMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2022-07-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2021-11-01 2022-07-31 0001100397 ADXS:ExercisePriceRangeTwoMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2022-07-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2021-11-01 2022-07-31 0001100397 ADXS:ExercisePriceRangeThreeMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeFourMember 2022-07-31 0001100397 ADXS:ExercisePriceRangeFourMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeFourMember 2021-11-01 2022-07-31 0001100397 ADXS:ExercisePriceRangeFourMember 2020-11-01 2021-10-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2022-07-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2021-10-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2021-11-01 2022-07-31 0001100397 ADXS:ExercisePriceRangeFiveMember 2020-11-01 2021-10-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember us-gaap:PrivatePlacementMember 2021-10-31 0001100397 ADXS:WarrantLiabilityMember 2022-07-31 0001100397 ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember 2022-07-31 0001100397 us-gaap:MeasurementInputExpectedTermMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember 2022-07-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember 2022-07-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember ADXS:WarrantLiabilityMember 2021-10-31 0001100397 ADXS:InstitutionalInvestorsMember us-gaap:SeriesDPreferredStockMember us-gaap:PrivatePlacementMember 2022-01-01 2022-01-31 0001100397 ADXS:InstitutionalInvestorsMember us-gaap:SeriesDPreferredStockMember us-gaap:PrivatePlacementMember 2021-11-01 2022-07-31 0001100397 ADXS:InstitutionalInvestorsMember us-gaap:SeriesDPreferredStockMember us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:SeriesDPreferredStockMember 2022-07-31 0001100397 2022-01-31 0001100397 2022-01-01 2022-01-31 0001100397 us-gaap:SeriesDPreferredStockMember 2022-04-06 0001100397 us-gaap:SeriesDPreferredStockMember 2022-04-04 2022-04-06 0001100397 ADXS:SeriesDConvertiblePreferredStockMember 2022-04-04 2022-04-06 0001100397 2022-04-06 0001100397 ADXS:SeriesDConvertiblePreferredStockMember 2022-04-06 0001100397 us-gaap:MeasurementInputExercisePriceMember 2022-04-06 0001100397 us-gaap:MeasurementInputExercisePriceMember 2022-01-31 0001100397 us-gaap:MeasurementInputSharePriceMember 2022-04-06 0001100397 us-gaap:MeasurementInputSharePriceMember 2022-01-31 0001100397 us-gaap:MeasurementInputPriceVolatilityMember 2022-04-06 0001100397 us-gaap:MeasurementInputPriceVolatilityMember 2022-01-31 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-04-06 0001100397 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-01-31 0001100397 us-gaap:PreferredStockMember 2020-10-31 0001100397 us-gaap:CommonStockMember 2020-10-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-10-31 0001100397 us-gaap:RetainedEarningsMember 2020-10-31 0001100397 us-gaap:PreferredStockMember 2020-11-01 2021-01-31 0001100397 us-gaap:CommonStockMember 2020-11-01 2021-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2020-11-01 2021-01-31 0001100397 us-gaap:RetainedEarningsMember 2020-11-01 2021-01-31 0001100397 2020-11-01 2021-01-31 0001100397 us-gaap:PreferredStockMember 2021-01-31 0001100397 us-gaap:CommonStockMember 2021-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001100397 us-gaap:RetainedEarningsMember 2021-01-31 0001100397 2021-01-31 0001100397 us-gaap:PreferredStockMember 2021-02-01 2021-04-30 0001100397 us-gaap:CommonStockMember 2021-02-01 2021-04-30 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-02-01 2021-04-30 0001100397 us-gaap:RetainedEarningsMember 2021-02-01 2021-04-30 0001100397 2021-02-01 2021-04-30 0001100397 us-gaap:PreferredStockMember 2021-04-30 0001100397 us-gaap:CommonStockMember 2021-04-30 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-04-30 0001100397 us-gaap:RetainedEarningsMember 2021-04-30 0001100397 us-gaap:PreferredStockMember 2021-05-01 2021-07-31 0001100397 us-gaap:CommonStockMember 2021-05-01 2021-07-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-05-01 2021-07-31 0001100397 us-gaap:RetainedEarningsMember 2021-05-01 2021-07-31 0001100397 us-gaap:PreferredStockMember 2021-07-31 0001100397 us-gaap:CommonStockMember 2021-07-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-07-31 0001100397 us-gaap:RetainedEarningsMember 2021-07-31 0001100397 us-gaap:PreferredStockMember 2021-10-31 0001100397 us-gaap:CommonStockMember 2021-10-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-10-31 0001100397 us-gaap:RetainedEarningsMember 2021-10-31 0001100397 us-gaap:PreferredStockMember 2021-11-01 2022-01-31 0001100397 us-gaap:CommonStockMember 2021-11-01 2022-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2021-11-01 2022-01-31 0001100397 us-gaap:RetainedEarningsMember 2021-11-01 2022-01-31 0001100397 2021-11-01 2022-01-31 0001100397 us-gaap:PreferredStockMember 2022-01-31 0001100397 us-gaap:CommonStockMember 2022-01-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001100397 us-gaap:RetainedEarningsMember 2022-01-31 0001100397 us-gaap:PreferredStockMember 2022-02-01 2022-04-30 0001100397 us-gaap:CommonStockMember 2022-02-01 2022-04-30 0001100397 us-gaap:AdditionalPaidInCapitalMember 2022-02-01 2022-04-30 0001100397 us-gaap:RetainedEarningsMember 2022-02-01 2022-04-30 0001100397 2022-02-01 2022-04-30 0001100397 us-gaap:PreferredStockMember 2022-04-30 0001100397 us-gaap:CommonStockMember 2022-04-30 0001100397 us-gaap:AdditionalPaidInCapitalMember 2022-04-30 0001100397 us-gaap:RetainedEarningsMember 2022-04-30 0001100397 2022-04-30 0001100397 us-gaap:PreferredStockMember 2022-05-01 2022-07-31 0001100397 us-gaap:CommonStockMember 2022-05-01 2022-07-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2022-05-01 2022-07-31 0001100397 us-gaap:RetainedEarningsMember 2022-05-01 2022-07-31 0001100397 us-gaap:PreferredStockMember 2022-07-31 0001100397 us-gaap:CommonStockMember 2022-07-31 0001100397 us-gaap:AdditionalPaidInCapitalMember 2022-07-31 0001100397 us-gaap:RetainedEarningsMember 2022-07-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2022-05-01 2022-07-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2021-05-01 2021-07-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2021-11-01 2022-07-31 0001100397 us-gaap:ResearchAndDevelopmentExpenseMember 2020-11-01 2021-07-31 0001100397 srt:ChiefExecutiveOfficerMember 2022-07-31 0001100397 ADXS:OSTherapiesMember ADXS:DevelopmentLicenseAndSupplyAgreementMember 2020-04-29 2020-04-30 0001100397 ADXS:OSTherapiesMember ADXS:DevelopmentLicenseAndSupplyAgreementMember 2018-09-03 2018-09-04 0001100397 ADXS:OSTherapiesMember ADXS:DevelopmentLicenseAndSupplyAgreementMember 2021-04-25 2021-04-30 0001100397 ADXS:OSTherapiesMember ADXS:DevelopmentLicenseAndSupplyAgreementMember 2021-05-01 2021-05-31 0001100397 us-gaap:LicenseAndServiceMember ADXS:GlobalBioPharmaIncMember 2021-11-01 2022-07-31 0001100397 us-gaap:LicenseAndServiceMember ADXS:GlobalBioPharmaIncMember 2020-11-01 2021-07-31 0001100397 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-07-31 0001100397 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2022-07-31 0001100397 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2022-07-31 0001100397 us-gaap:MoneyMarketFundsMember 2022-07-31 0001100397 us-gaap:FairValueInputsLevel1Member 2022-07-31 0001100397 us-gaap:FairValueInputsLevel2Member 2022-07-31 0001100397 us-gaap:FairValueInputsLevel3Member 2022-07-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember us-gaap:FairValueInputsLevel1Member 2022-07-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember us-gaap:FairValueInputsLevel2Member 2022-07-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember us-gaap:FairValueInputsLevel3Member 2022-07-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2022-07-31 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:PrivatePlacementMember 2022-07-31 0001100397 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-10-31 0001100397 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2021-10-31 0001100397 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2021-10-31 0001100397 us-gaap:MoneyMarketFundsMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel1Member 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member 2021-10-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember us-gaap:FairValueInputsLevel1Member 2021-10-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember us-gaap:FairValueInputsLevel2Member 2021-10-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember us-gaap:FairValueInputsLevel3Member 2021-10-31 0001100397 ADXS:ThroughSeptemberTwoThousandTwentyFourMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel1Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel2Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:FairValueInputsLevel3Member us-gaap:PrivatePlacementMember 2021-10-31 0001100397 us-gaap:PrivatePlacementMember 2021-10-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2021-10-31 0001100397 ADXS:WarrantLiabilityMember 2021-10-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2021-11-01 2022-07-31 0001100397 ADXS:WarrantLiabilityMember 2021-11-01 2022-07-31 0001100397 ADXS:PreferredStockRedemptionLiabilityMember 2022-07-31 0001100397 ADXS:WarrantLiabilityMember 2022-07-31 iso4217:USD shares iso4217:USD shares pure ADXS:Integer 0001100397 false --10-31 Q3 10-Q true 2022-07-31 2022 false 001-36138 ADVAXIS, INC. DE 02-0563870 9 Deer Park Drive Suite K-1 Monmouth Junction NJ 08852 (609) 452-9813 Yes Yes Non-accelerated Filer true false false 1815951 28150000 41614000 1667000 1643000 29817000 43257000 73000 118000 181000 3354000 19000 40000 11000 11000 30101000 46780000 90000 87000 1510000 2836000 19000 28000 287000 4929000 1906000 7880000 12000 1906000 7892000 0.001 0.001 0 0 0 0 0 0 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 170000000 170000000 1815951 1815951 1820452 1820452 2000 2000 466561000 467486000 -438368000 -428600000 28195000 38888000 30101000 46780000 250000 250000 3240000 2233000 1703000 5371000 8616000 2053000 2678000 6331000 9038000 3005000 3005000 7291000 4381000 14707000 17654000 -7291000 -4131000 -14457000 -14414000 50000 1000 57000 3000 276000 846000 4685000 1814000 2000 -3000 229000 -6963000 -3284000 -9718000 -12368000 50000 50000 50000 -6963000 -3334000 -9768000 -12418000 1025000 -6963000 -3334000 -10793000 -12418000 -3.83 -1.83 -5.93 -8.04 1817761 1820452 1819545 1543927 -9768000 -12418000 74000 511000 4642000 1814000 43000 1530000 159000 90000 3005000 45000 366000 210000 203000 21000 327000 116000 24000 -488000 -171000 -1323000 513000 -165000 -21000 -1389000 -12307000 -11703000 219000 201000 323000 -201000 -104000 4312000 28115000 18000 5250000 3771000 -956000 31886000 -13464000 20079000 41614000 25178000 28150000 45257000 50000 50000 44000 1025000 <p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zR0ptzMmw7A" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_82B_zp5bVCszji2d">NATURE OF OPERATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advaxis, Inc. (“Advaxis” or the “Company”) is a clinical-stage biotechnology company focused on the development and commercialization of proprietary <i>Listeria monocytogenes</i> (“<i>Lm</i>”)-based antigen delivery products. The Company is using its <i>Lm </i>platform directed against tumor-specific targets in order to engage the patient’s immune system to destroy tumor cells. Through a license from the University of Pennsylvania, Advaxis has exclusive access to this proprietary formulation of attenuated <i>Lm</i> called <i>Lm</i> Technology<sup>TM</sup>. Advaxis’ proprietary approach is designed to deploy a unique mechanism of action that redirects the immune system to attack cancer in three distinct ways:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.6in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alerting and training the immune system by activating multiple pathways in Antigen-Presenting Cells (“APCs”) with the equivalent of multiple adjuvants;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attacking the tumor by generating a strong, cancer-specific T cell response; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breaking down tumor protection through suppression of the protective cells in the tumor microenvironment (“TME”) that shields the tumor from the immune system. This enables the activated T cells to begin working to attack the tumor cells.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advaxis’ proprietary <i>Lm</i> platform technology has demonstrated clinical activity in several of its programs and has been dosed in over 470 patients across multiple clinical trials and in various tumor types. The Company believes that <i>Lm</i> Technology immunotherapies can complement and address significant unmet needs in the current oncology treatment landscape. Specifically, its product candidates have the potential to work synergistically with other immunotherapies, including checkpoint inhibitors, while having a generally well-tolerated safety profile.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COVID-19</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 11, 2020, the World Health Organization characterized the outbreak of the novel coronavirus (“COVID-19”) as a global pandemic and recommended containment and mitigation measures. Since then, extraordinary actions have been taken by international, federal, state, and local public health and governmental authorities to contain and combat the outbreak and spread of COVID-19 in regions throughout the world. The continued impact of the COVID-19 pandemic cannot be predicted at this time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Capital Resources</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liquidity and Management’s Plans</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar to other development stage biotechnology companies, the Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses and requires significant cash resources to execute its business plans. These losses are expected to continue for the foreseeable future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of July 31, 2022, the Company had approximately $<span id="xdx_906_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20220731_zgDVFEkbGfr2" title="Cash and cash equivalents, at carrying value">28.2</span> million in cash and cash equivalents. Although the Company expects to have sufficient capital to fund its obligations, as they become due, in the ordinary course of business until at least one year from the issuance of these consolidated financial statements, the actual amount of cash that it will need to operate is subject to many factors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes it will need to raise additional capital in order to continue to execute its business plan in the future. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to further scale back its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 28200000 <p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zJPiteo5leea" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_82B_ziNXjjaBw614">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zPD1vgnDoAli" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zwWeLCAGjWo6">Basis of Presentation/Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed consolidated balance sheet as of July 31, 2022 has been derived from the Company’s October 31, 2021 audited financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2021 and notes thereto contained in the Company’s 2021 Annual Report on Form 10-K, as filed with the SEC on February 14, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zKHhWCmt9hqa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_ze2pustBNrN">Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zHMOJVDvv1yl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zxtwhzx7SZD9">Restricted Cash</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 31, 2022, the Company transferred $<span id="xdx_90B_eus-gaap--RestrictedCash_iI_c20220131__us-gaap--StatementClassOfStockAxis__custom--SeriesDPreferredStockRedemptionMember_zaFhL2pgsLze" title="Restricted cash">5,250,000</span> into an escrow fund to fund a potential Series D preferred stock redemption. On April 6, 2022, the Series D convertible preferred stock was redeemed utilizing the entire amount held in the escrow fund.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_ecustom--ConvertablePreferredStockPolicyTextBlock_zNTEbGbnEkLb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zQDVWrxrrYQi">Convertible Preferred Stock</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (“mezzanine”) until such time as the conditions are removed or lapse.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--DerivativesReportingOfDerivativeActivity_zqGxBiAOfBI2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z8Pemipl1uje">Derivative Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For share-based derivative financial instruments, the Company used the Monte Carlo simulation model, the Black Scholes model and a binomial model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months after the balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zinffIuuGnil" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zVuXG88FiBzj">Net Income (Loss) per Share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:</span></p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zU6fs0uZVI8e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zciRmZoIraJ4" style="display: none">SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20211101__20220731_zIP5KjdATplc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20201101__20210731_zdDFwIPa4b0d" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of July 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zYDdVOYLUSF3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 68%"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">377,818</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">377,818</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zHNvthn3UMk4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,118</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,892</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zOJnnfB3DYSd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">388,936</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">390,710</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A3_z4kroySoOJk1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--ReverseStockSplitPolicyTextBlock_zmL3QcfCUcta" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><i><span id="xdx_86D_zNtv5k1p6E37">Reverse Stock Split</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">On March 31, 2022, the Company’s stockholders voted to approve an amendment to allow the Company to execute a reverse stock split of common stock within a range of 1 for 20 to 1 for 80, without reducing the authorized number of shares of the common stock, at the discretion of the Board of Directors. On June 3, 2022, the Board of Directors approved a 1 for 80 reverse stock split, which became effective on June 6, 2022. All references in this Report to number of shares, price per share and weighted average number of shares of common stock outstanding prior to this reverse stock split have been adjusted to reflect the reverse stock split on a retroactive basis, unless otherwise noted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3ACupIyxbe1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zSjysOVlQRJc">Recent Accounting Standards</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU 2019-12, Simplification of Income Taxes (Topic 740) Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share (“EPS”) calculations as a result of these changes. The standard will be effective for the Company for fiscal years beginning after December 15, 2023 and can be applied on either a fully retrospective or modified retrospective basis. Early adoption is permitted for fiscal years beginning after December 15, 2020. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.</span></p> <p id="xdx_858_zx0PjzS9wUsi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zPD1vgnDoAli" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zwWeLCAGjWo6">Basis of Presentation/Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited interim condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements and the accompanying unaudited interim condensed consolidated balance sheet as of July 31, 2022 has been derived from the Company’s October 31, 2021 audited financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements furnished include all adjustments (consisting of normal recurring accruals) necessary for a fair statement of the results for the interim periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating results for interim periods are not necessarily indicative of the results to be expected for the full year. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates include the timelines associated with revenue recognition on upfront payments received, fair value and recoverability of the carrying value of property and equipment and intangible assets, fair value of warrant liability, grant date fair value of options, deferred tax assets and any related valuation allowance and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results could materially differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements of the Company as of and for the fiscal year ended October 31, 2021 and notes thereto contained in the Company’s 2021 Annual Report on Form 10-K, as filed with the SEC on February 14, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zKHhWCmt9hqa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_ze2pustBNrN">Principles of Consolidation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany accounts and transactions have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zHMOJVDvv1yl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_zxtwhzx7SZD9">Restricted Cash</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 31, 2022, the Company transferred $<span id="xdx_90B_eus-gaap--RestrictedCash_iI_c20220131__us-gaap--StatementClassOfStockAxis__custom--SeriesDPreferredStockRedemptionMember_zaFhL2pgsLze" title="Restricted cash">5,250,000</span> into an escrow fund to fund a potential Series D preferred stock redemption. On April 6, 2022, the Series D convertible preferred stock was redeemed utilizing the entire amount held in the escrow fund.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5250000 <p id="xdx_84F_ecustom--ConvertablePreferredStockPolicyTextBlock_zNTEbGbnEkLb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zQDVWrxrrYQi">Convertible Preferred Stock</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity (“mezzanine”) until such time as the conditions are removed or lapse.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--DerivativesReportingOfDerivativeActivity_zqGxBiAOfBI2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z8Pemipl1uje">Derivative Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For share-based derivative financial instruments, the Company used the Monte Carlo simulation model, the Black Scholes model and a binomial model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the consolidated balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months after the balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zinffIuuGnil" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_zVuXG88FiBzj">Net Income (Loss) per Share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, restricted stock units and other potential common stock outstanding during the period. In the case of a net loss, the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table below sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share:</span></p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zU6fs0uZVI8e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zciRmZoIraJ4" style="display: none">SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20211101__20220731_zIP5KjdATplc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20201101__20210731_zdDFwIPa4b0d" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of July 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zYDdVOYLUSF3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 68%"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">377,818</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">377,818</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zHNvthn3UMk4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,118</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,892</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zOJnnfB3DYSd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">388,936</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">390,710</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A3_z4kroySoOJk1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zU6fs0uZVI8e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B2_zciRmZoIraJ4" style="display: none">SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20211101__20220731_zIP5KjdATplc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20201101__20210731_zdDFwIPa4b0d" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">As of July 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zYDdVOYLUSF3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 68%"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">377,818</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">377,818</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zHNvthn3UMk4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock options</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,118</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,892</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zOJnnfB3DYSd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">388,936</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">390,710</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 377818 377818 11118 12892 388936 390710 <p id="xdx_848_ecustom--ReverseStockSplitPolicyTextBlock_zmL3QcfCUcta" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white"><i><span id="xdx_86D_zNtv5k1p6E37">Reverse Stock Split</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">On March 31, 2022, the Company’s stockholders voted to approve an amendment to allow the Company to execute a reverse stock split of common stock within a range of 1 for 20 to 1 for 80, without reducing the authorized number of shares of the common stock, at the discretion of the Board of Directors. On June 3, 2022, the Board of Directors approved a 1 for 80 reverse stock split, which became effective on June 6, 2022. All references in this Report to number of shares, price per share and weighted average number of shares of common stock outstanding prior to this reverse stock split have been adjusted to reflect the reverse stock split on a retroactive basis, unless otherwise noted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z3ACupIyxbe1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zSjysOVlQRJc">Recent Accounting Standards</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU 2019-12, Simplification of Income Taxes (Topic 740) Income Taxes (“ASU 2019-12”). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 is effective for public companies for annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain convertible instruments, amends guidance on derivative scope exceptions for contracts in an entity’s own equity, and modifies the guidance on diluted earnings per share (“EPS”) calculations as a result of these changes. The standard will be effective for the Company for fiscal years beginning after December 15, 2023 and can be applied on either a fully retrospective or modified retrospective basis. Early adoption is permitted for fiscal years beginning after December 15, 2020. The Company adopted this standard effective November 1, 2021 and it is not material to the financial results of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed consolidated financial statements.</span></p> <p id="xdx_804_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmxycIOGLH3f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span id="xdx_824_zU0yPdkmok8d">PROPERTY AND EQUIPMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjjyhoq1X1T8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zak2wks9otdk" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20220731_z0FNjrUIvwce" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20211031_zAK4rACeNN68" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzkmD_zebP3aSdj2Li" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Laboratory equipment</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">179</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">179</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzkmD_zL9inmyd5e97" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">241</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">241</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzkmD_maPPAENzKAl_zTe26VztFU79" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total property and equipment</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">420</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">420</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzKAl_zlIZGcqX8RNf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated depreciation</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(347</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(302</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzKAl_zIBVMN371PK" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net property and equipment</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">73</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">118</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AD_zL5IzSg44zL6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense for the three months ended July 31, 2022 and 2021 was approximately $<span id="xdx_902_eus-gaap--Depreciation_pp0p0_c20220501__20220731_zVdgyy23dW59" title="Depreciation expense">13,000</span> and $<span id="xdx_901_eus-gaap--Depreciation_pp0p0_c20210501__20210731_zqW0N1wuknUl" title="Depreciation expense">50,000</span>, respectively. Depreciation expense for the nine months ended July 31, 2022 and 2021 was approximately $<span id="xdx_901_eus-gaap--Depreciation_c20211101__20220731_zMegZIjUGyil" title="Depreciation expense">45,000</span> and $<span id="xdx_90C_eus-gaap--Depreciation_c20201101__20210731_zDXET5dnimYf" title="Depreciation expense">366,000</span>, respectively. During the nine months ended July 31, 2021, the Company incurred a loss on disposal of equipment of approximately $<span id="xdx_90F_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_pp0p0_c20201101__20210731_ztolJVpiOjUk" title="Gain loss on sale of property plant equipment">1,530,000</span>, $<span id="xdx_902_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_pp0p0_c20201101__20210731__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndDevelopmentMember_zCDzPXWHNsO" title="Gain loss on sale of property plant equipment">968,000</span> of which is reflected in the research and development expenses and $<span id="xdx_905_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_pp0p0_c20201101__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zJocWd8nD4lj" title="Gain loss on sale of property plant equipment">562,000</span> of which is reflected in the general and administrative expenses in the condensed consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zjjyhoq1X1T8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zak2wks9otdk" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20220731_z0FNjrUIvwce" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20211031_zAK4rACeNN68" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzkmD_zebP3aSdj2Li" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Laboratory equipment</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">179</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">179</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzkmD_zL9inmyd5e97" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Computer equipment</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">241</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">241</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzkmD_maPPAENzKAl_zTe26VztFU79" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total property and equipment</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">420</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">420</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzKAl_zlIZGcqX8RNf" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated depreciation</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(347</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(302</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzKAl_zIBVMN371PK" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net property and equipment</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">73</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">118</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 179000 179000 241000 241000 420000 420000 347000 302000 73000 118000 13000 50000 45000 366000 1530000 968000 562000 <p id="xdx_804_eus-gaap--IntangibleAssetsDisclosureTextBlock_zbfzPjzNSMmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. <span id="xdx_82A_zvbBponxNo2e">INTANGIBLE ASSETS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zTED84orMt9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zqvTHNldMqS8" style="display: none">SUMMARY OF INTANGIBLE ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20220731_zfauGosaVh13" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20211031_z4bwiA1gL9Qc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedPatentsGross_iI_pn3n3_maFLIAGzVwq_zgkdbpqGfFZd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">275</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,836</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedLicenseAgreementsGross_iI_pn3n3_maFLIAGzVwq_zAyNL3Ts7lti" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">License</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">777</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_ecustom--FiniteLivedSoftwareGross_iI_pn3n3_maFLIAGzVwq_zk4unzGcwILi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Software</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">98</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">98</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsGross_iTI_pn3n3_mtFLIAGzVwq_maIANEGzsX7_zBgiUc1kIX76" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total intangibles</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">417</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,711</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msIANEGzsX7_zdBkhpecyxXc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated amortization</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(236</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,357</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtIANEGzsX7_zvvvQv49OQbc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">181</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,354</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A2_zvZEpdfVBab6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expiration dates of the existing patents range from 2022 to 2039 but the expiration dates can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to further pursue the application. Patent applications having a net book value of approximately $<span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2RnwqXHepIi" title="Book value patent applications, net">29,000</span> and $<span id="xdx_907_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20210501__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zq9T4DS4jz67" title="Book value patent applications, net">21,000</span> were abandoned and were charged to general and administrative expenses in the condensed consolidated statement of operations for the three months ended July 31, 2022 and 2021, respectively. Patent applications having a net book value of approximately $<span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20211101__20220731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z9ZIC7bOgco7" title="Book value patent applications, net">159,000</span> and $<span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_c20201101__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z5vPXML7skO" title="Book value patent applications, net">90,000</span> were abandoned and were charged to general and administrative expenses in the condensed consolidated statement of operations for the nine months ended July 31, 2022 and 2021, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the condensed consolidated statement of operations aggregated approximately $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20220501__20220731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z8Y7hQcqsShb" title="Intangible asset amortization expense">70,000</span> and $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_c20210501__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zAU6RUNNl222" title="Intangible asset amortization expense">68,000</span> for the three months ended July 31, 2022 and 2021, respectively. Amortization expense for intangible assets that was charged to general and administrative expense in the condensed consolidated statement of operations aggregated approximately $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20211101__20220731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zjbHzb2RGtMg" title="Intangible asset amortization expense">210,000</span> and $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20201101__20210731__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zboQ9hj26tk3" title="Intangible asset amortization expense">203,000</span> for the nine months ended July 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management reviews its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Net assets are recorded on the balance sheet for patents related to ADXS-HPV (AXAL), ADXS-HOT, ADXS-PSA, ADXS-HER2 and other products that are in development, and the <i>Lm </i>technology licensed from the University of Pennsylvania. There are various scenarios under which an impairment charge may be recorded, which include if a competitor were to gain FDA approval for a similar treatment before the Company, if future clinical trials fail to meet the targeted endpoints, or if a drug application is rejected or fails to be issued. Lastly, if the Company is unable to raise enough capital to continue funding its studies and developing its intellectual property, the Company would likely record an impairment to these assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended July 31, 2022, the Company identified the following indicators of impairment under ASC 360 indicating that the patents and license carrying amounts might not be recoverable:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse changes in the business climate for biotechnology companies, particularly raising capital; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A significant reduction in the Company’s market capitalization during the nine months ended July 31, 2022.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company performed an impairment test under ASC 350 on its patents owned and in-licensed intellectual property. Under this test a fair value of the relevant asset is compared with the carrying amount of such asset. Fair value is calculated using a discounted cash flow analysis. Cash flows are discounted using a weighted average cost of capital derived from comparable companies, which reflects the costs of borrowing as well as the associated risk. The results of the impairment test indicated that the carrying value of the patents owned and in-licensed intellectual property exceeded the fair value. During the three months ended July 31, 2022, the Company recorded an impairment charge for patents owned and in-licensed intellectual property of approximately $<span id="xdx_909_eus-gaap--AssetImpairmentCharges_c20220501__20220731_zwEzc4HTLmO5" title="Asset impairment charges">3,005,000</span> in its condensed consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zw4GfjNYYqx" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of July 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zNS5zL2Kcbvb" style="display: none">SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20220731_zm0Buk63Rnf3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fiscal year ending October 31,</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzybQ_zvIQnVHWQcf1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 79%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022 (Remaining)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzybQ_z5thUORUMHb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">94</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzybQ_z8seyW8mWS9i" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzybQ_zCbcscntMYN8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">181</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A4_zswin1NSoob" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zTED84orMt9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net consisted of the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zqvTHNldMqS8" style="display: none">SUMMARY OF INTANGIBLE ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20220731_zfauGosaVh13" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20211031_z4bwiA1gL9Qc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedPatentsGross_iI_pn3n3_maFLIAGzVwq_zgkdbpqGfFZd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">275</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,836</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedLicenseAgreementsGross_iI_pn3n3_maFLIAGzVwq_zAyNL3Ts7lti" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">License</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">777</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_ecustom--FiniteLivedSoftwareGross_iI_pn3n3_maFLIAGzVwq_zk4unzGcwILi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Software</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">98</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">98</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsGross_iTI_pn3n3_mtFLIAGzVwq_maIANEGzsX7_zBgiUc1kIX76" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total intangibles</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">417</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,711</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pn3n3_di_msIANEGzsX7_zdBkhpecyxXc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated amortization</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(236</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,357</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtIANEGzsX7_zvvvQv49OQbc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">181</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,354</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 275000 4836000 44000 777000 98000 98000 417000 5711000 236000 2357000 181000 3354000 29000 21000 159000 90000 70000 68000 210000 203000 3005000 <p id="xdx_890_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zw4GfjNYYqx" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of July 31, 2022, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zNS5zL2Kcbvb" style="display: none">SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20220731_zm0Buk63Rnf3" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Fiscal year ending October 31,</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANzybQ_zvIQnVHWQcf1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 79%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022 (Remaining)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzybQ_z5thUORUMHb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">94</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzybQ_z8seyW8mWS9i" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzybQ_zCbcscntMYN8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">181</span></td><td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 24000 94000 63000 181000 <p id="xdx_80E_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zFTxYk0S94gl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. <span id="xdx_822_z4HQuqtpdka7">ACCRUED EXPENSES</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z6jWr5h3dQih" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_z5HqCIiQAvvf" style="display: none">SUMMARY OF ACCRUED EXPENSES</span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20220731_zkoeKIYAF8R5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20211031_zcNm9WpqQkQi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzolp_zM0FUpL0lw1l" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Salaries and other compensation</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">116</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_maALCzolp_zkwP6st1EVge" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Vendors</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">851</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,968</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzolp_zxj6Ksyzr7Na" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional fees</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">343</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">613</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzolp_zGCzAuNZSWp" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzolp_zNbD0Z4th7G" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total accrued expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,510</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,836</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AA_zarLzQPbR0te" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z6jWr5h3dQih" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes accrued expenses included in the condensed consolidated balance sheets (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_z5HqCIiQAvvf" style="display: none">SUMMARY OF ACCRUED EXPENSES</span></span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20220731_zkoeKIYAF8R5" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20211031_zcNm9WpqQkQi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzolp_zM0FUpL0lw1l" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Salaries and other compensation</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">116</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_pn3n3_maALCzolp_zkwP6st1EVge" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Vendors</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">851</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,968</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzolp_zxj6Ksyzr7Na" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional fees</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">343</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">613</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzolp_zGCzAuNZSWp" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzolp_zNbD0Z4th7G" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total accrued expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,510</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,836</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 116000 55000 851000 1968000 343000 613000 200000 200000 1510000 2836000 <p id="xdx_801_eus-gaap--LesseeOperatingLeasesTextBlock_zpt0SxhhND41" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. <span id="xdx_825_zl5ozQsdHZJ4">LEASES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating Leases</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company previously leased a corporate office and manufacturing facility in Princeton, New Jersey under an operating lease that was set to expire in <span id="xdx_90C_ecustom--LeaseExpirationDateDescription_c20211101__20220731_zBkbRHsFyifj" title="Lease expiration date">November 2025</span>. On March 26, 2021, the Company entered into a Lease Termination and Surrender Agreement with respect to this lease agreement. The Lease Termination and Surrender Agreement provides for the early termination of the lease, which became effective on March 31, 2021. In connection with the early termination of the lease, the Company was required to pay a $<span id="xdx_90C_eus-gaap--GainLossOnTerminationOfLease_c20210301__20210326_zm52qR0oBpn" title="Lease termination">1,000,000</span> termination payment. The unapplied security deposit totaling approximately $<span id="xdx_904_eus-gaap--SecurityDeposit_iI_c20210326_z16mvuztPmQb" title="Security deposit">182,000</span> was credited against the termination fee for a net payment of approximately $<span id="xdx_909_eus-gaap--GainLossOnDispositionOfAssets1_c20210301__20210326_zlZbymXx549h" title="Net payment for termination fee">818,000</span>. The Company wrote off of the remaining right-of-use asset of approximately $<span id="xdx_902_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20210326_z85RQMUYKI8b" title="Operating lease, right of use asset">4,512,000</span> and lease liability of approximately $<span id="xdx_908_eus-gaap--OperatingLeaseLiability_iI_c20210326_za2ReYsEJmv7" title="Operating lease liability">5,628,000</span>. After consideration of the termination payment and write off of the remaining right-of-use asset and lease liability, the Company recorded a net gain of approximately $<span id="xdx_908_eus-gaap--ReceivablesNetCurrent_iI_c20210326_zRb8YReLznLc" title="Net gain on leases">116,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 25, 2021, the Company entered into a new one-year lease agreement for its corporate office/lab with base rent of approximately $<span id="xdx_901_ecustom--PaymentOfRent_iI_c20210325_zbw735qbDkx9" title="Payment of rent">29,000</span> per year, plus other expenses. This lease was accounted for as a short-term lease at inception, and the Company elected not to recognize a right-of-use asset and lease liability. In September 2021, the Company exercised its option to renew the lease, extending the lease term until <span id="xdx_902_ecustom--LesseeFinanceLeasesRenewalTerm_dd_c20210301__20210325_zQIA4iN5yzt5" title="Lessee finance lease renewal term date">March 25, 2023</span>. Since the renewed lease term exceeded one-year, the lease no longer qualified for the short-term lease exception, resulting in the recognition of a right-of-use asset and operating lease liability of approximately $<span id="xdx_90B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20210325_zAKxcNuByl64" title="Operating lease, right of use asset"><span id="xdx_900_eus-gaap--OperatingLeaseLiability_iI_c20210325_zuI5NPbrluCj" title="Operating lease liability">43,000</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zdHRYncsTo8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental balance sheet information related to leases was as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zrsNhkrpxWbd" style="display: none">SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20220731_zQYNVq6WIa8f" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20211031_z4KP7gbIqeWa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating leases: </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease right-of-use assets</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzSE5_zlGeSjQnigWb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease liability</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzSE5_zuHRlO1StZR1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease liability, net of current portion</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0545">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzSE5_z3ojBpLduRMh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total operating lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A9_z6oHOpxsfH13" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_z9IbnpwdNSnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental lease expense related to leases was as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zOJa2OhyHGte" style="display: none">SCHEDULE OF LEASE EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease Cost (in thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Statements of Operations Classification</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20220501__20220731_zaDirXrsXmxd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the Three</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20211101__20220731_zBR6DIjHTlsi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the Nine</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_maLCzh2P_z7Rb5IQHIJY8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease cost</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 24%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--VariableLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_maLCzh2P_zdnCO6JILBsj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Variable lease cost</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_mtLCzh2P_zGUeFoNHwyn" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total lease expense</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">58</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease Cost (in thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Statements of Operations Classification</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_499_20210501__20210731_zMTxMXsBpzW8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the Three</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31, 2021</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20201101__20210731_z1VNXeJ0VwX1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the nine</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31, 2021</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_maLCzh2P_z4fiMeULV7v3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease cost</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 24%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,301</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZfedRXBHGe5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Short-term lease cost</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--VariableLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_maLCzh2P_zgSM5dOt2tOk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Variable lease cost</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">165</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--LeaseCost_iT_pn3n3_mtLCzh2P_zM9K9b8puVu7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total lease expense</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,482</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A5_zfKHcw6iPLQ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_ecustom--ScheduleOfOtherInformationTableTextBlock_zY5f0obRuEZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other information related to leases where the Company is the lessee is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zN79ySbmaZr8" style="display: none">SCHEDULE OF OTHER INFORMATION RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Weighted-average remaining lease term</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220731_zVS9oR0D0Kdb" title="Weighted-average remaining lease term">0.7</span> years</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211031_zbmIbSn0R6Ea" title="Weighted-average remaining lease term">1.4</span> years</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-average discount rate</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220731_zEOFnsTSSNlf" title="Weighted-average discount rate">3.79</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211031_zzMWT5TZme3k" title="Weighted-average discount rate">3.79</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p id="xdx_8A6_zhnzaspjMCEd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zliXSupNYfgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to operating leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zznXxvYxWTy5" style="display: none">SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20211101__20220731_z4D4bWvoLGnk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the Nine</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20201101__20210731_z0fiH38XYkw8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the Nine</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31, 2021</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn3n3_zwj07sPV7o2j" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid for operating lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,363</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AD_z8ZtfUeJcCne" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zFplmFDhhw4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease payments under non-cancellable leases as of July 31, 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z4qocmqXXJ0i" style="display: none">SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_496_20220731_zPdY2uhOpi04" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Fiscal Year ending October 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzpLw_zk5ESf8RwFJh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif">2022 (Remaining)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzpLw_z5U4IeD8JoMe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzpLw_zfhtIPjN46q6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total minimum lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_zeELuj1rK8ic" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less: Imputed interest</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zZrc4ciCLzwd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AE_z0cbMG2rLSP6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> November 2025 1000000 182000 818000 4512000 5628000 116000 29000 2023-03-25 43000 43000 <p id="xdx_89B_ecustom--ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_zdHRYncsTo8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental balance sheet information related to leases was as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zrsNhkrpxWbd" style="display: none">SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20220731_zQYNVq6WIa8f" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20211031_z4KP7gbIqeWa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating leases: </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3n3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease right-of-use assets</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3n3_maOLLzSE5_zlGeSjQnigWb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease liability</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3n3_maOLLzSE5_zuHRlO1StZR1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease liability, net of current portion</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0545">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_pn3n3_mtOLLzSE5_z3ojBpLduRMh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total operating lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 19000 40000 19000 28000 12000 19000 40000 <p id="xdx_891_eus-gaap--LeaseCostTableTextBlock_z9IbnpwdNSnc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental lease expense related to leases was as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zOJa2OhyHGte" style="display: none">SCHEDULE OF LEASE EXPENSES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease Cost (in thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Statements of Operations Classification</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20220501__20220731_zaDirXrsXmxd" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the Three</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20211101__20220731_zBR6DIjHTlsi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the Nine</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_maLCzh2P_z7Rb5IQHIJY8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease cost</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 24%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--VariableLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_maLCzh2P_zdnCO6JILBsj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Variable lease cost</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--LeaseCost_iT_pn3n3_mtLCzh2P_zGUeFoNHwyn" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total lease expense</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">58</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Lease Cost (in thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Statements of Operations Classification</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_499_20210501__20210731_zMTxMXsBpzW8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the Three</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31, 2021</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20201101__20210731_z1VNXeJ0VwX1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the nine</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31, 2021</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_maLCzh2P_z4fiMeULV7v3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease cost</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 24%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,301</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--ShortTermLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zZfedRXBHGe5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Short-term lease cost</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--VariableLeaseCost_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_maLCzh2P_zgSM5dOt2tOk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Variable lease cost</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">165</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--LeaseCost_iT_pn3n3_mtLCzh2P_zM9K9b8puVu7" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total lease expense</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,482</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 7000 22000 17000 36000 24000 58000 1301000 12000 16000 4000 165000 16000 1482000 <p id="xdx_897_ecustom--ScheduleOfOtherInformationTableTextBlock_zY5f0obRuEZ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other information related to leases where the Company is the lessee is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zN79ySbmaZr8" style="display: none">SCHEDULE OF OTHER INFORMATION RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Weighted-average remaining lease term</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220731_zVS9oR0D0Kdb" title="Weighted-average remaining lease term">0.7</span> years</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211031_zbmIbSn0R6Ea" title="Weighted-average remaining lease term">1.4</span> years</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Weighted-average discount rate</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20220731_zEOFnsTSSNlf" title="Weighted-average discount rate">3.79</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211031_zzMWT5TZme3k" title="Weighted-average discount rate">3.79</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> P0Y8M12D P1Y4M24D 0.0379 0.0379 <p id="xdx_896_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zliXSupNYfgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to operating leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zznXxvYxWTy5" style="display: none">SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49E_20211101__20220731_z4D4bWvoLGnk" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the Nine</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20201101__20210731_z0fiH38XYkw8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">For the Nine</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31, 2021</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLeaseIncomeLeasePayments_pn3n3_zwj07sPV7o2j" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash paid for operating lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,363</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 22000 1363000 <p id="xdx_899_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zFplmFDhhw4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum lease payments under non-cancellable leases as of July 31, 2022 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z4qocmqXXJ0i" style="display: none">SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"> </td><td style="font-family: Times New Roman, Times, Serif"> </td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_496_20220731_zPdY2uhOpi04" style="font-family: Times New Roman, Times, Serif; text-align: right"> </td><td style="font-family: Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Fiscal Year ending October 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzpLw_zk5ESf8RwFJh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 80%"><span style="font-family: Times New Roman, Times, Serif">2022 (Remaining)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzpLw_z5U4IeD8JoMe" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzpLw_zfhtIPjN46q6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total minimum lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pn3n3_zeELuj1rK8ic" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less: Imputed interest</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zZrc4ciCLzwd" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 7000 13000 20000 1000 19000 <p id="xdx_805_ecustom--CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock_zST0Aq73cIpc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. <span id="xdx_823_ztqzGVvFBAzc">COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of July 31, 2022 and October 31, 2021, there were outstanding and exercisable warrants to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z26SPTyc77S6" title="Warrants outstanding"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrUWJQH232Hh" title="Grand total number of shares underlying warrants"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoWRmnOz6Weh" title="Warrants outstanding"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBIcFsYFvlye" title="Grand total number of shares underlying warrants">377,818</span></span></span></span> shares of our common stock with exercise prices ranging from $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zqD10IoBLkUf" title="Exercise price"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zb7Swjmywqu5">20.00</span></span> to $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z1anZv3Xzy07" title="Exercise price"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_ze0I4DC9QIA" title="Exercise price">224.00</span></span> per share. Information on the outstanding warrants is as follows:</span></p> <p id="xdx_895_ecustom--ScheduleOfOutstandingWarrantsTableTextBlock_znDkNKAy48c2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zcRpPTNwYVTd" style="display: none">SCHEDULE OF COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Number of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Shares</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Underlying</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Expiration Date</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Type of Financing</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_ziioziKMkiy4" title="Exercise Price"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_z60cLFuffqR1" title="Exercise Price">20.00</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zpllSYkqxJq7" title="Grand Total Number of Shares Underlying Warrants"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zG5Wp3uqikE7" title="Grand Total Number of Shares Underlying Warrants">879</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 29%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_ecustom--WarrantsExpirationDescription_dd_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zfBRcjqHHgy9" title="Expiration Date"><span id="xdx_908_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zuFWCIA6zp49" title="Expiration Date">September 2024</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 38%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zf01hglWlbNc" title="Type of financing"><span id="xdx_902_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zDsUw1kjjg4a" title="Type of financing">September 2018 Public Offering</span></span></span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zp0p0inwvjC6" title="Exercise Price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zaZP6VNw6qW6" title="Exercise Price">224.00</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zhG1V9GtXPf4" title="Grand Total Number of Shares Underlying Warrants"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_z6yTfxBxLQf4" title="Grand Total Number of Shares Underlying Warrants">4,092</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--WarrantsExpirationDescription_dd_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zDLZdA5RzHEk" title="Expiration Date"><span id="xdx_908_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zyy85ugooIJc" title="Expiration Date">July 2024</span></span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_z2rEC2dY4kic" title="Type of financing"><span id="xdx_908_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_ztnJ5c3DTmDk" title="Type of financing">July 2019 Public Offering</span></span></span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_ziqOChP5oco9" title="Exercise Price"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zlhMHStPZEKe" title="Exercise Price">28.00</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zywBZhSJ7uXb" title="Grand Total Number of Shares Underlying Warrants"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zHKbFC01oJr8" title="Grand Total Number of Shares Underlying Warrants">57,230</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--WarrantsExpirationDescription_dd_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zQfJ0jjnrTFe" title="Expiration Date"><span id="xdx_90A_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zqwjN4yHDwS8" title="Expiration Date">November 2025</span></span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_z39zW24UnL1b" title="Type of financing"><span id="xdx_90C_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zaBNjA6bBm4j" title="Type of financing">November 2020 Public Offering</span></span></span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z2YePUDX2ySa" title="Exercise Price"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zHPqfMtOaAJ7" title="Exercise Price">56.00</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zXHu4YKzWxod" title="Grand Total Number of Shares Underlying Warrants"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z52VMLNV3581" title="Grand Total Number of Shares Underlying Warrants">140,552</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--WarrantsExpirationDescription_dd_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z0RaZFd5Zd3e" title="Expiration Date"><span id="xdx_903_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zGZCjPZxEW71">April 2026</span></span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zqB9uKcSy4l5" title="Type of financing"><span id="xdx_902_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z8VdBUz4tEO6" title="Type of financing">April 2021 Registered Direct Offering (Accompanying Warrants)</span></span></span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zvjHsYFZ8Rh" title="Exercise Price"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zbqEf2lEj2A4" title="Exercise Price">56.00</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zDy2w7hlnuvj" title="Grand Total Number of Shares Underlying Warrants"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_znAnyxVH5Qkj" title="Grand Total Number of Shares Underlying Warrants">175,065</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--WarrantsExpirationDescription_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zYsLdWxpekia" title="Expiration Date"><span id="xdx_907_ecustom--WarrantsExpirationDescription_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zMpUUvta6ewi" title="Expiration Date">5 years after the date such warrants become exercisable, if ever</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zlen2iE1b6cd" title="Type of financing"><span id="xdx_902_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zdhWhqOpD4E1" title="Type of financing">April 2021 Private Placement (Private Placement Warrants)</span></span></span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grand Total</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220731_z7PX8qAKlYK9" title="Grand Total Number of Shares Underlying Warrants"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20211031_zbY6rGDF9Tk6" title="Grand Total Number of Shares Underlying Warrants">377,818</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AD_zI1goNt5oJch" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of July 31, 2022 and October 31, 2021, the Company had <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220731__us-gaap--StatementEquityComponentsAxis__custom--EquityWarrantsMember_ztt71hW8bXL2" title="Number of warrants to purchase common stock"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--StatementEquityComponentsAxis__custom--EquityWarrantsMember_zLKCONdkHyA4" title="Number of warrants to purchase common stock">201,874</span></span> of its total <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220731__us-gaap--StatementEquityComponentsAxis__custom--EquityWarrantsMember_ziHjDGIVH59i" title="Warrants outstanding"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211031__us-gaap--StatementEquityComponentsAxis__custom--EquityWarrantsMember_zlnXY4qSGcS6" title="Warrants outstanding">377,818</span></span> outstanding warrants classified as equity (equity warrants).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant Liability</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of July 31, 2022 and October 31, 2021, the Company had <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20220731__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zAwr8DFuaDM7" title="Number of warrants to purchase common stock"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zWg7AXImriU1" title="Number of warrants to purchase common stock">175,944</span></span> of its total <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20220731__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_znjkQM935p12" title="Warrants outstanding"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zul9k13JlBf8" title="Warrants outstanding">377,818</span></span> outstanding warrants from an April 2021 private offering of common stock and warrants (the “April 2021 Private Placement”) and a September 2018 public offering of common stock and warrants (the “September 2018 Public Offering”) classified as liabilities (liability warrants).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants issued in the April 2021 Private Placement will become exercisable only on such day, if ever, that is 14 days after the Company files an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210430_z8tXQFNyBeT8" title="Common stock, par value">0.001</span> par value per share from <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20210430_zGFwi2HP05k4" title="Common stock shares authorized">170,000,000</span> shares to <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_c20210501_zFKFRKafAl58" title="Common stock shares authorized">300,000,000</span> shares. These warrants expire five years after the date they become exercisable. As of July 31, 2022, the Company did not have sufficient authorized common stock to allow for the issuance of common stock underlying these warrants. The Company did not receive stockholder authorization to increase the authorized shares from <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20210603__srt--RangeAxis__srt--MinimumMember_zbwwFKGnt04e" title="Common stock shares authorized">170,000,000</span> to <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20210603__srt--RangeAxis__srt--MaximumMember_zx5RMfRFCkG2" title="Common stock shares authorized">300,000,000</span> shares at the stockholder’s meeting commenced on June 3, 2021. The Company was subsequently required to file a proxy to seek an increase in the number of authorized shares and did not file such a proxy but rather elected to seek a reverse stock split to, among other things, increase the shares available. Accordingly, based on certain indemnification provisions of the securities purchase agreement, the Company concluded that liability classification is warranted. The Company utilized the Black Scholes model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zQGt0ElHa3I6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at July 31, 2022 and October 31, 2021, the Company used the following inputs in its Black Scholes model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zluowKHTqf7l" style="display: none">SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z13IgJjeIxrl" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">56.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zB3zO0guzI35" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">56.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Stock Price</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20220731__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zCFPNAAHch3c" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif">3.73</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zVBFbWQcRZRf" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif">38.80</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected Term</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220731__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zYV6CqfGJ0gc" title="Expected Term">5.00</span> years</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zJcPo9sZdhMf" title="Expected Term">5.00</span> years</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Volatility %</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220731__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zE6OGu3qYs5i" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Measurement input percentage"><span style="font-family: Times New Roman, Times, Serif">112</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zhNUqLemJ80j" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Measurement input percentage"><span style="font-family: Times New Roman, Times, Serif">106</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk Free Rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220731__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zPtTixU8Weud" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Measurement input percentage"><span style="font-family: Times New Roman, Times, Serif">2.70</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZYqweVK3NCb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Measurement input percentage"><span style="font-family: Times New Roman, Times, Serif">1.18</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p id="xdx_8AE_z2GyHbddtkZa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The September 2018 Public Offering warrants contain a down round feature, except for exempt issuances as defined in the warrant agreement, in which the exercise price would immediately be reduced to match a dilutive issuance of common stock, options, convertible securities and changes in option price or rate of conversion. As of July 31, 2022, the down round feature was triggered four times and the exercise price of the warrants were reduced from $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220731__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__srt--RangeAxis__srt--MaximumMember_zpTjbR9Zigte" title="Warrant exercise price per share">1,800.00</span> to $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220731__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__srt--RangeAxis__srt--MinimumMember_ze1IWV8Eyxx7" title="Warrant exercise price per share">20.00</span>. The warrants require liability classification as the warrant agreement requires the Company to maintain an effective registration statement and does not specify any circumstances under which settlement in other than cash would be permitted or required. As a result, net cash settlement is assumed and liability classification is warranted. For these liability warrants, the Company utilized the Monte Carlo simulation model to calculate the fair value of these warrants at issuance and at each subsequent reporting date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zqUCYF1XO936" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In measuring the warrant liability for the September 2018 Public Offering warrants at July 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z37eZIgjsftc" style="display: none">SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zqK4KZ7ibEBi" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">20.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_z8YE7gsmeI69" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">24.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Stock Price</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20220731__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zFdwwA1u9Ft9" title="Stock Price">3.73</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_z5Ahtm0QEqzd" title="Stock Price">38.80</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected Term</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220731__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_z7n1XHMDtEUj" title="Expected Term">2.12</span> years</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zQhAVyEgYTMi" title="Expected Term">2.87</span> years</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Volatility %</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220731__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zRf0uuFz7crj" title="Measurement input percentage">104</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zujx3FltMlx5" title="Measurement input percentage">123</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk Free Rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220731__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zJaEv0QjZKa5" title="Measurement input percentage">2.89</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_z4fpQ5gZiIo1" title="Measurement input percentage">0.77</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p id="xdx_8AF_zeqWfKl8ugX5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At July 31, 2022 and October 31, 2021, the fair value of the warrant liability was approximately $<span id="xdx_907_ecustom--FairValueOfWarrantLiability_iI_c20220731_zD9aIW7godt7" title="Fair value of the warrant liability">287,000</span> and $<span id="xdx_900_ecustom--FairValueOfWarrantLiability_iI_c20211031_ziN7HO5KMHAg" title="Fair value of the warrant liability">4,929,000</span>, respectively. For the three months ended July 31, 2022 and 2021, the Company reported income of approximately $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220501__20220731_zx4x8G0ucsc3" title="Income on fair value of warrants">276,000</span> and $<span id="xdx_902_eus-gaap--FairValueAdjustmentOfWarrants_c20210501__20210731_zXZhDPKBuHli" title="Income on fair value of warrants">846,000</span>, respectively, due to changes in the fair value of the warrant liability. For the nine months ended July 31, 2022 and 2021, the Company reported income of approximately $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_c20211101__20220731_zyZL1slbTyk8" title="Income on fair value of warrants">4,642,000</span> and $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20201101__20210731_zgrNxgcKFXKc" title="Income on fair value of warrants">1,814,000</span>, respectively, due to changes in the fair value of the warrant liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 377818 377818 377818 377818 20.00 20.00 224.00 224.00 <p id="xdx_895_ecustom--ScheduleOfOutstandingWarrantsTableTextBlock_znDkNKAy48c2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zcRpPTNwYVTd" style="display: none">SCHEDULE OF COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Number of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Shares</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Underlying</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Warrants</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Expiration Date</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Type of Financing</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_ziioziKMkiy4" title="Exercise Price"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_z60cLFuffqR1" title="Exercise Price">20.00</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zpllSYkqxJq7" title="Grand Total Number of Shares Underlying Warrants"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zG5Wp3uqikE7" title="Grand Total Number of Shares Underlying Warrants">879</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 29%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_ecustom--WarrantsExpirationDescription_dd_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zfBRcjqHHgy9" title="Expiration Date"><span id="xdx_908_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zuFWCIA6zp49" title="Expiration Date">September 2024</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 38%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zf01hglWlbNc" title="Type of financing"><span id="xdx_902_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zDsUw1kjjg4a" title="Type of financing">September 2018 Public Offering</span></span></span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zp0p0inwvjC6" title="Exercise Price"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zaZP6VNw6qW6" title="Exercise Price">224.00</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zhG1V9GtXPf4" title="Grand Total Number of Shares Underlying Warrants"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_z6yTfxBxLQf4" title="Grand Total Number of Shares Underlying Warrants">4,092</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--WarrantsExpirationDescription_dd_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zDLZdA5RzHEk" title="Expiration Date"><span id="xdx_908_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zyy85ugooIJc" title="Expiration Date">July 2024</span></span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_z2rEC2dY4kic" title="Type of financing"><span id="xdx_908_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_ztnJ5c3DTmDk" title="Type of financing">July 2019 Public Offering</span></span></span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_ziqOChP5oco9" title="Exercise Price"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zlhMHStPZEKe" title="Exercise Price">28.00</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zywBZhSJ7uXb" title="Grand Total Number of Shares Underlying Warrants"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zHKbFC01oJr8" title="Grand Total Number of Shares Underlying Warrants">57,230</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--WarrantsExpirationDescription_dd_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zQfJ0jjnrTFe" title="Expiration Date"><span id="xdx_90A_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zqwjN4yHDwS8" title="Expiration Date">November 2025</span></span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_z39zW24UnL1b" title="Type of financing"><span id="xdx_90C_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zaBNjA6bBm4j" title="Type of financing">November 2020 Public Offering</span></span></span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z2YePUDX2ySa" title="Exercise Price"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zHPqfMtOaAJ7" title="Exercise Price">56.00</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zXHu4YKzWxod" title="Grand Total Number of Shares Underlying Warrants"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z52VMLNV3581" title="Grand Total Number of Shares Underlying Warrants">140,552</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--WarrantsExpirationDescription_dd_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z0RaZFd5Zd3e" title="Expiration Date"><span id="xdx_903_ecustom--WarrantsExpirationDescription_dd_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zGZCjPZxEW71">April 2026</span></span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_zqB9uKcSy4l5" title="Type of financing"><span id="xdx_902_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFourMember_z8VdBUz4tEO6" title="Type of financing">April 2021 Registered Direct Offering (Accompanying Warrants)</span></span></span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zvjHsYFZ8Rh" title="Exercise Price"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zbqEf2lEj2A4" title="Exercise Price">56.00</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zDy2w7hlnuvj" title="Grand Total Number of Shares Underlying Warrants"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_znAnyxVH5Qkj" title="Grand Total Number of Shares Underlying Warrants">175,065</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_ecustom--WarrantsExpirationDescription_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zYsLdWxpekia" title="Expiration Date"><span id="xdx_907_ecustom--WarrantsExpirationDescription_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zMpUUvta6ewi" title="Expiration Date">5 years after the date such warrants become exercisable, if ever</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zlen2iE1b6cd" title="Type of financing"><span id="xdx_902_ecustom--ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings_c20201101__20211031__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeFiveMember_zdhWhqOpD4E1" title="Type of financing">April 2021 Private Placement (Private Placement Warrants)</span></span></span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grand Total</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20220731_z7PX8qAKlYK9" title="Grand Total Number of Shares Underlying Warrants"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20211031_zbY6rGDF9Tk6" title="Grand Total Number of Shares Underlying Warrants">377,818</span></span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 20.00 20.00 879 879 September 2024 September 2024 September 2018 Public Offering September 2018 Public Offering 224.00 224.00 4092 4092 July 2024 July 2024 July 2019 Public Offering July 2019 Public Offering 28.00 28.00 57230 57230 November 2025 November 2025 November 2020 Public Offering November 2020 Public Offering 56.00 56.00 140552 140552 April 2026 April 2026 April 2021 Registered Direct Offering (Accompanying Warrants) April 2021 Registered Direct Offering (Accompanying Warrants) 56.00 56.00 175065 175065 5 years after the date such warrants become exercisable, if ever 5 years after the date such warrants become exercisable, if ever April 2021 Private Placement (Private Placement Warrants) April 2021 Private Placement (Private Placement Warrants) 377818 377818 201874 201874 377818 377818 175944 175944 377818 377818 0.001 170000000 300000000 170000000 300000000 <p id="xdx_893_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zQGt0ElHa3I6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In measuring the warrant liability for the warrants issued in the April 2021 Private Placement at July 31, 2022 and October 31, 2021, the Company used the following inputs in its Black Scholes model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zluowKHTqf7l" style="display: none">SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z13IgJjeIxrl" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">56.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zB3zO0guzI35" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">56.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Stock Price</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20220731__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zCFPNAAHch3c" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif">3.73</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--SharePrice_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zVBFbWQcRZRf" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif">38.80</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected Term</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220731__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zYV6CqfGJ0gc" title="Expected Term">5.00</span> years</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zJcPo9sZdhMf" title="Expected Term">5.00</span> years</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Volatility %</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220731__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zE6OGu3qYs5i" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Measurement input percentage"><span style="font-family: Times New Roman, Times, Serif">112</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zhNUqLemJ80j" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Measurement input percentage"><span style="font-family: Times New Roman, Times, Serif">106</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk Free Rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220731__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zPtTixU8Weud" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Measurement input percentage"><span style="font-family: Times New Roman, Times, Serif">2.70</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zZYqweVK3NCb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Measurement input percentage"><span style="font-family: Times New Roman, Times, Serif">1.18</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> 56.00 56.00 3.73 38.80 P5Y P5Y 112 106 2.70 1.18 1800.00 20.00 <p id="xdx_89D_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zqUCYF1XO936" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In measuring the warrant liability for the September 2018 Public Offering warrants at July 31, 2022 and October 31, 2021, the Company used the following inputs in its Monte Carlo simulation model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z37eZIgjsftc" style="display: none">SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zqK4KZ7ibEBi" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">20.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_z8YE7gsmeI69" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">24.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Stock Price</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20220731__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zFdwwA1u9Ft9" title="Stock Price">3.73</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20211031__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_z5Ahtm0QEqzd" title="Stock Price">38.80</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected Term</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20220731__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_z7n1XHMDtEUj" title="Expected Term">2.12</span> years</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zQhAVyEgYTMi" title="Expected Term">2.87</span> years</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Volatility %</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220731__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zRf0uuFz7crj" title="Measurement input percentage">104</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zujx3FltMlx5" title="Measurement input percentage">123</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk Free Rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20220731__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_zJaEv0QjZKa5" title="Measurement input percentage">2.89</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211031__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantLiabilityMember_z4fpQ5gZiIo1" title="Measurement input percentage">0.77</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> 20.00 24.00 3.73 38.80 P2Y1M13D P2Y10M13D 104 123 2.89 0.77 287000 4929000 276000 846000 4642000 1814000 <p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z0scOD3tOe57" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. <span id="xdx_829_zMccIP58HA3k">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Atachbarian</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 15, 2021, a purported stockholder of the Company commenced an action against the Company and certain of its directors in the U.S. District Court for the District of New Jersey, entitled Atachbarian v. Advaxis, Inc., et al., No. 3:21-cv-20006. The plaintiff alleges that the defendants breached their fiduciary duties and violated Section 14(a) and Rule 20(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder by allegedly failing to disclose certain matters in its Registration Statement on Form S-4 (Commission File No. 333-259065 (the “Registration Statement”) filed in connection with a proposed merger with Biosight Ltd. (the “Previously Proposed Merger”). On December 15, 2021, pursuant to an understanding reached with the plaintiff, the Company made certain other additional disclosures that mooted the demands asserted in the complaint. On December 17, 2021, the plaintiff filed a notice of voluntary dismissal with prejudice. On February 7, 2022, the Company and the plaintiff reached a settlement agreement, which is recorded in general and administrative expenses in the condensed consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purported Stockholder Claims Related to Biosight Transaction</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between September 16, 2021, and November 4, 2021, the Company received demand letters on behalf of six purported stockholders of the Company, alleging that the Company failed to disclose certain matters in the Registration Statement, and demanding that the Company disclose such information in a supplemental disclosure filed with the SEC. On October 14, 2021, the Company filed an amendment to the Registration Statement and on November 8, 2021, the Company made certain other additional disclosures that mooted the demands asserted in the above-referenced letters. The six plaintiffs have made settlement demands. On May 20, 2022, the Company and one of the plaintiffs have reached a settlement agreement, which is recorded in general and administrative expenses in the condensed consolidated statement of operations. The Company believes it has adequately accrued for settlements with the other five shareholders, which is recorded in accrued expenses in the condensed consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company received certain additional demands from stockholders asserting that the proxy materials filed by the Company in connection with the Previously Proposed Merger contained alleged material misstatements and/or omissions. Certain stockholders also demanded books and records of the Company pursuant to Delaware law. In response to these demands, the Company agreed to make, and did make, certain supplemental disclosures to the proxy materials. The stockholders have made settlement demands. On July 18, 2022, the Company and the plaintiffs reached settlement agreements, which is recorded in general and administrative expenses in the condensed consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purported Stockholder Claims Related to Series D Convertible Preferred Stock Offering</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2022, the Company received a letter on behalf of purported stockholders of the Company, demanding certain books and records pursuant to Delaware law regarding the proposed issuance of super voting preferred stock. The Company agreed to provide certain books and records to the stockholders and agreed to make, and did make, a supplemental disclosure to the proxy materials. The stockholders have made settlement demands. On July 18, 2022, the Company and the plaintiffs reached settlement agreements, which is recorded in general and administrative expenses in the condensed consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_809_ecustom--TemporaryEquityDisclosureTextBlock_z8bMXdfIW1P1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9. <span id="xdx_822_zizhwDof0Fe9">TEMPORARY EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series D Convertible Preferred Stock Offering</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 31, 2022, the Company consummated an offering with certain institutional investors for the private placement of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zRs2MiV3Rmh3" title="Shares issued">1,000,000</span> shares of Series D convertible redeemable preferred stock (the “Series D Preferred Stock”). The shares, which have since been redeemed in accordance with their terms as described below, and are thus no longer outstanding as of July 31, 2022, had an aggregate stated value of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20211101__20220731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zDPiyWOvrTIk" title="Stated value">5,000,000</span>. Each share of the Series D preferred stock had a purchase price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InstitutionalInvestorsMember_zWyM3W7Yw4Gj" title="Share purchase price">4.75</span>, representing an original issue discount of <span id="xdx_904_ecustom--PreferredStockDiscountRatePercentage_pid_dp_uPure_c20211101__20220731_zwJKT4FdCf9k" title="Issue discount">5</span>% of the stated value. The shares of Series D Preferred Stock were convertible into shares of the Company’s common stock, upon the occurrence of certain events, at a conversion price of $<span id="xdx_903_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20220731__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zDMx7Hz9bMv5" title="Preferred stock conversion price">20.00</span> per share. The conversion, at the option of the stockholder, could occur at any time following the receipt of the stockholders’ approval for a reverse stock split. The Company was permitted to compel conversion of the Series D Preferred Stock after the fulfillment of certain conditions and subject to certain limitations. The Series D Preferred Stock also had a liquidation preference over the shares of common stock, and could be redeemed by the investors, in accordance with certain terms, for a redemption price equal to <span id="xdx_908_ecustom--TemporaryEquityStockStatedValueAccumulatedDividends_pid_dp_uPure_c20211101__20220731_zQZfAn39HVe3" title="Temporary equity stock stated value accumulated dividends">105</span>% of the stated value, or in certain circumstances, <span id="xdx_90D_ecustom--TemporaryEquityStockStatedValueAccumulatedDividendsOnExtension_pid_dp_uPure_c20211101__20220731_zpNeujkUCFA6" title="Temporary equity stock stated value accumulated dividends on extension">110</span>% of the stated value. Total net proceeds from the offering, after deducting the financial advisor’s fees and other estimated offering expenses, were approximately $<span id="xdx_907_ecustom--ProceedsFromIssuanceOrEstimatedOffering_pn5n6_c20211101__20220731_zID72UJ5TfF8" title="Proceeds from issuance or estimated offering">4.3</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since the Series D preferred stock had a redemption feature at the option of the holder, it was classified as temporary equity. At the January 31, 2022 issuance date, the Series D preferred stock was recorded on the balance sheet at approximately $<span id="xdx_90A_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_c20220131_zndSnUbV8U35" title="Temporary equity, carrying amount, attributable to parent">4,225,000</span>, which is the $<span id="xdx_904_ecustom--ProceedsFromIssuanceOrEstimatedOffering_c20220101__20220131_zmJJZX9Pv5zf" title="Proceeds from issuance or estimated offering">4,312,000</span> net proceeds less the $<span id="xdx_907_eus-gaap--PreferredStockRedemptionAmount_iI_c20220131_zEKLmtk1peS8" title="Preferred stock, redemption amount">87,000</span> value of the bifurcated preferred stock redemption liability (see below).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 6, 2022, the holders of all <span id="xdx_901_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20220406__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zwPnlYBTJsV9" title="Temporary equity shares outstanding">1,000,000</span> outstanding shares of the Series D Preferred Stock exercised their right to cause the Company to redeem all of such shares at a price per share equal to <span id="xdx_90E_ecustom--TemporaryEquityStockStatedValueAccumulatedDividends_pid_dp_uPure_c20220404__20220406__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zZHY4AOpYVP9" title="Temporary equity stock stated value accumulated dividends">105</span>% of the stated value per share of $<span id="xdx_907_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_pid_c20220406__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zWVRRcDpFAr3" title="Temporary equity par value">5.00</span>, and such shares were redeemed accordingly. The $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20220404__20220406__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zJ05tJQ3Am8k" title="Stock issued during period value new issues">1,025,000</span> accretion of the Series D convertible preferred stock to its redemption value was recorded as a reduction in additional paid-in capital (see Note 10).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred Stock Redemption Liability</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated the preferred stock redemption feature under ASC 815. Since the preferred stock redemption feature is not considered to be clearly and closely related to the preferred stock host and the redemption feature meets the four characteristics of a derivative under ASC 815, the preferred stock redemption feature is required to be bifurcated from the preferred stock host and valued as a liability. The Company utilized a binomial model to calculate the fair value of the preferred stock redemption feature at issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_ecustom--PreferredStockRedemptionLiabilityTableTextBlock_zKXLBE8Q9FV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In measuring the preferred stock redemption liability at April 6, 2021 (redemption date) and January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zqyXP3ufHB0e" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">April 6, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">January 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220406__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zf7xLi8EYfS2" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">20.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zSwK3t62uzZi" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">20.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Stock Price</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220406__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zQuoEskMSYZb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif">9.04</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zzSxpVFevBEb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif">10.88</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Volatility %</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220406__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbeNTFqBOsu9" title="Measurement input percentage">96</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zsBsKpJVuuV1" title="Measurement input percentage">105</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk Free Rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220406__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z9XCWP2UKR8c" title="Measurement input percentage">1.25</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zCmDQkHuoUX2" title="Measurement input percentage">1.00</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> <p id="xdx_8AB_zBNFuEfotY9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At April 6, 2022 and January 31, 2022, the fair value of the preferred stock redemption liability was approximately $<span id="xdx_90B_eus-gaap--PreferredStockRedemptionAmount_iI_c20220406_z11iymjjc2e9" title="Preferred stock, redemption amount">44,000</span> and $<span id="xdx_90B_eus-gaap--PreferredStockRedemptionAmount_iI_c20220131_zI5xtWD41bGf" title="Preferred stock, redemption amount">87,000</span>, respectively. On April 6, 2022, the Series D convertible preferred stock was redeemed, and the $<span id="xdx_90A_eus-gaap--PreferredStockRedemptionAmount_iI_c20220406__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zDTrQR44OWz1" title="Preferred stock, redemption amount">44,000</span> preferred stock redemption liability was reclassified into other paid-in capital (see Note 10). For the three months and nine months ended July 31, 2022, the Company reported income of approximately $<span id="xdx_906_eus-gaap--RedemptionPremium_c20220501__20220731_zdYUJPD4O8p6" title="Change in preferred stock, redemption liability amount">0</span> and $<span id="xdx_902_eus-gaap--RedemptionPremium_c20211101__20220731_zXudq1biDYcl" title="Change in preferred stock, redemption liability amount">44,000</span>, respectively, due to a change in the fair value of the preferred stock redemption liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 1000000 5000000 4.75 0.05 20.00 1.05 1.10 4300000 4225000 4312000 87000 1000000 1.05 5.00 1025000 <p id="xdx_892_ecustom--PreferredStockRedemptionLiabilityTableTextBlock_zKXLBE8Q9FV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In measuring the preferred stock redemption liability at April 6, 2021 (redemption date) and January 31, 2022 (issuance date), the Company used the following inputs in its binomial model:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zqyXP3ufHB0e" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">April 6, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">January 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220406__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zf7xLi8EYfS2" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">20.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zSwK3t62uzZi" style="font-family: Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise Price"><span style="font-family: Times New Roman, Times, Serif">20.00</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Stock Price</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220406__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zQuoEskMSYZb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif">9.04</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zzSxpVFevBEb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Price"><span style="font-family: Times New Roman, Times, Serif">10.88</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Volatility %</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220406__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbeNTFqBOsu9" title="Measurement input percentage">96</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zsBsKpJVuuV1" title="Measurement input percentage">105</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk Free Rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220406__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z9XCWP2UKR8c" title="Measurement input percentage">1.25</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--EquitySecuritiesFvNiMeasurementInput_iI_pid_uPure_c20220131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zCmDQkHuoUX2" title="Measurement input percentage">1.00</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table> 20.00 20.00 9.04 10.88 96 105 1.25 1.00 44000 87000 44000 0 44000 <p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zsFh562lVylg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. <span id="xdx_82E_zJgZKyI23o04">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zJaG7mVCQlQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the changes in stockholders’ equity for the nine months ended July 31, 2022 and 2021 is presented below (in thousands, except share data):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zAqScjSDlG2g" style="display: none">SUMMARY OF STOCKHOLDERS EQUITY</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zaAGgrHLv06e" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zGAIzewnmHEa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zJJuYDjgn6I2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zXvI9aTboU0i" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_4B1_zxQ1DhAfkhTl" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common Stock</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional Paid-In</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total  Shareholders’</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_430_c20201101__20210131_eus-gaap--StockholdersEquity_iS_pn3n3_zkxywbsXqWkg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-family: Times New Roman, Times, Serif; width: 37%"><span style="font-family: Times New Roman, Times, Serif">Balance at November 1, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zzyPpgHuKuch" style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0855">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXrWfGKWL94" style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">975,897</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">440,916</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(410,738</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,180</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pn3n3_zRD31JBEuXu9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">      <span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">       <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0865">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIM22WyoFcDk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock-based compensation, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">       <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">236</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0868">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">236</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_zIzBQY3urzRl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Advaxis public offerings, net of offering costs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0873">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCVaY0zj0Irg" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Advaxis public offerings, net of offering costs, shares"><span style="font-family: Times New Roman, Times, Serif">383,333</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,550</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,550</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_zPFaOXCW71zi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant exercises</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0881">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfklXe8VA0Ok" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Warrant exercises, shares"><span style="font-family: Times New Roman, Times, Serif">92,375</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,586</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,586</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_zy6jOJupftYk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0889">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,977</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,977</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_43A_c20210201__20210430_eus-gaap--StockholdersEquity_iS_pn3n3_z8WZwmsOh9x9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at January 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20210201__20210430__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEHfk0MBFMZc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20210201__20210430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJciM90DSsg5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,451,605</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">452,288</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(414,715</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pn3n3_zYMFLKVZQdHc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0905">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20210201__20210430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9bCqZ4TYQW5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock-based compensation, shares"><span style="font-family: Times New Roman, Times, Serif">69</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0906">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">215</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0908">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">215</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pn3n3_zitYoUYIqyA1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock option exercises</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210201__20210430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxZwFxIJPnU4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock option exercises, shares"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0914">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0915">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_zNUooi01uQ47" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Advaxis public offerings, net of offering costs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210201__20210430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZUFnWvW1Hi1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Advaxis public offerings, net of offering costs, shares"><span style="font-family: Times New Roman, Times, Serif">230,794</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,683</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,683</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_pn3n3_zITpf7S7EQF4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant exercises</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_pid_c20210201__20210430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeXKznprAmAj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Warrant exercises, shares"><span style="font-family: Times New Roman, Times, Serif">137,968</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,185</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0932">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,185</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueEmployeesUnderESPPPlan_pn3n3_zavmxT3QzD96" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of shares to employees under ESPP Plan</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesEmployeesUnderESPPPlan_pid_c20210201__20210430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpTbhkqcO4i8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Issuance of shares to employees under ESPP Plan, shares"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0938">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0939">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_pn3n3_zAV4tX7ankZc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0945">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0946">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0947">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,107</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,107</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_439_c20210501__20210731_eus-gaap--StockholdersEquity_iS_pn3n3_zXaE2mcQAy28" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at April 30, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20210501__20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znPJqFhB57X1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0951">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20210501__20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziTIeDptn5P1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,820,452</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">467,371</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(419,822</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">47,551</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pn3n3_zNso2AozpiW1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">60</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">60</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--NetIncomeLoss_pn3n3_zN9J9vxtjm8h" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0967">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,334</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,334</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_434_c20210501__20210731_eus-gaap--StockholdersEquity_iE_pn3n3_zbgDh5eh23mi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at July 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20210501__20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zJlq2xJDRDDg" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0979">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20210501__20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMpj4DJUVZwf" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,820,452</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">467,431</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(423,156</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,277</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common Stock</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional Paid-In</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total  Shareholders’</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_43E_c20211101__20220131_eus-gaap--StockholdersEquity_iS_pn3n3_z1NETIYo6Xzb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 37%"><span style="font-family: Times New Roman, Times, Serif">Balance at November 1, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zRp1HzrTrOP" style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0989">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcc5mXvYdhrb" style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,820,452</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">467,486</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(428,600</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,888</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pn3n3_zZsf0rIGzcc3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">       <span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">       <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0993">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">         <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_zFiw0oYk54h8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0999">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(365</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(365</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_436_c20220201__20220430_eus-gaap--StockholdersEquity_iS_pn3n3_zSLZEOz85bhi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at January 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20220201__20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8YIlnGilDZ2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1011">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20220201__20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkqtlWylI6l8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,820,452</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">467,512</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(428,965</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,549</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pn3n3_zef6k6kKrBLg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1016">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueAccretionOfDiscountAndRedemptionFeatureOfConvertiblePreferredStock_pn3n3_zmC7RqFKP8y6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accretion of discount and redemption feature of convertible preferred stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1022">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,025</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,025</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueConvertiblePreferredStockRedemption_pn3n3_zZJFg7w9ND7j" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible preferred stock redemption</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1027">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1028">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1030">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_pn3n3_zuuSUbAsnM51" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1033">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1034">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1035">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,440</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,440</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_431_c20220501__20220731_eus-gaap--StockholdersEquity_iS_pn3n3_zd9TiI5tKeog" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at April 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z1w3WDT6rtuc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1039">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPipVdwQbqp9" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,820,452</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">466,554</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(431,405</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,151</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_439_c20220501__20220731_eus-gaap--StockholdersEquity_iS_pn3n3_zLbTbe3idb5" style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Beginning balance </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDT9qnWhQXU7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztZe0O5esyqb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,820,452</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">466,554</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(431,405</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,151</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pn3n3_z9M1ha68ikRh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1059">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_ecustom--FractionalSharesCashedOut_pn3n3_z4r7pRTYAma8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fractional shares cashed out</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--FractionalSharesCashedOutShares_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVQkU32xPRrf" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Fractional shares cashed out, shares"><span style="font-family: Times New Roman, Times, Serif">(4,501</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_pn3n3_zQWt2irP7lca" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,963</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,963</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_433_c20220501__20220731_eus-gaap--StockholdersEquity_iE_pn3n3_zvOumccYAjhl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zuYawQSyQJ87" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1085">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1079">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxA2iPGHUpJk" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,815,951</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">466,561</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(438,368</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,195</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_431_c20220501__20220731_eus-gaap--StockholdersEquity_iE_pn3n3_z40L6TytNFS6" style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zqImf6EpwD9f" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHXxgtWY0xU5" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,815,951</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">466,561</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(438,368</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,195</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A5_zkgj3yaKVQ2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zJaG7mVCQlQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the changes in stockholders’ equity for the nine months ended July 31, 2022 and 2021 is presented below (in thousands, except share data):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zAqScjSDlG2g" style="display: none">SUMMARY OF STOCKHOLDERS EQUITY</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_zaAGgrHLv06e" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zGAIzewnmHEa" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zJJuYDjgn6I2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zXvI9aTboU0i" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_4B1_zxQ1DhAfkhTl" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common Stock</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional Paid-In</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total  Shareholders’</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_430_c20201101__20210131_eus-gaap--StockholdersEquity_iS_pn3n3_zkxywbsXqWkg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-family: Times New Roman, Times, Serif; width: 37%"><span style="font-family: Times New Roman, Times, Serif">Balance at November 1, 2020</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zzyPpgHuKuch" style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0855">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXrWfGKWL94" style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">975,897</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">440,916</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(410,738</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,180</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pn3n3_zRD31JBEuXu9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">      <span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">       <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0865">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIM22WyoFcDk" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock-based compensation, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0871">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">       <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">236</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0868">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">236</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_zIzBQY3urzRl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Advaxis public offerings, net of offering costs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0873">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCVaY0zj0Irg" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Advaxis public offerings, net of offering costs, shares"><span style="font-family: Times New Roman, Times, Serif">383,333</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,550</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,550</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_zPFaOXCW71zi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant exercises</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0881">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_pid_c20201101__20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfklXe8VA0Ok" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Warrant exercises, shares"><span style="font-family: Times New Roman, Times, Serif">92,375</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,586</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,586</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_pn3n3_zy6jOJupftYk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0889">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0891">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,977</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,977</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_43A_c20210201__20210430_eus-gaap--StockholdersEquity_iS_pn3n3_z8WZwmsOh9x9" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at January 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20210201__20210430__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEHfk0MBFMZc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20210201__20210430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJciM90DSsg5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,451,605</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">452,288</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(414,715</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37,575</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pn3n3_zYMFLKVZQdHc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0905">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_pid_c20210201__20210430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9bCqZ4TYQW5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock-based compensation, shares"><span style="font-family: Times New Roman, Times, Serif">69</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0906">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">215</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0908">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">215</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pn3n3_zitYoUYIqyA1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock option exercises</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0913">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210201__20210430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxZwFxIJPnU4" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock option exercises, shares"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0914">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0915">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_zNUooi01uQ47" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Advaxis public offerings, net of offering costs</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210201__20210430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZUFnWvW1Hi1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Advaxis public offerings, net of offering costs, shares"><span style="font-family: Times New Roman, Times, Serif">230,794</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,683</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,683</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_pn3n3_zITpf7S7EQF4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Warrant exercises</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0929">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_pid_c20210201__20210430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeXKznprAmAj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Warrant exercises, shares"><span style="font-family: Times New Roman, Times, Serif">137,968</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,185</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0932">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,185</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueEmployeesUnderESPPPlan_pn3n3_zavmxT3QzD96" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance of shares to employees under ESPP Plan</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesEmployeesUnderESPPPlan_pid_c20210201__20210430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpTbhkqcO4i8" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Issuance of shares to employees under ESPP Plan, shares"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0938">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0939">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_pn3n3_zAV4tX7ankZc" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0945">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0946">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0947">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,107</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(5,107</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_439_c20210501__20210731_eus-gaap--StockholdersEquity_iS_pn3n3_zXaE2mcQAy28" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at April 30, 2021</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20210501__20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znPJqFhB57X1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0957">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0951">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20210501__20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziTIeDptn5P1" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,820,452</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">467,371</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(419,822</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">47,551</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pn3n3_zNso2AozpiW1" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0961">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">60</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">60</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--NetIncomeLoss_pn3n3_zN9J9vxtjm8h" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0967">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0968">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0969">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,334</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,334</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_434_c20210501__20210731_eus-gaap--StockholdersEquity_iE_pn3n3_zbgDh5eh23mi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at July 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20210501__20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zJlq2xJDRDDg" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0979">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20210501__20210731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMpj4DJUVZwf" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,820,452</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">467,431</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(423,156</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44,277</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common Stock</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Additional Paid-In</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Accumulated</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total  Shareholders’</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Capital</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Deficit</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_43E_c20211101__20220131_eus-gaap--StockholdersEquity_iS_pn3n3_z1NETIYo6Xzb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 37%"><span style="font-family: Times New Roman, Times, Serif">Balance at November 1, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zRp1HzrTrOP" style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0989">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20211101__20220131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcc5mXvYdhrb" style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,820,452</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">467,486</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(428,600</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,888</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pn3n3_zZsf0rIGzcc3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">       <span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">       <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0993">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">         <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0994">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0996">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_zFiw0oYk54h8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0999">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1000">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(365</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(365</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_436_c20220201__20220430_eus-gaap--StockholdersEquity_iS_pn3n3_zSLZEOz85bhi" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at January 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20220201__20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8YIlnGilDZ2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1011">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20220201__20220430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkqtlWylI6l8" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,820,452</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">467,512</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(428,965</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38,549</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pn3n3_zef6k6kKrBLg" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1015">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1016">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueAccretionOfDiscountAndRedemptionFeatureOfConvertiblePreferredStock_pn3n3_zmC7RqFKP8y6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accretion of discount and redemption feature of convertible preferred stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1021">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1022">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,025</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1024">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,025</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueConvertiblePreferredStockRedemption_pn3n3_zZJFg7w9ND7j" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Convertible preferred stock redemption</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1027">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1028">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1030">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_pn3n3_zuuSUbAsnM51" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1033">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1034">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1035">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,440</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,440</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_431_c20220501__20220731_eus-gaap--StockholdersEquity_iS_pn3n3_zd9TiI5tKeog" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance at April 30, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z1w3WDT6rtuc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1045">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1039">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPipVdwQbqp9" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,820,452</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">466,554</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(431,405</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,151</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_439_c20220501__20220731_eus-gaap--StockholdersEquity_iS_pn3n3_zLbTbe3idb5" style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Beginning balance </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDT9qnWhQXU7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1055">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztZe0O5esyqb" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Beginning balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,820,452</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">466,554</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(431,405</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,151</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_pn3n3_z9M1ha68ikRh" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1059">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_ecustom--FractionalSharesCashedOut_pn3n3_z4r7pRTYAma8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fractional shares cashed out</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_ecustom--FractionalSharesCashedOutShares_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVQkU32xPRrf" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Fractional shares cashed out, shares"><span style="font-family: Times New Roman, Times, Serif">(4,501</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(18</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_406_eus-gaap--NetIncomeLoss_pn3n3_zQWt2irP7lca" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1075">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,963</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(6,963</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_433_c20220501__20220731_eus-gaap--StockholdersEquity_iE_pn3n3_zvOumccYAjhl" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance at July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zuYawQSyQJ87" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1085">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1079">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxA2iPGHUpJk" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,815,951</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">466,561</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(438,368</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,195</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_431_c20220501__20220731_eus-gaap--StockholdersEquity_iE_pn3n3_z40L6TytNFS6" style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Ending balance</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zqImf6EpwD9f" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1095">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1089">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20220501__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHXxgtWY0xU5" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Ending balance, shares"><span style="font-family: Times New Roman, Times, Serif">1,815,951</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">466,561</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(438,368</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,195</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 975897 2000 440916000 -410738000 30180000 236000 236000 383333 8550000 8550000 92375 2586000 2586000 -3977000 -3977000 1451605 2000 452288000 -414715000 37575000 69 215000 215000 4 230794 13683000 13683000 137968 1185000 1185000 12 -5107000 -5107000 1820452 2000 467371000 -419822000 47551000 60000 60000 -3334000 -3334000 1820452 2000 467431000 -423156000 44277000 1820452 2000 467486000 -428600000 38888000 26000 26000 -365000 -365000 1820452 2000 467512000 -428965000 38549000 23000 23000 -1025000 -1025000 44000 44000 -2440000 -2440000 1820452 2000 466554000 -431405000 35151000 1820452 2000 466554000 -431405000 35151000 25000 25000 -4501 -18000 -18000 -6963000 -6963000 1815951 2000 466561000 -438368000 28195000 1815951 2000 466561000 -438368000 28195000 <p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zyGOzHE2jEjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11. <span id="xdx_827_zmQlzaRp7fNb">SHARE BASED COMPENSATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zMeeAMwMdLTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zJ5BeICPlK83" style="display: none">SUMMARY OF SHARE BASED COMPENSATION EXPENSE </span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20220501__20220731_z1VOyQkggvab" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20210501__20210731_zqzXEh2a234" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20211101__20220731_zcKTBCVWcIRf" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_497_20201101__20210731_z1UERcsHdqWi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5RzcQcNKPP4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 38%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">142</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z5hyD9s6vyo8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">369</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_pn3n3_zIIz46l0dXeb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">60</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">511</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AA_zH7Ndgkr6oKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z0fi0okna8ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of changes in the stock option plan for the nine months ended July 31, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zc4g8cbmugmi" style="display: none">SUMMARY OF CHANGES IN STOCK OPTION PLAN</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Exercise</span></p> <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Price</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Remaining Contractual Life In Years</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate Intrinsic Value (in thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 38%"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20211101__20220731_zV1CppzOZtz7" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Shares Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">11,192</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20211101__20220731_zcCFux4yFJZb" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif">1,550.26</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220731_z9ocj5AfU9gd" title="Weighted Average Remaining Contractual Life In Years, Beginning">7.80</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20211101__20220731_zauHj4O6jHrc" style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Beginning"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cancelled or expired</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20211101__20220731_zlKckUgqz9Gf" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares, Cancelled or Expired"><span style="font-family: Times New Roman, Times, Serif">(74</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20211101__20220731_z9CR6BXuNUKj" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled or Expired"><span style="font-family: Times New Roman, Times, Serif">22,200.00</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20211101__20220731_zRNugE5R4gSh" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares, Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">11,118</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20211101__20220731_zmFYqRGpSJa9" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif">1,412.82</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20211101__20220731_z4T4PD10kpli" title="Weighted Average Remaining Contractual Life In Years, Ending Balance">7.06</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20211101__20220731_zd1lcDK3nUYe" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Ending">       <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1138">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable at July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20211101__20220731_z5zPwuT4s7b6" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares, Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif">7,490</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20211101__20220731_zjS9fYL11KS3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif">2,077.20</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20211101__20220731_zwinFNXHThMa" title="Weighted Average Remaining Contractual Life In Years, Vested and Exercisable">6.64</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20211101__20220731_z9fpGfcnxjq4" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1146">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AC_zpkBbEYUkA4c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zkQlLmAQ0ZG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes information about the outstanding and exercisable options at July 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z0QxpF8h34e1" style="display: none">SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="13" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Exercisable</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price Range</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 22%"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zTCRUdcAgihl" title="Exercise Price Range, lower limit">24.00</span>-$<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zMcgnnWxRV99" title="Exercise Price Range, upper limit">50.00</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zQ11p6MuBCch" style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right" title="Number Outstanding, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">4,241</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zH8NdQ3wzy94" title="Weighted Average Remaining Contractual, Options Outstanding">7.86</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zyOCTeuafd7d" style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Exercise Price, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">32.53</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zH9HaesuVbe9" style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right" title="Number Exercisable, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">1,964</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zLQxJ1ffRzx8" title="Weighted Average Remaining Contractual Term Exercisable, Options Exercisable">7.69</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zcNMNalyY1j9" style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Exercise Price, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">30.40</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_z9NtWKfBM8L6" title="Exercise Price Range, lower limit">50.01</span>-$<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zpTfLXq5r0a8" title="Exercise Price Range, upper limit">100.00</span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zwrR3WD53Q8c" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">4,174</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_z0zsD98dGtkg" title="Weighted Average Remaining Contractual, Options Outstanding">7.74</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zwTkq9Nbmh9b" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">53.33</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zbVrGYcAfgG7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number Exercisable, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">2,824</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_z0tslOlqeZ37" title="Weighted Average Remaining Contractual Term Exercisable, Options Exercisable">7.73</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zrUG8OjJSPod" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">53.58</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zworDtzSAv5c" title="Exercise Price Range, lower limit">100.01</span>-<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zYHLID7EAwdl" title="Exercise Price Range, upper limit">20,664.00</span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zXQjqw81uMKc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">2,703</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zQKvq8xGq4L1" title="Weighted Average Remaining Contractual, Options Outstanding">4.75</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zOIeoIk1azxa" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">5,677.84</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zjs3utPTq0gj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number Exercisable, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">2,703</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zjxFnfxk9Rpa" title="Weighted Average Remaining Contractual Term Exercisable, Options Exercisable">4.75</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zGC43KZSTbR6" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">5,677.84</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A7_zfq3469b1ot6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of July 31, 2022, there was approximately $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20220731_zBdeiophbHb6" title="Unrecognized compensation cost">77,000</span> of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of <span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20211101__20220731_zLRxbaaReIj6" title="Unrecognized weighted average vesting period">0.94</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Potential Acceleration of Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event of a merger transaction, similar to the Previously Proposed Merger Agreement, all of the Chief Executive Officer’s <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20220731__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zHEsarGNJLak" title="Unvested stock options">624</span> unvested stock options as of July 31, 2022, pursuant to his employment agreement, would accelerate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_899_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zMeeAMwMdLTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes share-based compensation expense included in the condensed consolidated statements of operations (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zJ5BeICPlK83" style="display: none">SUMMARY OF SHARE BASED COMPENSATION EXPENSE </span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20220501__20220731_z1VOyQkggvab" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20210501__20210731_zqzXEh2a234" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20211101__20220731_zcKTBCVWcIRf" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_497_20201101__20210731_z1UERcsHdqWi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Three Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Nine Months Ended</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">July 31,</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5RzcQcNKPP4" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 38%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">142</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z5hyD9s6vyo8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">31</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">38</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">369</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_pn3n3_zIIz46l0dXeb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">60</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">511</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 12000 29000 36000 142000 13000 31000 38000 369000 25000 60000 74000 511000 <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z0fi0okna8ja" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of changes in the stock option plan for the nine months ended July 31, 2022 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zc4g8cbmugmi" style="display: none">SUMMARY OF CHANGES IN STOCK OPTION PLAN</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Exercise</span></p> <p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Price</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted Average Remaining Contractual Life In Years</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Aggregate Intrinsic Value (in thousands)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 38%"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20211101__20220731_zV1CppzOZtz7" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Shares Outstanding, Beginning Balance"><span style="font-family: Times New Roman, Times, Serif">11,192</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20211101__20220731_zcCFux4yFJZb" style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"><span style="font-family: Times New Roman, Times, Serif">1,550.26</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220731_z9ocj5AfU9gd" title="Weighted Average Remaining Contractual Life In Years, Beginning">7.80</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20211101__20220731_zauHj4O6jHrc" style="font-family: Times New Roman, Times, Serif; width: 10%; text-align: right" title="Aggregate Intrinsic Value, Beginning"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cancelled or expired</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20211101__20220731_zlKckUgqz9Gf" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares, Cancelled or Expired"><span style="font-family: Times New Roman, Times, Serif">(74</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20211101__20220731_z9CR6BXuNUKj" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Cancelled or Expired"><span style="font-family: Times New Roman, Times, Serif">22,200.00</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding as of July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20211101__20220731_zRNugE5R4gSh" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares, Outstanding, Ending Balance"><span style="font-family: Times New Roman, Times, Serif">11,118</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20211101__20220731_zmFYqRGpSJa9" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending"><span style="font-family: Times New Roman, Times, Serif">1,412.82</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20211101__20220731_z4T4PD10kpli" title="Weighted Average Remaining Contractual Life In Years, Ending Balance">7.06</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20211101__20220731_zd1lcDK3nUYe" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Ending">       <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1138">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable at July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20211101__20220731_z5zPwuT4s7b6" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Shares, Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif">7,490</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20211101__20220731_zjS9fYL11KS3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif">2,077.20</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20211101__20220731_zwinFNXHThMa" title="Weighted Average Remaining Contractual Life In Years, Vested and Exercisable">6.64</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20211101__20220731_z9fpGfcnxjq4" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1146">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 11192 1550.26 P7Y9M18D 34000 74 22200.00 11118 1412.82 P7Y21D 7490 2077.20 P6Y7M20D <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zkQlLmAQ0ZG4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes information about the outstanding and exercisable options at July 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z0QxpF8h34e1" style="display: none">SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="13" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Exercisable</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price Range</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 22%"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zTCRUdcAgihl" title="Exercise Price Range, lower limit">24.00</span>-$<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zMcgnnWxRV99" title="Exercise Price Range, upper limit">50.00</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zQ11p6MuBCch" style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right" title="Number Outstanding, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">4,241</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zH8NdQ3wzy94" title="Weighted Average Remaining Contractual, Options Outstanding">7.86</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zyOCTeuafd7d" style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Exercise Price, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">32.53</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zH9HaesuVbe9" style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right" title="Number Exercisable, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">1,964</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zLQxJ1ffRzx8" title="Weighted Average Remaining Contractual Term Exercisable, Options Exercisable">7.69</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeOneMember_zcNMNalyY1j9" style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right" title="Weighted Average Exercise Price, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">30.40</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_z9NtWKfBM8L6" title="Exercise Price Range, lower limit">50.01</span>-$<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zpTfLXq5r0a8" title="Exercise Price Range, upper limit">100.00</span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zwrR3WD53Q8c" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">4,174</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_z0zsD98dGtkg" title="Weighted Average Remaining Contractual, Options Outstanding">7.74</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zwTkq9Nbmh9b" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">53.33</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zbVrGYcAfgG7" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number Exercisable, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">2,824</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_z0tslOlqeZ37" title="Weighted Average Remaining Contractual Term Exercisable, Options Exercisable">7.73</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeTwoMember_zrUG8OjJSPod" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">53.58</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zworDtzSAv5c" title="Exercise Price Range, lower limit">100.01</span>-<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zYHLID7EAwdl" title="Exercise Price Range, upper limit">20,664.00</span></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zXQjqw81uMKc" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number Outstanding, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">2,703</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zQKvq8xGq4L1" title="Weighted Average Remaining Contractual, Options Outstanding">4.75</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zOIeoIk1azxa" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Outstanding"><span style="font-family: Times New Roman, Times, Serif">5,677.84</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zjs3utPTq0gj" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Number Exercisable, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">2,703</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211101__20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zjxFnfxk9Rpa" title="Weighted Average Remaining Contractual Term Exercisable, Options Exercisable">4.75</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20220731__us-gaap--DerivativeInstrumentRiskAxis__custom--ExercisePriceRangeThreeMember_zGC43KZSTbR6" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Exercisable"><span style="font-family: Times New Roman, Times, Serif">5,677.84</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 24.00 50.00 4241 P7Y10M9D 32.53 1964 P7Y8M8D 30.40 50.01 100.00 4174 P7Y8M26D 53.33 2824 P7Y8M23D 53.58 100.01 20664.00 2703 P4Y9M 5677.84 2703 P4Y9M 5677.84 77000000 P0Y11M8D 624 <p id="xdx_80D_ecustom--LicensingAgreementsDisclosuresTextBlock_zafRCPcNoGa9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12. <span id="xdx_823_z3gFPqQIucQh">LICENSING AGREEMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>OS Therapies LLC</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 4, 2018, the Company entered into a development, license and supply agreement with OS Therapies (“OST”) for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, as amended, OST will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. Under the most recent amendment to the licensing agreement, OST agreed to pay Advaxis $<span id="xdx_903_eus-gaap--Revenues_pp0p0_c20200429__20200430__us-gaap--TypeOfArrangementAxis__custom--DevelopmentLicenseAndSupplyAgreementMember__srt--StatementScenarioAxis__custom--OSTherapiesMember_zKGtdLpZ2MUf" title="Revenue">25,000</span> per month (“Monthly Payment”) starting on April 30, 2020 until it achieved its funding milestone of $<span id="xdx_90C_ecustom--FundingMilestonePayment_pp0p0_c20180903__20180904__us-gaap--TypeOfArrangementAxis__custom--DevelopmentLicenseAndSupplyAgreementMember__srt--StatementScenarioAxis__custom--OSTherapiesMember_zMFNShw5TLQh" title="Funding milestone payment">2,337,500</span>. Upon receipt of the first Monthly Payment, Advaxis initiated the transfer of the intellectual property and licensing rights of ADXS31-164, which were licensed pursuant to the Penn Agreement, back to the University of Pennsylvania. Contemporaneously, OST will enter negotiations with the University of Pennsylvania to establish a licensing agreement for ADXS31-164 to OST for clinical and commercial development of the ADXS31-164 technology.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In December 2020 and January 2021, </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_ecustom--MilestoneAchievementDescription_c20211101__20220731_z3fW0M0b1WDk" title="Milestone achievement, description">the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement and recorded $1,615,000 in revenue.</span> The Company therefore transferred, and OST took full ownership of, the IND application for ADXS31-164 in its entirety along with agreements and promises contained therein, as well as all obligations associated with this IND or any HER2 product/program development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In April 2021, the Company achieved the second milestone set forth in the license agreement for evaluation in the treatment of osteosarcoma in humans and recorded $<span id="xdx_903_eus-gaap--Revenues_pp0p0_c20210425__20210430__us-gaap--TypeOfArrangementAxis__custom--DevelopmentLicenseAndSupplyAgreementMember__srt--StatementScenarioAxis__custom--OSTherapiesMember_zCc8U7ZBjZoa" title="Revenue">1,375,000</span> in revenue. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received the amount due from OS Therapies of $<span id="xdx_90A_ecustom--FundingForSecondMilestonePayment_pp0p0_c20210501__20210531__us-gaap--TypeOfArrangementAxis__custom--DevelopmentLicenseAndSupplyAgreementMember__srt--StatementScenarioAxis__custom--OSTherapiesMember_zoAGAWAw82o3" title="Funding for milestone payment">1,375,000</span> in May 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Global BioPharma Inc.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of axalimogene filolisbac with Global BioPharma, Inc. (“GBP”), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC). During each of the nine months ended July 31, 2022 and 2021, the Company recorded $<span id="xdx_90D_eus-gaap--Revenues_c20211101__20220731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GlobalBioPharmaIncMember__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zOxTr2dVKC0g" title="Revenue"><span id="xdx_904_eus-gaap--Revenues_c20201101__20210731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GlobalBioPharmaIncMember__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zbPBzojDFD39">250,000</span></span> in revenue for the annual license fee renewal. Since Advaxis has no significant obligation to perform after the license transfer and has provided GBP with the right to use its intellectual property, performance is satisfied when the license renews.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 25000 2337500 the Company received an aggregate of $1,615,000 from OS Therapies upon achievement of the funding milestone set forth in the license agreement and recorded $1,615,000 in revenue. 1375000 1375000 250000 250000 <p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_z7ejKlcovGH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. <span id="xdx_829_zkz4skHt77U5">FAIR VALUE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 1 — Quoted prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 2— Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">● Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zWtafReRZetf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of July 31, 2022 and October 31, 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zb2zJh3kJSp6" style="display: none">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20220731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zU0xHYdXHY2h" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20220731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zA7SKZdbs6za" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20220731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgmeKMzoLAy2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20220731_z7HbyDIuxzU1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="17" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fair Value Measured at July 31, 2022</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial assets at fair value:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_hus-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zvVBGXNge1W6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents (money market funds)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,183</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1224">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1225">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,183</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_ztj2uHPs4V8e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Financial Assets at Fair Value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,183</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1229">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1230">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,183</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial liabilities at fair value:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--CommonStockWarrantLiability_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--ThroughSeptemberTwoThousandTwentyFourMember_zCmDDleo9zW" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock warrant liability, warrants exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUsIEFTU0VUUyBBTkQgTElBQklMSVRJRVMgTUVBU1VSRUQgT04gUkVDVVJSSU5HIEJBU0lTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731_zSqevBDlrFVd" title="Warrant exercise price per share">20.00</span> through September 2024</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1233">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--CommonStockWarrantLiability1_iI_pn3n3_hus-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zquFiAfV19q3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock warrant liability, warrants exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUsIEFTU0VUUyBBTkQgTElBQklMSVRJRVMgTUVBU1VSRUQgT04gUkVDVVJSSU5HIEJBU0lTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zuZdLDvyxwzj" title="Warrant exercise price per share">56.00</span> through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1240">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">285</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">285</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zs2h8eWt8Qt8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total financial liabilities at fair value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1247">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1248">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">287</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">287</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20211031__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zdcfJqdhJdbi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20211031__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjBkeJFXaqPh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20211031__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zijhRhJ0LSki" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20211031_z90ILv2tswgl" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="17" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fair Value Measured at October 31, 2021</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial assets at fair value:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_hus-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zWjA0Ep00HM3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents (money market funds)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,153</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1253">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1254">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,153</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_zOJOS3XFXxRb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Financial Assets at Fair Value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,153</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1258">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1259">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,153</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial liabilities at fair value:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--CommonStockWarrantLiability_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--ThroughSeptemberTwoThousandTwentyFourMember_zVBeTWrcwah3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock warrant liability, warrants exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUsIEFTU0VUUyBBTkQgTElBQklMSVRJRVMgTUVBU1VSRUQgT04gUkVDVVJSSU5HIEJBU0lTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031_z9C1cEOld8Pc" title="Warrant exercise price per share">24.00</span> through September 2024</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1262">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">          <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--CommonStockWarrantLiability_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--ThroughSeptemberTwoThousandTwentyFourMember_zVi4nwN4ruG2" style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock warrant liability, warrants exercisable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">          <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1270">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--CommonStockWarrantLiability1_iI_pn3n3_hus-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zbeOI5AoDsc5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock warrant liability, warrants exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUsIEFTU0VUUyBBTkQgTElBQklMSVRJRVMgTUVBU1VSRUQgT04gUkVDVVJSSU5HIEJBU0lTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zAiQmpM9nOXh" title="Warrant exercise price per share">56.00</span> through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1274">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1275">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,902</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,902</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zk3DdzNrXRj5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total financial liabilities at fair value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1281">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1282">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,929</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,929</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A8_zpS5eeyHuaY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zv4Vtp1QMuwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents changes in Level 3 liabilities measured at fair value (in thousands) for the nine months ended July 31, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zTaFbazXQoLd" style="display: none">SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS</span> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_4B6_us-gaap--FairValueByLiabilityClassAxis_custom--PreferredStockRedemptionLiabilityMember_zsTw9vpHOs8l" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_4B9_us-gaap--FairValueByLiabilityClassAxis_custom--WarrantLiabilityMember_zfnpIqJ8klfc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_4B0_z7UegBGYb1oh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Preferred</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Stock</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Redemption</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Liability</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Warrant</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Liabilities</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_438_c20211101__20220731_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zvf5xx8atlJ" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 46%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fair value at October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 15%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1288">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 15%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,929</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,929</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_zhfTaaaZPV1g" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Additions</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">87</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">87</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zlBGaQLZE6vk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in fair value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(43</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,642</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,685</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_405_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodRedemption_zqvllqAFwQh8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Redemption</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(44</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(44</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_43D_c20211101__20220731_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_z2FQzQ0bWVMj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fair value at July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">287</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">287</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A2_zqoknCOUzRN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zWtafReRZetf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of July 31, 2022 and October 31, 2021 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zb2zJh3kJSp6" style="display: none">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20220731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zU0xHYdXHY2h" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20220731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zA7SKZdbs6za" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20220731__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgmeKMzoLAy2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20220731_z7HbyDIuxzU1" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="17" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fair Value Measured at July 31, 2022</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial assets at fair value:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_hus-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zvVBGXNge1W6" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents (money market funds)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,183</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1224">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1225">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,183</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iI_ztj2uHPs4V8e" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Financial Assets at Fair Value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,183</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1229">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1230">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,183</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial liabilities at fair value:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--CommonStockWarrantLiability_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--ThroughSeptemberTwoThousandTwentyFourMember_zCmDDleo9zW" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock warrant liability, warrants exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUsIEFTU0VUUyBBTkQgTElBQklMSVRJRVMgTUVBU1VSRUQgT04gUkVDVVJSSU5HIEJBU0lTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731_zSqevBDlrFVd" title="Warrant exercise price per share">20.00</span> through September 2024</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1233">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left">$</td><td style="font-family: Times New Roman, Times, Serif; text-align: right">            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1234">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_ecustom--CommonStockWarrantLiability1_iI_pn3n3_hus-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zquFiAfV19q3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock warrant liability, warrants exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUsIEFTU0VUUyBBTkQgTElBQklMSVRJRVMgTUVBU1VSRUQgT04gUkVDVVJSSU5HIEJBU0lTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zuZdLDvyxwzj" title="Warrant exercise price per share">56.00</span> through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1240">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">285</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">285</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zs2h8eWt8Qt8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total financial liabilities at fair value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1247">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1248">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">287</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">287</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20211031__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zdcfJqdhJdbi" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20211031__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjBkeJFXaqPh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20211031__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zijhRhJ0LSki" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20211031_z90ILv2tswgl" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="17" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fair Value Measured at October 31, 2021</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 1</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 2</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Level 3</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial assets at fair value:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_hus-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_zWjA0Ep00HM3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash equivalents (money market funds)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,153</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1253">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1254">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 3%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,153</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--AssetsFairValueDisclosure_iI_zOJOS3XFXxRb" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Financial Assets at Fair Value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,153</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1258">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1259">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,153</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial liabilities at fair value:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_ecustom--CommonStockWarrantLiability_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--ThroughSeptemberTwoThousandTwentyFourMember_zVBeTWrcwah3" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock warrant liability, warrants exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUsIEFTU0VUUyBBTkQgTElBQklMSVRJRVMgTUVBU1VSRUQgT04gUkVDVVJSSU5HIEJBU0lTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031_z9C1cEOld8Pc" title="Warrant exercise price per share">24.00</span> through September 2024</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1262">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">          <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_ecustom--CommonStockWarrantLiability_iI_pn3n3_hus-gaap--AwardTypeAxis__custom--ThroughSeptemberTwoThousandTwentyFourMember_zVi4nwN4ruG2" style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock warrant liability, warrants exercisable</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right">          <span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1270">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_ecustom--CommonStockWarrantLiability1_iI_pn3n3_hus-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zbeOI5AoDsc5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Common stock warrant liability, warrants exercisable at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEZBSVIgVkFMVUUsIEFTU0VUUyBBTkQgTElBQklMSVRJRVMgTUVBU1VSRUQgT04gUkVDVVJSSU5HIEJBU0lTIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20211031__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zAiQmpM9nOXh" title="Warrant exercise price per share">56.00</span> through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1274">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1275">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,902</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,902</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--FairValueNetAssetLiability_iI_pn3n3_zk3DdzNrXRj5" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total financial liabilities at fair value</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1281">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1282">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,929</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,929</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 17183000 17183000 17183000 17183000 20.00 2000 2000 56.00 285000 285000 287000 287000 17153000 17153000 17153000 17153000 24.00 27000 27000 27000 27000 56.00 4902000 4902000 4929000 4929000 <p id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zv4Vtp1QMuwa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents changes in Level 3 liabilities measured at fair value (in thousands) for the nine months ended July 31, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zTaFbazXQoLd" style="display: none">SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS</span> </span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_4B6_us-gaap--FairValueByLiabilityClassAxis_custom--PreferredStockRedemptionLiabilityMember_zsTw9vpHOs8l" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_4B9_us-gaap--FairValueByLiabilityClassAxis_custom--WarrantLiabilityMember_zfnpIqJ8klfc" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_4B0_z7UegBGYb1oh" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"> </td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Preferred</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Stock</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Redemption</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Liability</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Warrant</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Liabilities</span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_438_c20211101__20220731_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zvf5xx8atlJ" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 46%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fair value at October 31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 15%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1288">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 15%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,929</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; width: 2%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 12%; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,929</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_zhfTaaaZPV1g" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Additions</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">87</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1293">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">87</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zlBGaQLZE6vk" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in fair value</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(43</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,642</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,685</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_405_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodRedemption_zqvllqAFwQh8" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Redemption</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(44</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1301">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(44</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_43D_c20211101__20220731_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_z2FQzQ0bWVMj" style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fair value at July 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1304">-</span></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">287</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">287</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 4929000 4929000 87000 87000 -43000 -4642000 -4685000 -44000 -44000 287000 287000 EXCEL 71 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

&PO=V]R M:W-H965T&UL M4$L! A0#% @ )9,L56[+AU % P 2@P !D ("!U-0 M 'AL+W=O=L# "?$@ &0 @($0V >&PO=V]R:W-H965T&UL4$L! A0#% @ M)9,L51P+O;TV! S14 !D ("!^^$ 'AL+W=O&PO=V]R:W-H965T(( 0!X;"]W;W)K&UL4$L! A0#% @ )9,L51QE:4GP P \0T !D M ("!M P! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ )9,L5:#!Q3DB! &Q4 !D ("!P1@! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ )9,L M542VG][3 P PP\ !D ("! B&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M" EDRQ58B/G&-@! !((@ $P @ &A-@$ 6T-O;G1E;G1? @5'EP97-=+GAM;%!+!08 0@!" 42 "J. $ ! end XML 72 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 73 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 74 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 204 254 1 false 42 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://advaxis.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://advaxis.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://advaxis.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://advaxis.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://advaxis.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - NATURE OF OPERATIONS Sheet http://advaxis.com/role/NatureOfOperations NATURE OF OPERATIONS Notes 6 false false R7.htm 00000007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION Notes 7 false false R8.htm 00000008 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://advaxis.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 8 false false R9.htm 00000009 - Disclosure - INTANGIBLE ASSETS Sheet http://advaxis.com/role/IntangibleAssets INTANGIBLE ASSETS Notes 9 false false R10.htm 00000010 - Disclosure - ACCRUED EXPENSES Sheet http://advaxis.com/role/AccruedExpenses ACCRUED EXPENSES Notes 10 false false R11.htm 00000011 - Disclosure - LEASES Sheet http://advaxis.com/role/Leases LEASES Notes 11 false false R12.htm 00000012 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY Notes 12 false false R13.htm 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://advaxis.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 00000014 - Disclosure - TEMPORARY EQUITY Sheet http://advaxis.com/role/TemporaryEquity TEMPORARY EQUITY Notes 14 false false R15.htm 00000015 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://advaxis.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 15 false false R16.htm 00000016 - Disclosure - SHARE BASED COMPENSATION Sheet http://advaxis.com/role/ShareBasedCompensation SHARE BASED COMPENSATION Notes 16 false false R17.htm 00000017 - Disclosure - LICENSING AGREEMENTS Sheet http://advaxis.com/role/LicensingAgreements LICENSING AGREEMENTS Notes 17 false false R18.htm 00000018 - Disclosure - FAIR VALUE Sheet http://advaxis.com/role/FairValue FAIR VALUE Notes 18 false false R19.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies) Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies) Policies 19 false false R20.htm 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables) Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables) Tables http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation 20 false false R21.htm 00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://advaxis.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://advaxis.com/role/PropertyAndEquipment 21 false false R22.htm 00000022 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://advaxis.com/role/IntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://advaxis.com/role/IntangibleAssets 22 false false R23.htm 00000023 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://advaxis.com/role/AccruedExpensesTables ACCRUED EXPENSES (Tables) Tables http://advaxis.com/role/AccruedExpenses 23 false false R24.htm 00000024 - Disclosure - LEASES (Tables) Sheet http://advaxis.com/role/LeasesTables LEASES (Tables) Tables http://advaxis.com/role/Leases 24 false false R25.htm 00000025 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables) Tables http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability 25 false false R26.htm 00000026 - Disclosure - TEMPORARY EQUITY (Tables) Sheet http://advaxis.com/role/TemporaryEquityTables TEMPORARY EQUITY (Tables) Tables http://advaxis.com/role/TemporaryEquity 26 false false R27.htm 00000027 - Disclosure - STOCKHOLDERS??? EQUITY (Tables) Sheet http://advaxis.com/role/StockholdersEquityTables STOCKHOLDERS??? EQUITY (Tables) Tables http://advaxis.com/role/StockholdersEquity 27 false false R28.htm 00000028 - Disclosure - SHARE BASED COMPENSATION (Tables) Sheet http://advaxis.com/role/ShareBasedCompensationTables SHARE BASED COMPENSATION (Tables) Tables http://advaxis.com/role/ShareBasedCompensation 28 false false R29.htm 00000029 - Disclosure - FAIR VALUE (Tables) Sheet http://advaxis.com/role/FairValueTables FAIR VALUE (Tables) Tables http://advaxis.com/role/FairValue 29 false false R30.htm 00000030 - Disclosure - NATURE OF OPERATIONS (Details Narrative) Sheet http://advaxis.com/role/NatureOfOperationsDetailsNarrative NATURE OF OPERATIONS (Details Narrative) Details http://advaxis.com/role/NatureOfOperations 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) Sheet http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) Details 31 false false R32.htm 00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative) Sheet http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative) Details http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables 32 false false R33.htm 00000033 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Sheet http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Details 33 false false R34.htm 00000034 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://advaxis.com/role/PropertyAndEquipmentTables 34 false false R35.htm 00000035 - Disclosure - SUMMARY OF INTANGIBLE ASSETS (Details) Sheet http://advaxis.com/role/SummaryOfIntangibleAssetsDetails SUMMARY OF INTANGIBLE ASSETS (Details) Details 35 false false R36.htm 00000036 - Disclosure - SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details) Sheet http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details) Details 36 false false R37.htm 00000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative) Sheet http://advaxis.com/role/IntangibleAssetsDetailsNarrative INTANGIBLE ASSETS (Details Narrative) Details http://advaxis.com/role/IntangibleAssetsTables 37 false false R38.htm 00000038 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details) Sheet http://advaxis.com/role/SummaryOfAccruedExpensesDetails SUMMARY OF ACCRUED EXPENSES (Details) Details 38 false false R39.htm 00000039 - Disclosure - SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details) Sheet http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details) Details 39 false false R40.htm 00000040 - Disclosure - SCHEDULE OF LEASE EXPENSES (Details) Sheet http://advaxis.com/role/ScheduleOfLeaseExpensesDetails SCHEDULE OF LEASE EXPENSES (Details) Details 40 false false R41.htm 00000041 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details) Sheet http://advaxis.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details) Details 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details) Sheet http://advaxis.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details) Details 42 false false R43.htm 00000043 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details) Sheet http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details) Details 43 false false R44.htm 00000044 - Disclosure - LEASES (Details Narrative) Sheet http://advaxis.com/role/LeasesDetailsNarrative LEASES (Details Narrative) Details http://advaxis.com/role/LeasesTables 44 false false R45.htm 00000045 - Disclosure - SCHEDULE OF COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details) Sheet http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails SCHEDULE OF COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details) Details 45 false false R46.htm 00000046 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details) Sheet http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details) Details 46 false false R47.htm 00000047 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative) Sheet http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative) Details http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables 47 false false R48.htm 00000048 - Disclosure - SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY (Details) Sheet http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY (Details) Details 48 false false R49.htm 00000049 - Disclosure - TEMPORARY EQUITY (Details Narrative) Sheet http://advaxis.com/role/TemporaryEquityDetailsNarrative TEMPORARY EQUITY (Details Narrative) Details http://advaxis.com/role/TemporaryEquityTables 49 false false R50.htm 00000050 - Disclosure - SUMMARY OF STOCKHOLDERS EQUITY (Details) Sheet http://advaxis.com/role/SummaryOfStockholdersEquityDetails SUMMARY OF STOCKHOLDERS EQUITY (Details) Details 50 false false R51.htm 00000051 - Disclosure - SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details) Sheet http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details) Details 51 false false R52.htm 00000052 - Disclosure - SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details) Sheet http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details) Details 52 false false R53.htm 00000053 - Disclosure - SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details) Sheet http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details) Details 53 false false R54.htm 00000054 - Disclosure - SHARE BASED COMPENSATION (Details Narrative) Sheet http://advaxis.com/role/ShareBasedCompensationDetailsNarrative SHARE BASED COMPENSATION (Details Narrative) Details http://advaxis.com/role/ShareBasedCompensationTables 54 false false R55.htm 00000055 - Disclosure - LICENSING AGREEMENTS (Details Narrative) Sheet http://advaxis.com/role/LicensingAgreementsDetailsNarrative LICENSING AGREEMENTS (Details Narrative) Details http://advaxis.com/role/LicensingAgreements 55 false false R56.htm 00000056 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) Sheet http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) Details 56 false false R57.htm 00000057 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical) Sheet http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical) Details 57 false false R58.htm 00000058 - Disclosure - SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS (Details) Sheet http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS (Details) Details 58 false false All Reports Book All Reports form10-q.htm adxs-20220731.xsd adxs-20220731_cal.xml adxs-20220731_def.xml adxs-20220731_lab.xml adxs-20220731_pre.xml ex10-1.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 17, "contextCount": 204, "dts": { "calculationLink": { "local": [ "adxs-20220731_cal.xml" ] }, "definitionLink": { "local": [ "adxs-20220731_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "adxs-20220731_lab.xml" ] }, "presentationLink": { "local": [ "adxs-20220731_pre.xml" ] }, "schema": { "local": [ "adxs-20220731.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 414, "entityCount": 1, "hidden": { "http://advaxis.com/20220731": 38, "http://fasb.org/us-gaap/2022": 109, "http://xbrl.sec.gov/dei/2022": 4, "total": 151 }, "keyCustom": 43, "keyStandard": 211, "memberCustom": 17, "memberStandard": 23, "nsprefix": "ADXS", "nsuri": "http://advaxis.com/20220731", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://advaxis.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - ACCRUED EXPENSES", "role": "http://advaxis.com/role/AccruedExpenses", "shortName": "ACCRUED EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - LEASES", "role": "http://advaxis.com/role/Leases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY", "role": "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability", "shortName": "COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://advaxis.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:TemporaryEquityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - TEMPORARY EQUITY", "role": "http://advaxis.com/role/TemporaryEquity", "shortName": "TEMPORARY EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:TemporaryEquityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "role": "http://advaxis.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SHARE BASED COMPENSATION", "role": "http://advaxis.com/role/ShareBasedCompensation", "shortName": "SHARE BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:LicensingAgreementsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - LICENSING AGREEMENTS", "role": "http://advaxis.com/role/LicensingAgreements", "shortName": "LICENSING AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:LicensingAgreementsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - FAIR VALUE", "role": "http://advaxis.com/role/FairValue", "shortName": "FAIR VALUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies)", "role": "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://advaxis.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables)", "role": "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://advaxis.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - INTANGIBLE ASSETS (Tables)", "role": "http://advaxis.com/role/IntangibleAssetsTables", "shortName": "INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - ACCRUED EXPENSES (Tables)", "role": "http://advaxis.com/role/AccruedExpensesTables", "shortName": "ACCRUED EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - LEASES (Tables)", "role": "http://advaxis.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:ScheduleOfOutstandingWarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables)", "role": "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables", "shortName": "COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:ScheduleOfOutstandingWarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ADXS:TemporaryEquityDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:PreferredStockRedemptionLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - TEMPORARY EQUITY (Tables)", "role": "http://advaxis.com/role/TemporaryEquityTables", "shortName": "TEMPORARY EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ADXS:TemporaryEquityDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:PreferredStockRedemptionLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)", "role": "http://advaxis.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - SHARE BASED COMPENSATION (Tables)", "role": "http://advaxis.com/role/ShareBasedCompensationTables", "shortName": "SHARE BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - FAIR VALUE (Tables)", "role": "http://advaxis.com/role/FairValueTables", "shortName": "FAIR VALUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://advaxis.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - NATURE OF OPERATIONS (Details Narrative)", "role": "http://advaxis.com/role/NatureOfOperationsDetailsNarrative", "shortName": "NATURE OF OPERATIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)", "role": "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails", "shortName": "SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31_custom_SeriesDPreferredStockRedemptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative)", "role": "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-01-31_custom_SeriesDPreferredStockRedemptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MachineryAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "role": "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:MachineryAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-05-012022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "role": "http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2020-11-012021-07-31", "decimals": "0", "lang": null, "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SUMMARY OF INTANGIBLE ASSETS (Details)", "role": "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails", "shortName": "SUMMARY OF INTANGIBLE ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details)", "role": "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails", "shortName": "SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - INTANGIBLE ASSETS (Details Narrative)", "role": "http://advaxis.com/role/IntangibleAssetsDetailsNarrative", "shortName": "INTANGIBLE ASSETS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-05-012022-07-31_us-gaap_GeneralAndAdministrativeExpenseMember", "decimals": "0", "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SUMMARY OF ACCRUED EXPENSES (Details)", "role": "http://advaxis.com/role/SummaryOfAccruedExpensesDetails", "shortName": "SUMMARY OF ACCRUED EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details)", "role": "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails", "shortName": "SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-05-012021-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://advaxis.com/role/StatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-05-012021-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-05-012022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - SCHEDULE OF LEASE EXPENSES (Details)", "role": "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails", "shortName": "SCHEDULE OF LEASE EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-05-012022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "ADXS:ScheduleOfOtherInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details)", "role": "http://advaxis.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails", "shortName": "SCHEDULE OF OTHER INFORMATION RELATED TO LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "ADXS:ScheduleOfOtherInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details)", "role": "http://advaxis.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails", "shortName": "SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details)", "role": "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails", "shortName": "SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:LeaseExpirationDateDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - LEASES (Details Narrative)", "role": "http://advaxis.com/role/LeasesDetailsNarrative", "shortName": "LEASES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:LeaseExpirationDateDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - SCHEDULE OF COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details)", "role": "http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "shortName": "SCHEDULE OF COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "ADXS:ScheduleOfOutstandingWarrantsTableTextBlock", "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31_custom_ExercisePriceRangeOneMember", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details)", "role": "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "shortName": "SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31_custom_WarrantLiabilityMember", "decimals": "INF", "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "ADXS:ScheduleOfOutstandingWarrantsTableTextBlock", "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative)", "role": "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "shortName": "COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "ADXS:CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-04-30", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ADXS:PreferredStockRedemptionLiabilityTableTextBlock", "ADXS:TemporaryEquityDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-04-06_us-gaap_MeasurementInputExercisePriceMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY (Details)", "role": "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails", "shortName": "SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ADXS:PreferredStockRedemptionLiabilityTableTextBlock", "ADXS:TemporaryEquityDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-04-06_us-gaap_MeasurementInputExercisePriceMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-02-012021-04-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - TEMPORARY EQUITY (Details Narrative)", "role": "http://advaxis.com/role/TemporaryEquityDetailsNarrative", "shortName": "TEMPORARY EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "ADXS:TemporaryEquityDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": "INF", "lang": null, "name": "ADXS:PreferredStockDiscountRatePercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://advaxis.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": "-3", "lang": null, "name": "ADXS:GainOnChangeInValueOfWarrants", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-04-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - SUMMARY OF STOCKHOLDERS EQUITY (Details)", "role": "http://advaxis.com/role/SummaryOfStockholdersEquityDetails", "shortName": "SUMMARY OF STOCKHOLDERS EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-05-012022-07-31", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-05-012022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details)", "role": "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails", "shortName": "SUMMARY OF SHARE BASED COMPENSATION EXPENSE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-05-012022-07-31_us-gaap_ResearchAndDevelopmentExpenseMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-10-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details)", "role": "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails", "shortName": "SUMMARY OF CHANGES IN STOCK OPTION PLAN (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-10-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-012022-07-31_custom_ExercisePriceRangeOneMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details)", "role": "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails", "shortName": "SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-012022-07-31_custom_ExercisePriceRangeOneMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - SHARE BASED COMPENSATION (Details Narrative)", "role": "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative", "shortName": "SHARE BASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "p", "ADXS:LicensingAgreementsDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:MilestoneAchievementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - LICENSING AGREEMENTS (Details Narrative)", "role": "http://advaxis.com/role/LicensingAgreementsDetailsNarrative", "shortName": "LICENSING AGREEMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "ADXS:LicensingAgreementsDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "ADXS:MilestoneAchievementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)", "role": "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "shortName": "SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical)", "role": "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical", "shortName": "SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-10-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS (Details)", "role": "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails", "shortName": "SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-10-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000006 - Disclosure - NATURE OF OPERATIONS", "role": "http://advaxis.com/role/NatureOfOperations", "shortName": "NATURE OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION", "role": "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://advaxis.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - INTANGIBLE ASSETS", "role": "http://advaxis.com/role/IntangibleAssets", "shortName": "INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-11-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 42, "tag": { "ADXS_AccretionOfDiscountAndRedemptionFeatureOfConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accretion of discount and redemption feature of convertible preferred stock.", "label": "Accretion of discount and redemption feature of convertible preferred stock" } } }, "localname": "AccretionOfDiscountAndRedemptionFeatureOfConvertiblePreferredStock", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ADXS_ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of Financing.", "label": "Type of financing" } } }, "localname": "ClassOfWarrantOrRightTitleOfSecurityWarrantsOrRightsOutstandings", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "ADXS_CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Purchase Warrants And Warrant Liability [Text Block]", "label": "COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY" } } }, "localname": "CommonStockPurchaseWarrantsAndWarrantLiabilityTextBlock", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiability" ], "xbrltype": "textBlockItemType" }, "ADXS_CommonStockWarrantLiability": { "auth_ref": [], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock warrant liability.", "label": "Common stock warrant liability", "verboseLabel": "Common stock warrant liability, warrants exercisable" } } }, "localname": "CommonStockWarrantLiability", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "ADXS_CommonStockWarrantLiability1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock warrant liability.", "label": "Common stock warrant liability, warrants exercisable at $56.00 through 5 years after the date such warrants become exercisable, if ever (Private Placement Warrants)" } } }, "localname": "CommonStockWarrantLiability1", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "ADXS_ConvertablePreferredStockPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertable Preferred Stock [Policy Text Block]", "label": "Convertible Preferred Stock" } } }, "localname": "ConvertablePreferredStockPolicyTextBlock", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ADXS_DevelopmentLicenseAndSupplyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development, License and Supply Agreement [Member]", "label": "Development, License and Supply Agreement [Member]" } } }, "localname": "DevelopmentLicenseAndSupplyAgreementMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ADXS_DisclosureCommonStockPurchaseWarrantsAndWarrantLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Purchase Warrants And Warrant Liability" } } }, "localname": "DisclosureCommonStockPurchaseWarrantsAndWarrantLiabilityAbstract", "nsuri": "http://advaxis.com/20220731", "xbrltype": "stringItemType" }, "ADXS_DisclosureLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases", "terseLabel": "Schedule Of Other Information Related To Leases", "verboseLabel": "Schedule Of Supplemental Balance Sheet Related To Leases" } } }, "localname": "DisclosureLeasesAbstract", "nsuri": "http://advaxis.com/20220731", "xbrltype": "stringItemType" }, "ADXS_DisclosureLicensingAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Licensing Agreements" } } }, "localname": "DisclosureLicensingAgreementsAbstract", "nsuri": "http://advaxis.com/20220731", "xbrltype": "stringItemType" }, "ADXS_DisclosureTemporaryEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Temporary Equity" } } }, "localname": "DisclosureTemporaryEquityAbstract", "nsuri": "http://advaxis.com/20220731", "xbrltype": "stringItemType" }, "ADXS_EquityWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Warrants [Member]", "label": "Equity Warrants [Member]" } } }, "localname": "EquityWarrantsMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "ADXS_ExercisePriceRangeFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Five [Member].", "label": "Exercise Price Range Five [Member]" } } }, "localname": "ExercisePriceRangeFiveMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "ADXS_ExercisePriceRangeFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Four [Member]", "label": "Exercise Price Range Four [Member]" } } }, "localname": "ExercisePriceRangeFourMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "ADXS_ExercisePriceRangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range One [Member]", "label": "Exercise Price Range One [Member]" } } }, "localname": "ExercisePriceRangeOneMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "domainItemType" }, "ADXS_ExercisePriceRangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Three [Member]", "label": "Exercise Price Range Three [Member]" } } }, "localname": "ExercisePriceRangeThreeMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "domainItemType" }, "ADXS_ExercisePriceRangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Two [Member]", "label": "Exercise Price Range Two [Member]" } } }, "localname": "ExercisePriceRangeTwoMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "domainItemType" }, "ADXS_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodRedemption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability period redemption.", "label": "Redemption" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodRedemption", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "ADXS_FairValueOfWarrantLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the warrant liability.", "label": "Fair value of the warrant liability" } } }, "localname": "FairValueOfWarrantLiability", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ADXS_FiniteLivedSoftwareGross": { "auth_ref": [], "calculation": { "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-lived software, gross.", "label": "Software" } } }, "localname": "FiniteLivedSoftwareGross", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ADXS_FractionalSharesCashedOut": { "auth_ref": [], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fractional shares cashed out.", "label": "Fractional shares cashed out", "negatedLabel": "Fractional shares cashed out" } } }, "localname": "FractionalSharesCashedOut", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows", "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "ADXS_FractionalSharesCashedOutShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fractional shares cashed out shares.", "label": "Fractional shares cashed out, shares" } } }, "localname": "FractionalSharesCashedOutShares", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "ADXS_FundingForSecondMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Funding for second milestone payment.", "label": "Funding for milestone payment" } } }, "localname": "FundingForSecondMilestonePayment", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ADXS_FundingMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Funding milestone payment.", "label": "Funding milestone payment" } } }, "localname": "FundingMilestonePayment", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ADXS_GainOnChangeInValueOfPreferredStockRedemptionLiability": { "auth_ref": [], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on change in value of preferred stock redemption liability.", "label": "GainOnChangeInValueOfPreferredStockRedemptionLiability", "negatedLabel": "Gain on change in value of preferred stock redemption liability" } } }, "localname": "GainOnChangeInValueOfPreferredStockRedemptionLiability", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ADXS_GainOnChangeInValueOfWarrants": { "auth_ref": [], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on change in value of warrants.", "label": "GainOnChangeInValueOfWarrants", "negatedLabel": "Gain on change in value of warrants" } } }, "localname": "GainOnChangeInValueOfWarrants", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ADXS_GlobalBioPharmaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global BioPharma, Inc [Member]", "label": "Global BioPharma, Inc [Member]" } } }, "localname": "GlobalBioPharmaIncMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ADXS_ImpairmentChargesOnIntangibleAssets": { "auth_ref": [], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impairment charges in intangible assets.", "label": "Impairment charges on intangible assets" } } }, "localname": "ImpairmentChargesOnIntangibleAssets", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ADXS_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease liabilities.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ADXS_InstitutionalInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Institutional Investors [Member]", "label": "Institutional Investors [Member]" } } }, "localname": "InstitutionalInvestorsMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "ADXS_LeaseExpirationDateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease expiration date description", "label": "Lease expiration date" } } }, "localname": "LeaseExpirationDateDescription", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "ADXS_LesseeFinanceLeasesRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee finance lease renewal term.", "label": "Lessee finance lease renewal term date" } } }, "localname": "LesseeFinanceLeasesRenewalTerm", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "dateItemType" }, "ADXS_LicensingAgreementsDisclosuresTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licensing Agreements Disclosures [Text Block]", "label": "LICENSING AGREEMENTS" } } }, "localname": "LicensingAgreementsDisclosuresTextBlock", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/LicensingAgreements" ], "xbrltype": "textBlockItemType" }, "ADXS_LossOnSaleOfPropertyPlantEquipment": { "auth_ref": [], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss on sale of property plant equipment.", "label": "Loss on disposal of property and equipment" } } }, "localname": "LossOnSaleOfPropertyPlantEquipment", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ADXS_MilestoneAchievementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone achievement description", "label": "Milestone achievement, description" } } }, "localname": "MilestoneAchievementDescription", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ADXS_NetGainOnWriteOffOfRightofuseAssetAndLeaseLiability": { "auth_ref": [], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net gain on write off of right-of-use asset and lease liability.", "label": "NetGainOnWriteOffOfRightofuseAssetAndLeaseLiability", "negatedLabel": "Net gain on write-off of right-of-use asset and lease liability" } } }, "localname": "NetGainOnWriteOffOfRightofuseAssetAndLeaseLiability", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ADXS_OSTherapiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OS Therapies [Member]", "label": "OS Therapies [Member]" } } }, "localname": "OSTherapiesMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ADXS_PaymentOfRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments for rent.", "label": "Payment of rent" } } }, "localname": "PaymentOfRent", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ADXS_PreferredStockDiscountRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock discount rate percentage", "label": "Issue discount" } } }, "localname": "PreferredStockDiscountRatePercentage", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "ADXS_PreferredStockRedemptionLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock redemption liability [Member]", "label": "Preferred stock redemption liability [Member]" } } }, "localname": "PreferredStockRedemptionLiabilityMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ADXS_PreferredStockRedemptionLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock Redemption Liability [Table Text Block]", "label": "SCHEDULE OF PREFERRED STOCK REDEMPTION LIABILITY" } } }, "localname": "PreferredStockRedemptionLiabilityTableTextBlock", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/TemporaryEquityTables" ], "xbrltype": "textBlockItemType" }, "ADXS_ProceedsFromIssuanceOrEstimatedOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance or estimated offering", "label": "Proceeds from issuance or estimated offering" } } }, "localname": "ProceedsFromIssuanceOrEstimatedOffering", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ADXS_RedemptionOfSeriesDPreferredStock": { "auth_ref": [], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Redemption of series D preferredStock.", "label": "RedemptionOfSeriesDPreferredStock", "negatedLabel": "Redemption of Series D preferred stock" } } }, "localname": "RedemptionOfSeriesDPreferredStock", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ADXS_ResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research And Development [Member]", "label": "Research And Development [Member]" } } }, "localname": "ResearchAndDevelopmentMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "ADXS_ReverseStockSplitPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reverse Stock Split [Policy Text Block]", "label": "Reverse Stock Split" } } }, "localname": "ReverseStockSplitPolicyTextBlock", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ADXS_ScheduleOfOtherInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Other Information [TableTextBlock]", "label": "SCHEDULE OF OTHER INFORMATION RELATED TO LEASES" } } }, "localname": "ScheduleOfOtherInformationTableTextBlock", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ADXS_ScheduleOfOutstandingWarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Outstanding Warrants [Table Text Block]", "label": "SCHEDULE OF COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY" } } }, "localname": "ScheduleOfOutstandingWarrantsTableTextBlock", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables" ], "xbrltype": "textBlockItemType" }, "ADXS_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block]", "label": "SCHEDULE OF SUPPLEMENTAL BALANCE SHEET RELATED TO LEASES" } } }, "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "ADXS_SeriesDConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D convertible preferred stock [Member]", "label": "Series D convertible preferred stock [Member]" } } }, "localname": "SeriesDConvertiblePreferredStockMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "ADXS_SeriesDConvertibleRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Convertible Redeemable Preferred Stock [Member]", "label": "Series D Convertible Redeemable Preferred Stock [Member]" } } }, "localname": "SeriesDConvertibleRedeemablePreferredStockMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "domainItemType" }, "ADXS_SeriesDPreferredStockRedemptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series D Preferred Stock Redemption [Member]", "label": "Series D Preferred Stock Redemption [Member]" } } }, "localname": "SeriesDPreferredStockRedemptionMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ADXS_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award options outstanding weighted average remaining contractual term ending.", "label": "Weighted Average Remaining Contractual Life In Years, Ending Balance" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "durationItemType" }, "ADXS_StockIssuedDuringPeriodSharesEmployeesUnderESPPPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares employees under ESPP plan.", "label": "Issuance of shares to employees under ESPP Plan, shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeesUnderESPPPlan", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "ADXS_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares warrants exercised.", "label": "Warrant exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "ADXS_StockIssuedDuringPeriodValueAccretionOfDiscountAndRedemptionFeatureOfConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value accretion of discount and redemption feature of convertible preferred stock.", "label": "StockIssuedDuringPeriodValueAccretionOfDiscountAndRedemptionFeatureOfConvertiblePreferredStock", "verboseLabel": "Accretion of discount and redemption feature of convertible preferred stock" } } }, "localname": "StockIssuedDuringPeriodValueAccretionOfDiscountAndRedemptionFeatureOfConvertiblePreferredStock", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "ADXS_StockIssuedDuringPeriodValueConvertiblePreferredStockRedemption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value convertible preferred stock redemption.", "label": "Convertible preferred stock redemption" } } }, "localname": "StockIssuedDuringPeriodValueConvertiblePreferredStockRedemption", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "ADXS_StockIssuedDuringPeriodValueEmployeesUnderESPPPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value employees under ESPP plan.", "label": "Issuance of shares to employees under ESPP Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeesUnderESPPPlan", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "ADXS_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "StockIssuedDuringPeriodValueWarrantsExercised", "verboseLabel": "Warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "ADXS_TemporaryEquityDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary Equity Disclosure [Text Block]", "label": "TEMPORARY EQUITY" } } }, "localname": "TemporaryEquityDisclosureTextBlock", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/TemporaryEquity" ], "xbrltype": "textBlockItemType" }, "ADXS_TemporaryEquityStockStatedValueAccumulatedDividends": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock stated value accumulated dividends.", "label": "Temporary equity stock stated value accumulated dividends" } } }, "localname": "TemporaryEquityStockStatedValueAccumulatedDividends", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "ADXS_TemporaryEquityStockStatedValueAccumulatedDividendsOnExtension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock stated value accumulated dividends on extension.", "label": "Temporary equity stock stated value accumulated dividends on extension" } } }, "localname": "TemporaryEquityStockStatedValueAccumulatedDividendsOnExtension", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "ADXS_ThroughSeptemberTwoThousandTwentyFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Through September 2024 [Member]", "label": "Through September 2024 [Member]" } } }, "localname": "ThroughSeptemberTwoThousandTwentyFourMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "ADXS_WarrantLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant Liability [Member]", "label": "Warrant Liability [Member]" } } }, "localname": "WarrantLiabilityMember", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ADXS_WarrantsExpirationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants expiration description.", "label": "Expiration Date" } } }, "localname": "WarrantsExpirationDescription", "nsuri": "http://advaxis.com/20220731", "presentation": [ "http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r403", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://advaxis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r160", "r161", "r162", "r163", "r176", "r186", "r218", "r220", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r376", "r378", "r389", "r390" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r160", "r161", "r162", "r163", "r176", "r186", "r218", "r220", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r376", "r378", "r389", "r390" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r116", "r161", "r162", "r203", "r204", "r339", "r375", "r377" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r116", "r161", "r162", "r203", "r204", "r339", "r375", "r377" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r154", "r160", "r161", "r162", "r163", "r176", "r186", "r207", "r218", "r220", "r249", "r250", "r251", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r376", "r378", "r389", "r390" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r154", "r160", "r161", "r162", "r163", "r176", "r186", "r207", "r218", "r220", "r249", "r250", "r251", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r376", "r378", "r389", "r390" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r76", "r81", "r159", "r219" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r76", "r81", "r159", "r219", "r326" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r119", "r321" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r22", "r325" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r22", "r66", "r320", "r322" ], "calculation": { "http://advaxis.com/role/SummaryOfAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Vendors" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://advaxis.com/role/SummaryOfAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/SummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://advaxis.com/role/SummaryOfAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r9", "r149" ], "calculation": { "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r35", "r36", "r298", "r299", "r300", "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r16", "r325" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r68", "r69", "r70", "r260", "r261", "r262", "r285" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r51", "r136", "r141" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization expense of intangible assets", "verboseLabel": "Intangible asset amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative", "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Total" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r51", "r146" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Intangible asset impairment", "verboseLabel": "Asset impairment charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative", "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r12", "r64", "r105", "r108", "r114", "r121", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r272", "r275", "r296", "r323", "r325", "r356", "r364" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r21", "r64", "r121", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r272", "r275", "r296", "r323", "r325" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total Financial Assets at Fair Value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r222", "r223", "r224", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation/Estimates" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r391" ], "calculation": { "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Computer equipment" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r7", "r53" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents, at carrying value" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash equivalents (money market funds)" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r54", "r355" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r48", "r53", "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r48", "r297" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r13", "r14", "r15", "r62", "r64", "r84", "r85", "r86", "r89", "r91", "r99", "r100", "r101", "r121", "r165", "r169", "r170", "r171", "r174", "r175", "r183", "r184", "r188", "r192", "r198", "r296", "r408" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical", "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Exercise Price", "verboseLabel": "Warrant exercise price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Grand Total Number of Shares Underlying Warrants", "verboseLabel": "Number of warrants to purchase common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r27", "r358", "r370" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Contingencies \u2013 Note 8" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r156", "r157", "r158", "r164", "r385" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r68", "r69", "r285" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized", "verboseLabel": "Common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r198" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r325" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock - $0.001 par value; 170,000,000 shares authorized, 1,815,951 and 1,820,452 shares issued and outstanding at July 31, 2022 and October 31, 2021." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r61", "r274" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r51", "r147" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative", "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r280" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Net changes in fair value of derivative liabilities" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r32", "r279", "r281", "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesReportingOfDerivativeActivity": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.", "label": "Derivative Financial Instruments" } } }, "localname": "DerivativesReportingOfDerivativeActivity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r221", "r222", "r255", "r256", "r258", "r264" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "SHARE BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r41", "r73", "r74", "r75", "r76", "r77", "r82", "r84", "r89", "r90", "r91", "r95", "r96", "r286", "r287", "r361", "r372" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per common share, basic and diluted" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r93", "r94" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Income (Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://advaxis.com/role/SummaryOfAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Salaries and other compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Unrecognized weighted average vesting period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r257" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r35", "r36", "r37", "r68", "r69", "r70", "r72", "r78", "r80", "r98", "r122", "r198", "r200", "r260", "r261", "r262", "r267", "r268", "r285", "r298", "r299", "r300", "r301", "r302", "r303", "r317", "r379", "r380", "r381" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiMeasurementInput": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Measurement Input", "verboseLabel": "Measurement input percentage" } } }, "localname": "EquitySecuritiesFvNiMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r51", "r180" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Income on fair value of warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r288", "r289", "r295" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r177", "r178", "r179", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r217", "r289", "r327", "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "FAIR VALUE" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/FairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r177", "r208", "r209", "r214", "r217", "r289", "r327" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r177", "r178", "r179", "r208", "r209", "r214", "r217", "r289", "r328" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r177", "r178", "r179", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r217", "r289", "r329" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r292", "r295" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r292", "r295" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "SCHEDULE OF FAIR VALUE MEASURING UNOBSERVABLE INPUTS" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r293" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Additions" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair value at July 31, 2022", "periodStartLabel": "Fair value at October 31, 2021" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueMeasuringUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r177", "r178", "r179", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r217", "r327", "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Total financial liabilities at fair value" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r10", "r140" ], "calculation": { "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r142" ], "calculation": { "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "2022 (Remaining)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r142" ], "calculation": { "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r140", "r341" ], "calculation": { "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "totalLabel": "Total intangibles" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r140", "r340" ], "calculation": { "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfCarryingValueOfIntangibleAssetsDetails", "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedLicenseAgreementsGross": { "auth_ref": [ "r140" ], "calculation": { "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.", "label": "License" } } }, "localname": "FiniteLivedLicenseAgreementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedPatentsGross": { "auth_ref": [ "r140" ], "calculation": { "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.", "label": "Patents" } } }, "localname": "FiniteLivedPatentsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Net payment for termination fee" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain loss on sale of property plant equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "Lease termination" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r43" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative", "http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative", "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails", "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Impaired Assets to be Disposed of by Method Other than Sale [Line Items]" } } }, "localname": "ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTable": { "auth_ref": [ "r145", "r151" ], "lang": { "en-us": { "role": { "documentation": "When an entity determines it will dispose of a long-lived asset by a method other than sale (for example, by abandonment, distribution in a spin-off), impairment of such assets is separately disclosed from those assets held and used.", "label": "Impaired Assets to be Disposed of by Method Other than Sale [Table]" } } }, "localname": "ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r51", "r143" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Abandonment of intangible assets", "verboseLabel": "Book value patent applications, net" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative", "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r39", "r105", "r107", "r110", "r113", "r115", "r354", "r359", "r362", "r373" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r152", "r155" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative", "http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative", "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails", "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative", "http://advaxis.com/role/PropertyAndEquipmentDetailsNarrative", "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails", "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r65", "r79", "r80", "r104", "r266", "r269", "r270", "r374" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r55" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r50" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r50", "r337" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r50" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r50" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses, other current assets and deferred expenses" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r135", "r138" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets (net of accumulated amortization)" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest income, net" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r312", "r314" ], "calculation": { "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "SCHEDULE OF LEASE EXPENSES" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELLABLE LEASES" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r313" ], "calculation": { "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r313" ], "calculation": { "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r313" ], "calculation": { "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "verboseLabel": "2022 (Remaining)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r24", "r64", "r109", "r121", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r273", "r275", "r276", "r296", "r323", "r324" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r64", "r121", "r296", "r325", "r357", "r367" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r26", "r64", "r121", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r273", "r275", "r276", "r296", "r323", "r324", "r325" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAndServiceMember": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License and Service [Member]" } } }, "localname": "LicenseAndServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r148" ], "calculation": { "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Laboratory equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfPreferredStockRedemptionLiabilityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r48" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash (used in) provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r48" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r48", "r49", "r52" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r33", "r34", "r37", "r40", "r52", "r64", "r71", "r73", "r74", "r75", "r76", "r79", "r80", "r87", "r105", "r107", "r110", "r113", "r115", "r121", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r287", "r296", "r360", "r371" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://advaxis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows", "http://advaxis.com/role/StatementsOfOperations", "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r73", "r74", "r75", "r76", "r82", "r83", "r88", "r91", "r105", "r107", "r110", "r113", "r115" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Income available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF NON-CASH AND FINANCING ACTIVITIES" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Offsetting Assets [Line Items]" } } }, "localname": "OffsettingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingAssetsTable": { "auth_ref": [ "r30", "r31" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements.", "label": "Offsetting Assets [Table]" } } }, "localname": "OffsettingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfCommonStockPurchaseWarrantsAndWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r105", "r107", "r110", "r113", "r115" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r307", "r314" ], "calculation": { "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "auth_ref": [ "r97", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.", "label": "Cash paid for operating lease liabilities" } } }, "localname": "OperatingLeaseLeaseIncomeLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r306" ], "calculation": { "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating lease liability", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative", "http://advaxis.com/role/ScheduleOfFutureMinimumLeasePaymentsUnderNon-cancellableLeasesDetails", "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r306" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current portion of operating lease liability", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r306" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r305" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating right-of-use asset (net of accumulated amortization)", "terseLabel": "Operating lease, right of use asset", "verboseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/LeasesDetailsNarrative", "http://advaxis.com/role/ScheduleOfSupplementalBalanceSheetRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r51" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization of right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r311", "r314" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r310", "r314" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfOtherInformationRelatedToLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r277" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "NATURE OF OPERATIONS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/NatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://advaxis.com/role/SummaryOfAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r11" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r44" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r46" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Cost of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConvertibleConversionPrice": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Per share conversion price of preferred stock.", "label": "Preferred stock conversion price" } } }, "localname": "PreferredStockConvertibleConversionPrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "auth_ref": [ "r83", "r92" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.", "label": "Preferred Stock Dividends and Other Adjustments", "negatedLabel": "Accretion of discount and redemption feature of convertible preferred stock" } } }, "localname": "PreferredStockDividendsAndOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14", "r183" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionAmount": { "auth_ref": [ "r28", "r182" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Preferred stock, redemption amount" } } }, "localname": "PreferredStockRedemptionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14", "r183" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14", "r325" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.001 par value; 5,000,000 shares authorized, 0 shares issued and outstanding at July 31, 2022 and October 31, 2021." } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r21" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r47" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Net proceeds of issuance of common stock and warrants" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r47" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Net proceeds of issuance of Series D preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r45" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from disposal of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r47" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Warrant exercises" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r153", "r386", "r387", "r388" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r8", "r148" ], "calculation": { "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r150", "r325", "r363", "r369" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment (net of accumulated depreciation)", "totalLabel": "Net property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "SCHEDULE OF PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r325", "r368", "r384" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Net gain on leases" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedemptionPremium": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.", "label": "Change in preferred stock, redemption liability amount" } } }, "localname": "RedemptionPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r216", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r216", "r318", "r322", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r265", "r338", "r391" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r7", "r59", "r355", "r365" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r200", "r325", "r366", "r382", "r383" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r68", "r69", "r70", "r72", "r78", "r80", "r122", "r260", "r261", "r262", "r267", "r268", "r285", "r379", "r381" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r102", "r103", "r106", "r111", "r112", "r116", "r117", "r118", "r202", "r203", "r339" ], "calculation": { "http://advaxis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r38", "r64", "r102", "r103", "r106", "r111", "r112", "r116", "r117", "r118", "r121", "r165", "r166", "r167", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r296", "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "verboseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "SUMMARY OF ACCRUED EXPENSES" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF ANTI -DILUTED SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "SCHEDULE OF ASSUMPTIONS USED IN WARRANT LIABILITY" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "SCHEDULE OF CASH FLOW INFORMATION RELATED TO LEASES" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "SUMMARY OF SHARE BASED COMPENSATION EXPENSE" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r205", "r206" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r254", "r263" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/FairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r137", "r139" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "SUMMARY OF INTANGIBLE ASSETS" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "SUMMARY OF OUTSTANDING AND EXERCISABLE OPTIONS" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r225", "r242", "r245" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "SUMMARY OF CHANGES IN STOCK OPTION PLAN" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "SUMMARY OF STOCKHOLDERS EQUITY" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "SCHEDULE OF CARRYING VALUE OF INTANGIBLE ASSETS" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r11" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [ "r13", "r14", "r198" ], "lang": { "en-us": { "role": { "documentation": "Series D preferred stock.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r50" ], "calculation": { "http://advaxis.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share based compensation", "verboseLabel": "Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows", "http://advaxis.com/role/SummaryOfShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Shares, Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Vested and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Shares, Cancelled or Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r230" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Weighted Average Exercise Price, Cancelled or Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r259" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Ending", "periodStartLabel": "Aggregate Intrinsic Value, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r226", "r228" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Shares, Outstanding, Ending Balance", "periodStartLabel": "Shares Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r226", "r228" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending", "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r222", "r223", "r224", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Exercise Price Range, lower limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Number Exercisable, Options Exercisable" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Number Outstanding, Options Outstanding" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Exercise Price Range, upper limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Stock Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r259" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value, Vested and Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life In Years, Vested and Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Unvested stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Life In Years, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfChangesInStockOptionPlanDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Weighted Average Exercise Price, Options Exercisable" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual Term Exercisable, Options Exercisable" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Weighted Average Exercise Price, Options Outstanding" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining Contractual, Options Outstanding" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfOutstandingAndExercisableOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Share purchase price" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r308", "r314" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r60", "r67" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r13", "r14", "r15", "r62", "r64", "r84", "r85", "r86", "r89", "r91", "r99", "r100", "r101", "r121", "r165", "r169", "r170", "r171", "r174", "r175", "r183", "r184", "r188", "r192", "r198", "r296", "r408" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical", "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r29", "r35", "r36", "r37", "r68", "r69", "r70", "r72", "r78", "r80", "r98", "r122", "r198", "r200", "r260", "r261", "r262", "r267", "r268", "r285", "r298", "r299", "r300", "r301", "r302", "r303", "r317", "r379", "r380", "r381" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/LicensingAgreementsDetailsNarrative", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails", "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r68", "r69", "r70", "r98", "r339" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/LicensingAgreementsDetailsNarrative", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails", "http://advaxis.com/role/SummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r56", "r57", "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Reclassification of preferred stock redemption liability into equity upon redemption of preferred stock" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r14", "r15", "r198", "r200" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Shares issued", "verboseLabel": "Advaxis public offerings, net of offering costs, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r15", "r198", "r200", "r232" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock option exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r14", "r15", "r198", "r200" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock issued during period value new issues", "verboseLabel": "Advaxis public offerings, net of offering costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r29", "r198", "r200" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r18", "r19", "r64", "r120", "r121", "r296", "r325" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/SummaryOfStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r63", "r184", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r200", "r201", "r284" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables", "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityTables", "http://advaxis.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetailsParenthetical", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r165", "r169", "r170", "r171", "r174", "r175" ], "calculation": { "http://advaxis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Series D convertible preferred stock- $0.001 par value; 0 shares authorized, 0 shares issued and outstanding at July 31, 2022 and October 31, 2021.", "verboseLabel": "Temporary equity, carrying amount, attributable to parent" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheets", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r6", "r181" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary equity, par value", "verboseLabel": "Temporary equity par value" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary equity, shares authorized" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary equity, shares issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary equity, shares outstanding", "verboseLabel": "Temporary equity shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/BalanceSheetsParenthetical", "http://advaxis.com/role/TemporaryEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r309", "r314" ], "calculation": { "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/CommonStockPurchaseWarrantsAndWarrantLiabilityDetailsNarrative", "http://advaxis.com/role/ScheduleOfAnti-dilutedSecuritiesExcludedFromDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Measurement input percentage" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected Term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/ScheduleOfAssumptionsUsedInWarrantLiabilityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r82", "r91" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://advaxis.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r153": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r264": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r315": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r392": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r393": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r394": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r395": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r396": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r397": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r398": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r399": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r400": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r401": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r402": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r403": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r404": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r405": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r406": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r407": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r408": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r409": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r410": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r411": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r412": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" } }, "version": "2.1" } ZIP 77 0001493152-22-025666-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-025666-xbrl.zip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�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